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Abstract
Introduction: Breast cancer is a leading cause of death in women of all ages in many parts
of the world. The management of this disease is typically based upon its clinico-pathological
features and usually involves a combination of surgery and systemic therapy. Many patients
however, do not respond to these therapies as anticipated and may therefore suffer
needlessly from medication side effects and delayed initiation of more effective treatment, all
of which impose an enormous financial burden on healthcare systems.
Efforts are underway to improve the classification, prognostication and prediction of
response to treatment for breast cancer patients, in the hope of providing better,
individualised care Advances in our understanding of the disease and its management are
anticipated to come from investigations into the molecular pathways and gene expression
underlying breast cancer development, growth and metastasis.
Microarray technology, used to simultaneously analyse the patterns of expression of tens of
thousands of genes from tumour biopsies, has permitted the identification of new intrinsic
subtypes of breast cancer based upon their transcriptional signatures, and of prognostic and
predictive markers that are beginning to show clinical utility and promise to outperform
standard clinico-pathological markers.
Methods: Microarray and quantitative polymerase chain reaction (qPCR) technologies were
used to compare the efficacy of five multi-gene signatures for their ability to predict clinical
response to three months of neoadjuvant treatment with the Aromatase inhibitor Letrozole, in
a population of postmenopausal ER positive breast cancer patients. The levels of gene
expression in biopsy samples acquired from each patient were measured prior to treatment
and at week two of a three-month treatment regimen. Tumour response was assessed
dynamically by means of three-dimensional ultrasound scanning. The predictive capacity of
proliferation markers was further explored by focusing on the expression of several key
genes involved in different stages of cell cycle progression, including Cyclins B1, A2, D1,
CDKs 1, 2 and 4 and the NUSAP1 and Ki67 genes. In addition, changes in Ki67 after 3
months of neo-adjuvant treatment were related to long-term survival.
Results: A total of 394 women with large or locally advanced oestrogen receptor positive
breast tumours were enrolled into the study population in two independent datasets.
A previously defined neoadjuvant predictive signature from our unit has been validated on
both independent and extended datasets. In addition, two further proliferative-gene
signatures were shown to have significant power to predict longer-term clinical response to
Letrozole therapy, based upon their gene expression activity after two weeks of treatment.
On the other hand, neither of the two stromal-gene signatures chosen for inclusion in this
study was able to predict response based on their absolute expression profiles at two weeks.
However, when considering the change in their gene expression profiles between baseline
and two weeks, both stromal signatures became informative in one of the datasets. Only one
of the proliferative signatures was predictive in this way.
Analysis focusing on the genes representing different phases of the cell cycle, demonstrated
that two weeks of Letrozole therapy strongly decreased the expression of Cyclins B1, A2,
D1, CDK1 and NUSAP1 but not CDK 2 and 4. Significant correlations between the change in
Ki67 and changes in Cyclins B1/CDK1 and Cyclin A2/CDK2 were observed, demonstrating
the importance of transcriptional regulation of S and G2-M phase Cyclins/CDKs for the anti¬
proliferative effect of neoadjuvant Letrozole.
Changes in the expression of NUSAP1 and Cyclin B1 significantly correlated with clinical
response and Ki67 positivity, especially after two weeks of treatment.
The following factors were found to be significantly associated with breast cancer specific
survival: T-stage at diagnosis; Nodal status at the time of surgery; and Ki67 at diagnosis and
at three months and the corresponding change in Ki67 expression between these time-
points.
Conclusions: The results presented here demonstrate that changes in the expression of
multi-gene transcriptional signatures as well as single genes, can be measured in sequential
tumour biopsies taken from patients during neoadjuvant treatment for breast cancer. The
ability of several signatures and individual genes to predict the clinical response to
neoadjuvant treatment has been compared and evaluated. The difference between the
signatures composed of proliferative and stromal genes highlights the different contributions
of these components to tumour development and response to treatment.
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Breast cancer is by far the most commonly diagnosed cancer in women worldwide. Over
1.38 million new cases are diagnosed globally each year, representing around 23% of all
female cancers and 11% of all cancers regardless of gender[1].
The incidence of breast cancer is highest in Western Europe and lowest in Eastern and
Middle Africa, with a nearly five-fold variation in age-adjusted incidence between various
countries. In the United Kingdom, age standardised incidence and mortality for breast cancer
remains amongst the highest in the world, ranking sixth amongst fellow European Union (EU)
countries, with little variation between Scotland, England, Wales and Northern Ireland 12 4|.
Breast cancer has been the most common malignancy in the UK since 1997, despite its
relatively low incidence in men (<1 % of breast cancers). In 2009 more than 48,400 breast
cancers were detected in women (317 in men), and an average of 133 new cancers were
diagnosed each day. It has been estimated that breast cancer now constitutes over one third
of all female cancers in the UK (Figure 1.1A) and affects 1 in 8 women [3 5 6l.
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Figure 1.1A: The 10 Most Commonly Diagnosed Cancers in Females, Percentages of All
Cancer Cases Excluding Non-Melanoma Skin Cancer, UK, 2009 [3 5).
1
Furthermore, the UK has seen a rise in the age adjusted incidence of breast cancer of almost
70% since the mid 1970's and a 6% rise over the last decade (Figure 1.1B) [3 5|. These
figures are only partly explained by both a heightened public awareness of the disease and
by the introduction of the National Health Service (NHS) breast-screening programme in















Figure 1.1 B: Female Age Standardised Breast Cancer Trends for the UK, 1975-2009 [3 5l
Mammographic screening is presently offered to women between the ages of 50-69 years,
although a trial programme to include those aged 47 to 73 years is currently underway in
England. Not surprisingly therefore, nearly half of all female breast cancer cases are
diagnosed in the screened population and more than 80% are in women aged over 50 [3,5l.
Indeed, there is a strong positive correlation between age and breast cancer incidence, which
doubles every 10 years until the menopause and then slows considerably. A further rise in
incidence occurs beyond the age of 65, dropping between 70-74, and rising again steadily
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Figure 1.1C: Average Number of new cases of Female Breast Cancer in the UK each year
and Age Specific Incidence rates (2007-2009)13 5!.
A subtle downward trend is notable in breast cancer incidence in the over 50 population since
the mid 2000's 15 71. This is likely to be attributable to a decline in the use of hormone
replacement therapy (HRT), a risk factor for breast cancer development, since the late 1990's
[8-14]
1.1.2 Mortality
Each year, breast cancer is responsible for the death of over 458,000 women worldwide.
Europe accounts for around 89,000 of the total annual mortality and the UK, ranking 7th
among its EU counterparts, has around 11,550 deaths 115 ,61. In fact, with an estimated
average daily mortality rate of 32, breast cancer is now second only to lung cancer as a
leading cause of cancer death in British women, representing 15% of all UK female cancer
deaths [1,3]
Female breast cancer mortality is also strongly related to age, with rates increasing steadily
from the age of 30 onwards (Figure 1.1D). In women over the age of 74, a rapid acceleration
in mortality is seen [15'161
3
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Figure 1.1D: Average Number of Deaths per Year and Age Specific Mortality Rates in UK
Females (2008-10)[3).
On a more optimistic note, the overall breast cancer death rates in the UK have fallen by
almost 40% since peaking in the late 1980's, and by as much as 20% over the past decade
(Figure 1.1E)(15'161.
Advances in early diagnosis as well as improvements in early detection and treatment have
no doubt driven this reduction in mortality 117 181. The mortality rates have fallen most
dramatically for women under the age of 70 years. The slower change in mortality rates in
the older group may be explained by the fact that women aged over 71 are not eligible for
screening and are less likely to receive surgery and/or radiotherapy for their cancer and may







Figure 1.1E: Breast Cancer Mortality Rates, UK 1971-2010 '3|
1.1.3 Survival
Conversely, breast cancer survival rates have been improving over the past four decades. In
the 1970's around half of women survived their disease beyond five years, that number has
now risen to more than 80% l22]. Three-quarters of those currently diagnosed will survive
beyond 10 years and two-thirds survive more than 20 years following their original diagnosis
[22]
For most other cancers, survival rates decrease with age whilst in breast cancer, women
diagnosed in their 50's and 60's have consistently higher survival rates than younger or older
women (Figure 1.1F)[23 2A\
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Figure 1.1 F: Five Year Survival by Age in UK Breast Cancer Patients [22].
Clearly, survival rates are generally better the earlier the cancer is diagnosed and treated. It is
estimated that whilst 90% of women diagnosed with early (Stage I) disease will survive
beyond 5 years, this falls to 10% for advanced (stage IV) disease [22\
In terms of socio-economic effect, the chance of survival is significantly higher for women
living in affluent areas compared to their more deprived counterparts. When survival by
cancer stage is compared internationally, Scotland in general and Glasgow in particular, fare
poorly with respect to many other parts of the UK, after adjustment for known prognostic
factors [25].
1.1.4 Risk Factors
The strongest risk factor for breast cancer, after gender, is age [28]. Although an interplay of
both genetic and environmental factors also contribute to the risk of developing the disease,
the incidence patterns amongst migrant populations suggest that environmental factors are of
greater importance [27l In developed countries, it has been estimated that genetic factors
contribute around 25% of the differences in individual susceptibility, whilst environmental and
lifestyle factors contribute the remaining three quarters l28l
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1.1.5 Reproductive Risks Factors
Age at Menarche
An early age at menarche has been consistently associated with an increased risk of breast
cancer and each five-year delay is estimated to reduce this risk by 22% [29!. The average age
of menarche in developed countries has fallen since the mid 19th century by around 4-5 years
[3Dl, largely as a consequence of improved nutrition [31).
Parity
Child bearing reduces the risk of breast cancer, with a higher number of pregnancies
conferring greater protection. Mothers have a 30% lower risk of developing breast cancer
compared to nulliparous women. This equates to a 7% risk reduction for each pregnancy [32~
34]
The risk is also affected by a woman's age at first full term pregnancy. The older a woman is
when she begins childbearing, the higher her risk of developing breast cancer. The relative
risk is thought to increase by 3% for each year of delay, though it is possible that this may
only be applicable to oestrogen receptor positive tumours. The highest risk appears to be for
women who have a first child beyond 35 years of age. These women appear to be at even
higher risk than nulliparous women [32'33].
Breast Feeding
Women who breastfeed reduce their relative risk of developing breast cancer compared to
those who do not, by an order of 4.3% for every 12 months of breast feeding [32].
Age at Menopause
Early menopause decreases the risk of breast cancer. In fact, women who have undergone
the menopause have a lower risk of developing breast cancer than pre-menopausal women
of the same age. This risk is thought to increase by 3% with each year of delay in onset of
the menopause I35!. Women who experience a natural menopause after the age of 55 years




Women who took the synthetic oestrogen, Diethylstilboestrol during pregnancy in the 1940-
60's, to decrease their risk of miscarriage, were exposed to high levels of oestrogen in early
pregnancy and have been shown to have a 27% increase in their risk of breast cancer.
Whilst more commonly used in the USA than the UK, this drug is no longer prescribed [36l
Oral Contraceptives (OC)
The use of the oral contraceptive pill (OCP) is associated with a 25% increase in breast
cancer risk for current and recent users, but with no excess risk ten or more years after
discontinuation I37]. OC users are generally young women whose breast cancer risk is
comparatively low, so this equates to a relatively small increase in cases each year of around
1 %[37].
Hormone Replacement Therapy (HRT)
Women currently using HRT have a 66% increased risk of breast cancer. Again this risk is
temporary, returning to that of a non-user within five years of discontinuation [38] . The risk is
larger for oestrogen-progestogen therapy compared to oestrogen only and larger still for
women with a low BMI [35,38, 39!. Evidence also suggests that breast cancers in women on
HRT tend to be larger and are more likely to be node positive, possibly because HRT renders
mammographic detection more difficult [14]. The use of HRT in recent years has fallen. It is




Higher levels of endogenous hormones have long been hypothesised to increase breast
cancer risk. It would appear that post-menopausal women with particularly high levels of
oestrogen and testosterone are indeed at much greater risk than the normal population t41].
Similarly, high levels of prolactin, insulin and insulin-like growth factor are associated with a
higher incidence of oestrogen receptor positive post-menopausal cancers possibly explaining
the slightly higher relative risk seen in diabetic patients t42"45) The |jnk between these
hormones and pre menopausal cancers is however less clear t46 4^]
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In-Utero Exposure
It has been suggested that in-utero exposure to high levels of oestrogen as may occur with
older mothers who have offspring with high birth weights, may significantly increase the
subsequent risk of breast cancer for the offspring. Conversely, studies suggest that breast
cancer risk may be reduced in the offspring of mothers who suffered from pre-eclampsia or
eclampsia, where maternal oestrogens are often low [48].
1.1.6 Non-Reproductive Risk Factors
A Study published in December 2011 which excluded reproductive factors, estimated that
27% of female breast cancers in the UK are linked to largely modifiable lifestyle and
environmental risk factors [49'.
Lifestyle Factors
Obesity
The correlation between breast cancer risk and body weight is likely to be hormonally driven.
Obesity increases the risk of post-menopausal breast cancer by up to 30% and is one of the
modifiable risk factors for breast cancer. The main source of endogenous oestrogen in post¬
menopausal women is from the peripheral conversion in adipose tissue [501. Studies have
shown that breast cancer incidence is higher if the extra fat is around the waist and if
significant weight is gained between the ages of 20-40 years 1511 . In contrast, obese pre¬
menopausal women have a 20% reduction in risk [51'. In this case, the risk reduction may well
be due to their greater proportion of anovulatory menstrual cycles l52].
Diet
The role of the diet in breast cancer development is controversial and may not be nearly as
important as was initially thought. The strongest evidence suggests that saturated fat intake
significantly increases risk 153 551. Phyto-oestrogens (plant compounds containing oestrogens)
have been studied extensively and implicated in breast cancer development [56,571. Alcohol
intake also appears to increase the risk 158-631
9
Physical Activity
An active lifestyle appears to reduce breast cancer risk, particularly for post-menopausal
women 164 65'. Once again, this is probably due to the effect of exercise on hormone levels,
with a reduction in oestrogen and testosterone seen in women who are more physically active
1661 A significant number of breast cancers in the UK are linked to an indolent lifestyle l67].
Sleep
It is thought that a lack of sleep suppresses the production of melatonin, which has anti-
carcinogenic properties. Sleep deprivation may therefore increase breast cancer risk.
Melatonin also suppresses the production of other hormones with similar anti-carcinogenic
effects168"711.
Medication
Regular use of Aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) is associated
with a risk reduction of up to 25%, possibly due to a lowering of Oestradiol l72~751. Conversely,
the use of anti-hypertensive medication for more than five years is associated with an
increased risk of breast cancer developmentI76'.
Smoking
The evidence linking tobacco smoking to breast cancer is limited [771. The increased risk
reported in the relevant studies was of the order of 10-20% in heavy smokers I78, 79'.
However, the evidence remains inconsistent and inconclusive for both pre and post¬




Ionising radiation is an established risk factor for breast cancer, especially at younger ages of
exposure 180 81). Studies have shown up to 25 fold increases in secondary breast cancer
development in women treated with mantle radiation therapy to the chest for Hodgkin's
lymphoma before the age of 30 i82_85i a much lower relative risk increase of 9% has been
shown in women treated with radiotherapy for a previous breast cancer [86'871. Overall, it is
estimated that around 1% of UK breast cancers in 2010 were linked to radiation. Almost half
of these were linked to medical radiation and the rest attributable to background radiation [88].
Stature
The Million women study confirmed a 17% increase in the risk of breast cancer for every
10cm increase in a woman's height. The underlying mechanism is unclear but it seems likely
that height is a marker for other environmental or lifestyle factors that influence breast cancer
development[89 9Ql. it may also be the case that the hormones that affect a woman's height,
cause an increase in the volume of breast parenchymal tissue, and therefore susceptibility to
breast cancer.
Family History
Approximately 5% of breast cancer cases in Western countries appear to have a strong
genetic or familial predisposition. In general, individuals with a mother, sister or daughter with
breast cancer have an almost two-fold increased risk of developing the disease themselves.
This risk increases with the number of affected first-degree relatives and is higher if the
relative is diagnosed under the age of 50 years [91,92!.
The Breast Cancer Genes
A number of genes may predispose to breast cancer and are usually inherited in an
autosomal dominant manner, with limited penetrance. Thus they can be transmitted through
the maternal or paternal lines and an individual can transmit the gene without him or herself
developing cancer. Inheritance of a predisposing gene may result in breast cancer developing
at a young age, often involving both breasts.
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a) High Risk Genes
There are very few families in whom it is possible to be certain of the dominant inheritance of
a cancer predisposing gene. A small proportion of women have a particularly strong family
history, with four or more affected family members, and are, not surprisingly, at very high risk.
Rare mutations in two well-documented cancer susceptibility genes, BRCA1 and BRCA2,
located on the long arms of chromosomes 17 and 13 respectively, account for a substantial
proportion of these high-risk families l93]. The estimated prevalence of BRCA1 and 2
mutations in the general population is only 0.11% and 0.12% respectively but carriers have a
60-85% chance of developing breast cancer over their lifetime, due to the high penetrance of
the genes [94 951, along with a risk of ovarian cancer.
Mutations of the tumour suppressing genes TP53 (chromosome 17p) and PTEN (phosphate
and tensin homolog), associated with Li Fraumeni (sarcoma, brain malignancy and other
tumours) and Cowden's syndromes (skin lesions and skull abnormalities) respectively, are
also associated with a very small proportion of familial breast cancers [961.
b) Moderate Risk Genes
Intermediate penetrance gene variants that confer a 2-3 fold increase in risk, have been
found in the genes that regulate the identification of DNA damage leading to cell cycle arrest,
DNA repair or apoptosis including CHEK2, ATM (ataxic telangiectasia), BRIP1 and PALB2
genes. These genes are relatively rare, with a population frequency of 0.1-0.2%.
c) Low Risk Common Alleles
Common single nucleotide polymorphisms (SNPs) have now been identified by genome-wide
association studies. Around 20 SNPs with population frequencies of >5% are associated with
increases in the relative risk of breast cancer varying from 1.05-1.24. Other low penetrance
gene variants have yet to be identified [96].
Whilst 85% of breast cancers still occur in women with a negative family history I911, it may be
that hereditary factors still play a part in a proportion of these cases. Testing of genes, other
than BRCA1/2 and, rarely, TP53, has however not been shown to have clinical utility.
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Previous Breast Disease
Women with benign proliferative breast changes without atypia have a two-fold increase in
risk while those with atypical epithelial hyperplasia have four to five times the risk of
developing breast cancer [9?1. On the other hand, women with non-proliferative, benign
pathologies including palpable cysts, complex fibroadenomata, ductal papillomata and
sclerosing adenosis only carry a significantly higher risk if they have a particularly strong
family history of breast cancer I97l
Ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS) and, atypical lobular
hyperplasia (ALH), combined now as lobular intra-epithelial neoplasia (LIN), are non-invasive
conditions of the breast which can progress to invasive disease. Overall, women with LIN are
four to five times more likely to develop an invasive breast cancer compared to the general
population. Whilst it is not possible to predict which women will progress to invasive cancer,
the risk is higher with high grade compared to low-grade in-situ disease [98].
A previous diagnosis of breast cancer also increases the risk of developing a second primary
breast cancer. Whilst reported risk ratios vary, this is of the order of 3-4 fold l"-102!
Breast Density
The breast is composed of fat, connective tissue and epithelium. Breasts with a high epithelial
content are described as dense in comparison with those with a higher fat content. Breast
density is an independent risk factor for breast cancer[103,1041 associated with an almost five
times greater risk of developing the disease [1051.
1.2 Diagnosis
1.2.1 Triple Assessment
In the UK, women may present to a breast clinic with symptoms of disease, or they may be
detected through the NHS breast screening programmes. All patients with a suspicious
breast lesion should undergo triple assessment. This comprises:
(i) Clinical examination of both breasts and the regional lymph nodes in the axilla
and supraclavicular fossae.
(ii) Radiological imaging of the breast by mammography or ultrasound, depending on
the patient's age.




Outwith breast cancer screening programmes, mammography is performed on symptomatic
women over forty years of age. Below this age the normal breast tissues are too radio-dense
and mammography is of limited value and should only be performed if a strong clinical
suspicion of a cancer exists. Two views, oblique and cranio-caudal are obtained to allow
detection of mass lesions, parenchymal distortion and, breast micro-calcifications, which may
warrant further investigation. Cancers usually appear as solid, spiculated lesions on the
radiographs.
Screening mammography is performed every 2-3 years from the age of 50 and has been
shown known to reduce mortality through early diagnosis. In addition, all patients with a
proven cancer should undergo mammography, with or without magnification views and whole
breast ultrasound, prior to treatment to help assess the extent of their disease [1061.
Ultrasound
In women under the age of forty years, breast ultrasonography (US) is the most useful
imaging modality, whilst in older women it is used to further define localised palpable and
mammographically identified lesions. Cancers usually have indistinct outlines on US and are
hypoechoic. Patients with invasive cancer should also undergo axillary ultrasound with
guided biopsy of any suspicious nodes.
Ultrasound is also a useful modality in monitoring variations in tumour size in response to
treatment [106],
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) is not currently in routine clinical use for breast cancer
assessment in part because of its relatively high cost and time taken, although it can provide
the best image detail of any currently available breast imaging technique. MRI sensitivity is
high and it is valuable in demonstrating the extent of invasive and non-invasive breast
disease. It has proven to be a valuable screening tool for selected high-risk women between
the ages of 35 and 50 and is the optimum method for imaging the breast in patients with
implants. It can also be of value in assessing early treatment response !1061
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1.2.3 Breast Biopsy
If clinical examination and/or imaging raise suspicion of a malignancy, a breast biopsy is
required. In cases where there is difficulty due to small or impalpable lesions, image
guidance using mammography or ultrasound scan may increase the accuracy of the biopsy.
Core Needle Biopsy
Core biopsy is generally preferable to FNAC because it provides an architecturally intact
specimen for histological diagnosis and can differentiate between invasive and non-invasive
cancers. Whilst core biopsy samples may take a number of days to process in the laboratory,
a portion of the sample can also be rolled onto microscope slides for immediate cytology to
distinguish benign and malignant lesions. Providing the core biopsy samples the lesion
adequately, this technique is highly sensitive and specific. For this reason core biopsy with
touch or roll cytology has superseded FNAC [1071.
Fine Needle Aspiration Cytology (FNAC)
Needle aspiration can differentiate between solid and cystic lesions and aims to extract
sufficient tissue for cytological analysis, which can quickly differentiate between benign cells
and malignancy.
1.2.4 Accuracy of Investigations
The sensitivity of clinical examination and mammography varies with age. Only two thirds of
cancers in women aged less than 50 years are correctly identified as 'suspicious' or 'definitely
malignant' on clinical examination and mammography alone. In addition, breast cancer in
women under 40 years may fail to present with an identifiable discrete lump. Since FNAC
suffers from a false negative rate of 4-5%, a histological diagnosis, based on core biopsy,
which allows classification of individual cancers is therefore now considered an essential
prerequisite to proceeding with treatment1107 1081. All methods of assessment, whether clinical,
radiological, or pathological, are subject to human errors in sampling, processing and




Breast cancer classifications subdivide the disease in different ways, with different criteria and
for different purposes. Each of these can influence treatment, predict response to treatment
and help define an individual's prognosis as well as providing a standard nomenclature for
use in audit and research.
Classical Descriptions
Current standard classification systems for breast cancers incorporate all of the following:
(i) Histopathological type and grade.
(ii) Oestrogen and progesterone receptors and HER2 status.
(iii) The clinical stage of the cancer.
Molecular Descriptions
The introduction of new molecular tests and gene expression profiling are changing current
understanding of breast cancer biology and as they do so, new classification systems are
likely to evolve which will improve the accuracy of diagnosis as well as improving
prognostication and prediction of the efficacy of treatment. As these systems are not yet in




Breast cancers whose cells remain within the basement membrane of the terminal duct
lobular units and their draining ducts are described as 'in-situ' or 'non-invasive'. An invasive
cancer on the other hand, is one in which the basement membrane has been breached and
there may be dissemination of cancer cells into the surrounding breast tissue and beyond.
Both in situ and invasive cancers have characteristic histopathological appearances by which
they can be recognised and classified on light microscopy I109).
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In situ carcinoma was until recently, classified as ductal or lobular (DCIS and LCIS), each
having differing characteristics.
DCIS is the most common type of non-invasive breast cancer, accounting for approximately 1
in 5 new breast cancers and, whilst not life threatening in itself, does confer an increased
probability of progression towards invasive carcinoma. DCIS can be subdivided histologically
into solid, cribriform, papillary, and micropapillary types of high, intermediate or low grade,
and with the presence or absence of comedo histology. The latter subtype being
characterised by ducts plugged with necrotic cellular debris and exhibiting a tendency
towards higher grade and aggressive behaviour.
DCIS is almost always detected by microcalcifications on screening mammography as it
rarely presents symptomatically as a discrete mass. The natural history of DCIS varies by
grade such that approximately 40-60% of low-grade DCIS lesions will become invasive at 40
years of follow-up. On the other hand, inadequately treated high-grade DCIS has a 50%
chance of becoming invasive within seven years [27,110l
LCIS is considered to be a marker for increased risk of invasive cancer development.
Estimates of this increase suggest a 3-4 times relative risk compared to average women or a
21% risk of developing invasive disease within the 15 years following diagnosis. A lack of
clinical and radiological signs however, means that LCIS is almost always diagnosed as an
incidental finding on biopsy specimens [111].
Invasive breast cancer is also subdivided into ductal and lobular types, based on the now
somewhat outdated belief that these cancers arise from the ducts and lobules respectively. It
is now clear that both invasive ductal (IDC) and lobular cancers (ILC) arise from the terminal
duct lobular unit. Nevertheless this terminology remains in common use and is incorporated
into the 2003 World Health Organisation (WHO) histopathological classification system for
both benign and malignant breast tumours [1121.
Together, the invasive ductal and lobular carcinomas, along with ductal carcinoma in situ
(DCIS) account for approximately three quarters of all breast cancers. The ILC's can be
difficult to diagnose because their pattern of single-file cell infiltration, like that of lobular
carcinoma in situ, does not form a well defined mass lesion that can be readily detected
clinically nor microcalcifications that can be seen radiologically 11091.
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Inflammatory breast cancer (IBC), a form of invasive ductal carcinoma, is distinguished
clinically from other carcinomas by the presence of oedema and erythema in the overlying
skin secondary to dermal lymphatic involvement and is associated with increased cancer
aggression and a particularly poor prognosis [113].
Some tumours show atypical, distinct patterns of growth and cellular morphology and are
sub-classified as 'invasive carcinomas of special type'. This classification has clinical
relevance in that certain special type tumours have a much better prognosis or different
clinical characteristics and behaviour compared with those of no special type [21].
Grade
Grading focuses on the appearance of breast cancer cells with respect to that of normal
breast tissues. Normal cells within the breast are 'differentiated', meaning that they have
specific morphological characteristics that reflect their function as part of the breast as a
whole. Cancers lose their differentiation and cells become disorganised. Control of cellular
division is lost and the cell nuclei become larger and less uniform (nuclear pleomorphism).
Pathologists grade the differentiation of breast tumours by considering glandular formation,
nuclear pleomorphism and the frequency of mitoses. Each of these are scored using the
Nottingham Modification of the Scarff-Bloom-Richardson grading system from 1-3 and their
values are added to produce three overall grades 1114 1151:
Grade 1 cancers (scoring 3-5) are low-grade, well differentiated tumours. These confer the
most favourable prognosis, can be treated less aggressively and have the best survival
rate.
Grade 2 cancers (scoring 6-7) are of intermediate grade and moderately differentiated.
Grade 3 cancers (scoring 8-9) are of high grade. These are poorly differentiated and have
lost many of the features seen in normal breast cells. They appear large and immature,
will divide more rapidly and have a greater tendency to spread, thus conferring the poorest
prognosis.
Among tumours of no special type, the derived grade yields important prognostic information,
guides treatment and is an important predictor of both disease free and overall survival[109].
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1.3.3 Molecular Classification
Cells express proteins on their surface and in their cytoplasm and nuclei that act as receptors
for chemical messengers, such as hormones. The interaction between the receptors and their
ligands cause responses in cellular behaviour. Breast cancer cells variably exhibit many
different types of receptor but presently, three receptors are known to influence both
prognosis and treatment and are therefore included in standard breast cancer classification
systems. These receptors are the oestrogen receptor (ER), the progesterone receptor (PR)
and the Human Epidermal Growth Factor receptor (HER2/neu). Cells with or without these
receptors are labelled with the + or - suffix respectively. For example ER+ or ER-. Cells with
none of these receptors are known as basal-like or triple negative breast cancers (TNBC).
The latter include metaplastic and apocrine cancers.
The receptor status of breast cancers has traditionally been measured by
immunohistochemistry (IHC), for inclusion in the pathologist's report. This laboratory
technique identifies receptors on the cancer cells using labelled antibodies against the ER,
PR and HER2 receptors. A similar technique known as fluorescent in-situ hybridisation
(FISH) is also used to assess HER2 status. Receptor status is critical for all breast cancers
as it determines the appropriate and targeted use of some of the most effective treatments.
Oestrogen Receptor
Approximately 75% of breast cancers express the oestrogen receptor (ER) 11161. ER can be
quantified by using the Allred histochemical scoring system (detailed later). Most ER positive
cancers tend to be ER rich, with an Allred score of 7-8. Most ER positive cancer cells depend
on oestrogen for their growth and are therefore susceptible to drugs that either reduce the
levels of oestrogen, or modify the activity of the receptor. These cancers consequently have
a better prognosis with respect to their ER negative counterparts when appropriately treated.
Progesterone Receptor
Most ER positive cancers also express progesterone receptors (PR), increasing the likelihood
of a favourable response to hormone therapy. Very few PR positive, ER negative cancers
exist. The progesterone receptor is scored in the same way as the oestrogen receptor
through immunohistochemical methods including the Allred score.
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Human Epidermal Growth Factor Receptors
Four human epidermal growth factors exist. These are Epidermal growth factor receptor
(EGFR / HER1), HER2 and the less well known HER3 and HER4. Among these, HER2 is the
only one routinely included in the pathologist's report
Almost one fifth of all breast cancers are HER2 positive and these respond to agents that
target the HER2 receptor. Monoclonal antibodies raised against HER2, prevent HER2
receptor activation and in combination with conventional chemotherapy, improve the
prognosis for these patients [117]. The majority of ER positive tumours however, are HER2
negative.
Targeted treatment options for patients with triple negative breast cancers, which are
relatively common among BRCA1 carriers, are very limited due to the lack of receptor
expression. They therefore carry a comparatively poor prognosis although the introduction of
PARP inhibitors, which prevent DNA repair in cancer cells, is showing great promise. These
tumours respond to cytotoxic chemotherapy in about half of all cases '118!.
Clinical Staging
Once a breast cancer has been diagnosed and histologically classified, the local and distant
extent of the disease should be assessed. This process is known as staging and allows
further classification and stratification of disease extent, which will now be discussed in more
detail.
1.4 Staging
Staging based upon clinical examination and radiological investigations alone is known as
'clinical' staging as distinct from 'pathological' staging, which can only be completed after
biopsy specimens are processed. Since some patients are appropriately treated without
surgical intervention, not all will achieve full pathological staging.
1.4.1 TNM and UICC
Two staging systems are commonly applied to breast cancer and are often used together,
although neither are perfectly suited to the disease. They are promoted by The American
Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) I119i
(Appendix I).
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The Tumour, Node, Metastases (TNM) system depends upon clinical (radiological or
pathological) measurements of the tumour size (T) and clinical assessment of the lymph node
status (N) and the presence or absence of distant (metastatic) disease (M). Although each is
clearly subject to potential errors, the accuracy of the TNM classification can be improved
when the tumour size and nodal status, as assessed by a pathologist, are taken into account.
The International Union against Cancer (UICC) system groups various combinations of the
TNM factors into 'stages'. Stage 0 equates to non-invasive or in-situ disease; Stages 1-3
represent disease confined to the breast and lymph node basins and stage 4 to metastatic
disease.
Patients with small tumours (stage I and II) have a low risk of metastatic disease and require
no further investigations, unless prompted by clinical symptoms and signs. For those with




The most recent 2010 staging scheme incorporates a number of new features:
Tumour - As in previous systems, the T values (TX, TO, Tis, T1, T2, T3 or T4) depend on the
primary cancer size within the breast. TX describes an inability to assess that site; Tis (in situ)
refers to DCIS, LCIS, or Paget's disease, a rare type of cancer involving the nipple areolar
complex that is often associated with deeper tumour within the breast. T4d refers to
inflammatory breast cancer, a clinical variant with skin involvement over at least a third of the
breast.
Node - The lymph node values (NX, NO, N1, N2 or N3) reflect the number, size and location
of cancer deposits in regional lymph node basins, such as the axillae, supraclavicular and
internal mammary lymph nodes. There is an additional sub-classification for NO disease,
which includes NO (i+) for nodes containing Isolated Tumour Cell clusters (ITC), which are
small clusters of fewer than 200 cells, not greater than 0.2 mm in diameter. NO (mol-) nodes
contain no histologically detectable metastases, but have molecular evidence of tumour
deposits, as measured by the polymerase chain reaction (PCR).
21
Metastases - Classically, MO and M1 refer respectively to the absence or presence of
metastases in locations other than the breast and regional lymph nodes, such as bone, brain
and lung. MX formally referred to an incomplete assessment of metastasis but this has been
dropped from the present TNM edition, which introduces one additional category, MO (i+) to
denote the detection of ITCs no larger than 0.2mm in circulating blood, bone marrow or non-
regional nodal tissue but without clinical or radiographic evidence of metastases. M1 also now
includes the detection of any metastasis larger than 0.2 mm. Perhaps surprisingly, MO (i+)
does not affect the cancer staging of the tumour.
1.4.3 Staging the Axilla
Axillary node status is the single most significant prognostic factor in patients with breast
cancer. Both the number of involved nodes and their anatomical level have predictive value
for survival1120). With up to 40% of early invasive breast cancer patients having involvement of
the axillary nodes at the time of diagnosis, the early evaluation of axillary lymph node status is
clearly critical for the accurate staging of patients and to provide a basis for planning
treatment.
Clinical and radiological assessment of lymph node status are however unreliable, whilst
routine US scan followed by FNAC or core biopsy of clinically suspicious nodes, can detect
up to 50% of patients with axillary node involvement[1211. Pre-operative identification of nodal
malignancy allows for prompt and definitive axillary surgery. In many patients however
pathological staging is only complete following surgical sampling of the lymph nodes.
Standard histopathological examination of excised nodes is therefore essential and when
positive, is of greater prognostic significance than metastases only detected using
histochemical techniques.
Lymphatic Drainage of the Breast
Approximately 95% of the lymphatic drainage of the breast passes to the axilla. The
remaining 5% is via the internal mammary and intercostal systems.
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Sentinel Lymph Node Biopsy (SNB)
The principle behind SNB is that lymphatic drainage occurs through a series of nodes in a
sequential manner. Therefore, the status of the first node directly draining the tumour bed
helps predict the status of the remaining nodes in the axilla. Sentinel nodes can be identified
using a combination of radiolabeled colloid that can be visualised on lymphoscintigraphy or
detected by means of a hand-held gamma counter together with the use of a blue dye that
can be detected intra-operatively. Histological assessment of sentinel nodes predicts overall
node status with over 95% accuracy. The false negative rate is less than 5% in experienced
hands and can be reduced further by removing any additional palpable or suspicious nodes at
the time of SNB.
SNB is standard practice for patients with clinically NO tumours, particularly those with
tumours <2cm, in whom the likelihood of nodal involvement is low.
Axillary Node Sampling (ANS)
Several centres use the blue dye alone to identify and biopsy at least four palpable nodes and
claim results equivalent to SNB [1221.
1.4.4 Clinical Terminology
Whilst it does not form part of a separate classification system, breast cancer is often referred
to as either early, locally advanced or advanced depending upon the results of staging
investigations.
Early Breast Cancer
Early breast cancer (EBC) is confined to the breast and to the loco-regional lymph nodes
(Stages l-lll).
Locally Advanced Breast Cancer
Locally advanced breast cancer (LABC) is a heterogeneous and relatively rare form of breast
cancer that is located extensively throughout the breast, the ipsilateral regional lymph node
basin or both. The tumour is usually large (>5cm), although size is not an absolute criterion,
and the characterisation is based upon one or more of the following:
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(i) Skin or chest wall involvement
(ii) Fixed axillary lymph nodes
(iii) Involvement of ipsilateral internal mammary, supraclavicular or infraclavicular nodes
Advanced Breast Cancer
Advanced breast cancer (ABC) is metastatic and has therefore spread beyond the breast and
the regional lymph nodes (Stage IV).
The prognosis and treatment of breast cancer relate to the stage of the disease at
presentation.
1.5 Prognosis in Breast Cancer
A prognostic factor is one that is objectively measureable at the time of diagnosis and can
help to predict clinical outcome, independent of therapy I1231. Ideally, they should have
biological significance, be reliable, easily interpreted and applied. Accordingly, patients are
stratified into low or high-risk groups, which aim to provide a relative, but not absolute,
prediction of the future behaviour of their disease.
Many of the most powerful prognostic factors in current clinical use are reflected in the TNM
staging and other classification systems already discussed. These can be divided into
clinical, histological and molecular factors, which often interrelate with one another.
1.5.1 Clinical Factors
Tumour Size
The size of a cancer, as measured by a pathologist following surgical excision and confirmed
or amended after histological examination, correlates with survival. Patients with smaller
cancers have better survival than those with larger cancers I124l
Node Status
Histologically proven axillary node status is the most powerful prognostic factor in breast
cancer. Survival is correlated directly with the number and level of axillary nodes involved
[125]
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Recent interest has focused on the assessment of small deposits of tumour within axillary
lymph nodes known as micrometastases. The new TNM system uses a pragmatic definition
of a micrometastasis as one measuring between 0.2mm and 2 mm in diameter. The
importance of these is however unclear and such metastatic foci are currently treated in a
similar manner to node negative disease [126].
Metastatic Disease
Patients with metastatic disease, particularly the 10% of patients with metastases at the time
of presentation, have a poorer prognosis than those with apparently localised disease.
Survival differs according to the site of spread such that patients with supraclavicular fossa
disease have a better survival than those with disease at other sites l127]. Similarly, patients
with bony metastases alone, have a better outlook than those with visceral disease [1281.
Survival outcomes for breast cancer according to stage are shown in the Table 1.5A.
These figures are however based on women diagnosed in the early 1990's. The current
outlook for equivalent stage cancers has improved thanks to advances in screening and
treatment[22].
Breast Cancer Stage 5-year Survival 10-year Survival
Stage 1 90% 85%
Stage II 70% 60%
Stage III 50% 40%
Stage IV 13% 10%
Table 1.5A: Breast Cancer Survival According to TNM Stage.
1.5.2 Histological Factors
Histological Type
Special types of invasive breast cancer, including tubular, mucinous and invasive cribriform
cancer, are associated with a better prognosis than invasive ductal cancer of no special type.
Additionally the histological type may also provide information about the biological behaviour
of that cancer and its particular pattern of spread [129i
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Histological Grade
The histological grade (1-3) as assessed by tubule formation, nuclear pleomorphism and
mitotic frequency correlates with survival. Low grade cancers (grade 1) have a better
prognosis than intermediate (grade 2) or high grade (grade 3) tumours 1130].
Lymphatic or Vascular Invasion (LVI)
The presence of cancer cells in the blood or lymphatic vessels and
within a breast biopsy occurs in approximately 25% of cases and
aggressive disease that is associated with both an increase in the
recurrence and short term systemic relapse [131).
Extensive In-Situ Component
If more than 25% of the main tumour mass contains non-invasive disease and there is in-situ
cancer in the surrounding breast tissue, the cancer is classified as having an extensive in-situ
component. Patients with such tumours are considered to be at increased risk of local
recurrence after breast conserving surgery if the margins of excision are not clear11321. If the
surgical margins of excision are clear however, then there is no greater risk of recurrence11321.
LIN and atypical ductal hyperplasia are not markers for increased recurrence I109).
Other Histological Factors
The prognostic significance of peri-tumoural vascular and lymphatic angiogenesis and lymph
node micrometastases is not clear at the present time'1331.
1.5.3 Molecular Biological Factors
A variety of biological factors have also been used in the prognostication of breast cancers
(Table 1.5B).








Table 1.5B: Biological Factors Used For Prognostication11341.
into perineural tissue
is a marker of more
rate of local disease
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ER
ER positivity is associated with a good prognosis Maq whj|st epidermal growth factor receptor
(HER 1) correlates inversely with ER status and is associated with poorer survival t136l
HER2
HER2 has similarly been associated with a worse prognosis in node negative patients'1371
The advent of anti-HER2 therapies has, however, produced marked improvements in survival
[138]
An increased expression of cellular proliferation markers, indicative of uncontrolled growth, is
associated with poor clinical outcomes in breast cancer [1391. Immunohistochemical (IHC)
staining of Ki67, a nuclear antigen that is present only in proliferating cells [1401, has been
shown to be a reliable marker to enumerate the growth fraction of normal and neoplastic cell
populations [141l The Ki67 labelling index, based on the percentage of cells with positive Ki67
staining, correlates with the mitotic index. Ki67 is variably expressed in cells throughout the
cell cycle but not during the resting GO phase and is thus most frequently expressed in poorly
differentiated tumours with high rates of mitotic activity '142]. It is expressed at low levels in
normal breast tissue (<3%) and only in ER negative cells. In cancers however Ki67 is
expressed in ER positive and negative cells and the level of expression increases with the
degree of malignancy from in situ to invasive [143'.
Multiple studies have shown that baseline tumour Ki67 is a prognostic factor for breast cancer
1144 1451 wjth a positive correlation to histological tumour grade and lymph node status [146 147].
In a meta-analysis of 29 studies and over 12,000 patients with early stage breast cancer, Ki67
positivity was associated with a higher probability of relapse and a worse survival I14S|.
Similarly, Stuart-Harris et al. conducted a meta-analysis of 43 studies and over 15000
patients and found a clear correlation between Ki67 and overall survival [1491. These studies
however were all retrospective and lacked internationally standardised methods for antigen
retrieval, staining procedures and scoring. Consequently, there is a lack of confidence in the
clinical use of baseline Ki67 for prognostic assessment '1501. The American Society of Clinical
Oncology does not currently recommend routine use of Ki67 in clinical practice l1511. Many
other biological factors are of uncertain clinical significance (Table 1.5C).
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Biological Markers of Uncertain Clinical Significance
Proliferation markers Ki67









Cell cycle regulatory genes Cyclin A, B, D, E
Overexpression of p21, p27, p53






Tissue inhibitor of matrix metalloproteinase
Oncogenes HER3
HER4
Oestrogen receptor related Progesterone receptor (PR)
pS2
Signal transduction pathways Extracellular signal regulated kinase %
J N-terminal kinase
P38
Allelic imbalance -1 p,7q,8p, 10q, 11 q, 15q, 16q, 17p, 17q
Table 1.5C: Biological Markers of Uncertain Clinical Significance11341.
1.5.4 Prognostic Indices
Many clinical, histological and biological factors that determine prognosis are interrelated.
Some are difficult to determine and many do not have confirmed independent prognostic
value. A number of tools in current clinical use attempt to combine these factors in order to
estimate prognosis and plan treatment effectively.
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The Nottingham Prognostic Index (NPI)
The Nottingham Prognostic Index (NPI) incorporates invasive tumour size, lymph node status
and, histological grade and is calculated using the following equation [152' 1531:
NPI= 0.2 x invasive size (cm) + lymph node stage (score 1 for no nodes, 2 for 1-3
nodes, 3 for > 4 nodes) + grade (score 1 for grade 1, 2 for grade 2, 3 for grade 3)
Originally the NPI was used to divide patients into good, intermediate, or poor prognostic
groups. Subsequent studies have led to a refined NPI with six categories (Table 1.5D) l124].
Nonetheless, its use in clinical practice has declined with the development of more
sophisticated online tools.
Nottingham Prognostic Index (NPI)
Group Index Value Survival at 10 years (%)
Excellent (EPG) 2.0-2.4 96
Good (GPG) 2.41-3.4 93
Moderate 1 (MPG1) 3.41-4.4 82
Moderate 2 (MPG2) 4 41-5.4 75
Poor (PPG) 5.41-6.4 53
Very Poor (VPPG) >6.41 39
Table 1.5D: Breast Cancer Specific Survival According to NPI [124].
1.5.5 Predictive Indices
In contrast to a prognostic factor, a predictive factor is one that provides information on the
likelihood of a favourable response to a particular treatment. Thus, it can be used to identify
subpopulations of patients likely to benefit from any given therapy.
Some prognostic factors are predictive and vice versa. For example in addition to providing
prognostic information, ER status predicts response to hormone treatment t154l Similarly
HER2 positivity predicts response to immunological treatment with Trastuzumab (Herceptin),
Lapatanib and Pertuzumab and HER1 (EGFR) positivity to treatment with Lapatanib,
Pertuzumab and Gefitinib [134'.
With this in mind, a number of attempts have been made to incorporate prognostic and




Adjuvant! online is a frequently updated site that provides information on the probability of
relapse and survival following the input of patient details including age, general health, tumour
size, nodal status, oestrogen receptor status and also HER2. This information is processed
to provide details of recurrence rates and survival with and without adjuvant therapy and the
likely benefits from alternative therapies (www.adiuvantonline.com).
PEPI Score
The Preoperative Endocrine Prognostic Index, though not widely used clinically, is designed
for use in patients who have undergone 3-4 months of treatment with endocrine therapy prior
to surgery. It incorporates information regarding pathological tumour size, lymph node status
and tumour expression of Ki67 in order to predict the long-term outcome for ER positive
breast cancer patients and in particular the likelihood of disease recurrence. Patients with a
score above 4 are thought to benefit from additional treatments following endocrine therapy
and surgery I1551.
ICH-4
Recently, a test combining measurement of ER, PR, HER2 and Ki67 has been described that
can predict low risk of tumour recurrence and may obviate the need for post-operative
chemotherapy in these patients [156].
1.5.6 Future Developments
Microarrays
Tissue microarrays, which will be discussed in detail later, allow the rapid evaluation of the
expression of an enormous number of genes on a single chip. Presently such technology is
being used to investigate the molecular mechanisms of breast cancer development, response
and resistance to treatment.
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These microarray studies have identified clusters of genes whose expression is significantly
up- or down-regulated during treatment. A few of these studies have led to the development
of commercially available molecular testing kits for clinical use, that reflect the pattern or
signatures of gene expression that are thought be prognostic or predictive. Examples include
MammaPrint® (Agendia, Amsterdam) 11571 and Oncofype Dx® (1581, which will be described
later. Ongoing investigations aim to determine whether these will prove to be clinically useful
prediction tools.
Proteomic Methods
Proteomic arrays and mass-spectrography, which examine the expression of known and
novel proteins in tissues from cancer patients, present possible alternative means to detect
'markers' of response to therapy and may be related to prognosis. These are not yet in
routine clinical use however and fall outwith the scope of this thesis.
1.5.7 Outcome Measures
Mortality and Survival
Clinical outcomes are generally defined by mortality and survival rates. These are easily
measured, objective endpoints that can reflect both the beneficial and harmful effects of an
intervention. They are considered to be the gold standard for measuring efficacy in clinical
trials evaluating cancer treatments.
Mortality rates are expressed as the number of deaths in a breast cancer population of a
defined size over a defined period of time. They may be breast cancer specific or include
death from all causes. Survival rates, on the other hand, indicate the proportion of breast
cancer patients still living at a defined time, usually 1, 5 or 10 years following diagnosis.
Secondary Endpoints
Secondary clinical outcomes, also known as 'Interim end points', may help with the prediction
of survival and mortality. Such measures include:
(i) Disease (or Event) free survival (DFS) - the length of time between an intervention
and the moment a patient experiences a recurrence, a new primary cancer or death.
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(ii) Progression-free survival (PFS) - the time from the beginning of an intervention until
a patient shows sign of disease progression. This is also sometimes known as Time
to progression (TTP) - This is typically measured in treatment trials involving
advanced breast cancer or metastatic disease.
(iii) Tumour response rate - a radiographic 'calliper' measurement of the reduction in
tumour size used in the setting of metastatic disease or neoadjuvant therapy.
(iv) Recurrence rate, which may refer to local or regional recurrence of a breast cancer
during or after a treatment at a selected follow up time point.
Clinical trials using secondary endpoints usually require a smaller number of patients and
shorter follow-up than those measuring mortality or survival directly, but do not provide
information on possible long-term effects of an intervention.
1.6 Management Pathways - Local Treatments
Treatment algorithms depend upon breast cancer classification and predictive indicators to
define how specific subgroups should be treated according to the best available evidence.
Most patients benefit from a combination of local treatments (surgery and radiotherapy) to
control disease in the breast and axilla, and systemic treatment to treat potential metastatic
disease. The aim is to achieve long-term local disease control with minimal morbidity.
1.6.1 Surgical Management of the Breast
Surgery is described as breast conserving (BCS) when excision of the tumour with a margin
of surrounding tissue preserves some of the breast volume in distinction to mastectomy. BCS
is always followed with radiotherapy.
At least 12 randomised trials have compared morbidity and mortality in mastectomy versus
BCS and shown a non-significant reduction in mortality with BCS. Local recurrence rates are
similar albeit with a non-significant but reduced incidence after mastectomy. Two large
randomised trials have shown no significant differences in survival after 20 years of follow up
[159, 160]
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Selection for BCS or Mastectomy
Patients deemed suitable for BCS are those with:
(i) Tumours staged as T1 or T2 < 4cm, without nodal disease or metastatic spread.
(ii) Tumours > 4cm in a large breast.
Patients not suitable for BCS will be offered mastectomy. Others may choose to have a full
mastectomy when BCS could be offered, because of personal preference or in some cases
where BCS would produce an unacceptable cosmetic result. Other indications for
mastectomy include those with multifocal or multi-centric operable breast cancer, patients
unsuitable for radiotherapy and those with a strong family history of breast cancer including
BRCA1 or 2 carriers.
Finally, some consideration of various clinico-pathological features of the patient or their
tumour may further influence the decision on breast conservation.
Breast Conserving Surgery
Breast conserving surgery aims to excise the entire tumour and any surrounding DCIS with a
1 cm margin of macroscopically normal tissue (wide local excision or WLE). This is combined
with removal of the sentinel node or all of the axillary nodes. Impalpable lesions can be
localised pre-operatively by several techniques such as the radiologically guided placement of
a hook wire.
Up to 10% of the breast volume can be removed without significant deformity whilst adequate
excision of lesions over 4 cm is generally associated with poor cosmesis. Extensive excisions
of larger tumours by quadrantectomy were performed in the past, but these are no longer
favoured as they do not significantly lower local recurrence rates and are associated with
poor cosmetic outcomes [1611. For this reason, most breast units offering BCS tend to limit it to
lesions less than 4 cm. An exception may be made in large breasted women in whom larger
tumours may be excised with acceptable cosmetic results [120,132l
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Where tumours are too large for routine BCS, consideration should be given to either
neoadjuvant medical treatment designed to shrink the tumour pre-operatively or to
oncoplastic surgery. The latter, also known as 'therapeutic mammoplasty' incorporates
tumour excision with breast reduction and re-shaping, usually necessitating a symmetrising
reduction mammaplasty on the contralateral breast. Alternatively, breast volume after tumour
excision can be replaced using a pedicled Latissimus dorsi flap reconstruction. These
procedures are associated with less psychological morbidity than that following mastectomy
[162]
Complete excision of all invasive and in-situ disease is of course essential and intra-operative
imaging of the specimen helps to confirm this. A negative margin of 1-2mm is considered
adequate I132]. Wider margins do not reduce local recurrence further but may adversely affect
cosmesis. Approximately 20-25% of cancers are incompletely excised at initial surgery.
Whilst re-excision of a single positive margin usually results in complete excision, the greater
the number of margins involved the less the likelihood of clearance and the greater the
chance of recurrence. Other risk factors for local recurrence include younger age, high-grade
tumours and the presence of lymphovascular invasion. Such patients may be advised to
proceed to mastectomy. On the other hand, the presence of atypical ductal hyperplasia or LIN
at the margins does not necessitate re-excision 1132 163_1651.
BCS is possible in multifocal cancers provided that all disease is excised.
BCS Following Neoadjuvant Therapy
Large breast cancers, initially unsuitable for BCS can be downsized with neoadjuvant
chemotherapy or endocrine therapy to enable breast conservation. Rates of subsequent
complete excision are higher with endocrine therapy, which reduces tumour volume in
general more effectively than chemotherapy, which has a tendency to reduce cellularity rather
than volume [166"1691.
Mastectomy
About one third of patients with localised breast cancers are unsuitable for BCS and require
or elect for a mastectomy, often including some overlying skin and the nipple-areolar
complex. Increasingly however, both skin and nipple sparing mastectomies are performed in
conjunction with immediate breast reconstruction to achieve optimal aesthetic results '120162.
170, 171]
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Down-Staging of Locally Advanced Cancers by Neoadjuvant Therapy
Locally advanced breast cancer was traditionally treated with mastectomy, where possible,
but this was associated with a high rate of both local and distant recurrence and was almost
never curative. The current approach is to attempt to downstage the primary tumour using
chemotherapy or endocrine therapy and thereafter to perform surgery to gain local control of
the disease I172].
1.6.2 Surgical Management of The Axilla
Breast conserving surgery and mastectomy for early stage invasive breast cancer, need to be
combined with an axillary procedure either for staging or treatment purposes.
SNB or Axillary Dissection
Before the introduction of SNB, axillary node dissection (AND, levels 1-2) or clearance (ANC,
levels 1-3), was standard practice. The morbidity of such procedures is unacceptably high for
node negative disease, which is better assessed with SNB. Where the sentinel nodes are not
involved, no further treatment is required to the axilla. Extensive axillary dissection should
now be limited to patients with either cytological or histological evidence of axillary node
involvement or to those who are highly likely to have involved nodes. Trials comparing SNB
with AND have shown that the former is associated with less morbidity and shortens hospital
stay 11731
Controversy currently surrounds the optimal management of the axilla in patients with only
one or two positive axillary nodes at SNB, who are also receiving systemic treatment and
whole breast radiotherapy. To date, the evidence from randomised trials suggests that local
recurrence and survival rates are similar, regardless of whether or not completion
lymphadenectomy or axillary radiotherapy were undertaken I174l These results could be set
to change current management for this group of patients.
Studies are ongoing to ascertain the need for axillary therapy where only isolated micro
metastases are present in the SNB [175 176i a conservative approach has been advocated for
some patients with low risk invasive cancers but, until the results from studies are available,
some form of axillary surgery should be considered.
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Treatment of Axillary Disease
In biopsy proven axillary disease, then either completion axillary node dissection or
radiotherapy is recommended. Both are effective and associated with similar survival rates.
Surgical dissection offers a lower rate of axillary recurrence but the morbidity of the procedure
is high. Radiotherapy as a treatment modality can only be used once [177].
1.6.3 Radiotherapy
Radiotherapy uses ionizing radiation to control or kill malignant cells. In breast cancer
patients, it may be prescribed:
(i) Before surgery to reduce tumour size.
(ii) During or after surgery to reduce the chance of local disease recurrence and improve
survival.
(iii) As an alternative to surgery for palliative care and pain control.
Targeted radiation damages the DNA of exposed tissue leading to cellular death. Cancer
cells are more susceptible than normal surrounding tissues due to their higher mitotic rate.
The radiation field can be shaped and applied from several different directions, all intersecting
at the tumour site, to increase the exposure of the tumour whilst minimising that of
surrounding healthy tissue.
The draining lymph node basins may also be targeted if they are clinically or radiologically
involved with tumour, or if there is thought to be a risk of sub-clinical malignant spread.
The aims of radiotherapy in an individual will vary depending upon the tumour type, location,
and stage, as well as the general health of the patient.
Radiotherapy is most commonly delivered as external beam radiotherapy but brachytherapy,
in which a radiation source is placed inside the breast or next to the tumour bed, is
sometimes used and minimises exposure to healthy tissue. Modern techniques provide more
scope for partial breast irradiation, with greater field and marginal dose control.
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Radiotherapy Following BCS
All patients should receive radiotherapy following BCS to reduce the rate of local recurrence
and improve survival [1781 t179"182] a n0Vel approach known as accelerated partial breast
irradiation (APBI) is used to deliver radiation as part of breast conservation therapy. It limits
treatment to the tumour bed and adjacent tissue, whilst reducing the duration of treatment to
just five days, compared to the typical six or seven weeks for whole breast irradiation. Its use
is usually limited to women with well-defined tumours that have not spread. A study by the
National Surgical Breast and Bowel Project (NSABP) is underway to determine whether
limiting the radiation field in this way is as effective as irradiating the whole breast[183'.
Radiotherapy Following Mastectomy
Post-mastectomy radiotherapy (PMRT) is more common than was the case 10 years ago I184).
Patients with a high risk of local recurrence benefit from treatment of the chest wall, as do
women with pectoral muscle involvement. PMRT results in a three fold reduction in local
recurrence at 15 years, with the most significant difference in the first five years [179]. The
effect of PMRT on mortality is variable, with 1% improvement in mortality in EBC and a 2-4 %
reduction in higher risk groups. [1791. At present there is no consensus opinion on which
lower-risk patients might benefit from PMRT. The ongoing SUPREMO trial aims to address
this (www.supremo-trial.com).
Radiotherapy for LABC
Radiotherapy plays an important role in the treatment of LABC with the aim of reducing the
risk of local recurrence following surgery, or to achieve local control where the primary tumour
is inoperable despite attempts to downstage it using medical treatments 11721 [185].
Radiotherapy Following Axillary Surgery
The American Society of Clinical Oncology suggests that routine post-operative axillary
radiotherapy is not necessary after complete level l/ll axillary dissection and may add to
morbidity '1861. However, the supraclavicular field should be irradiated in all patients with four
or more positive axillary nodes as this confers a survival benefit. The evidence regarding the
treatment of the internal mammary node chain (IMN) with radiotherapy is unclear but on
balance, the risks probably outweigh the benefits [178l
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Timing of Radiotherapy
The optimal timing of post-operative radiotherapy has not been established. It is usual for trial
eligibility criteria that radiotherapy is received within 12 weeks of surgery unless receiving
chemotherapy. In Scotland, the stated target is that 95% of patients receive radiotherapy
within four weeks of BCS or final dose of chemotherapy 1187 188). There is insufficient evidence
to recommend the ideal sequencing of PMRT and systemic therapy.
1.7 Management Pathways - Systemic Treatments
More than half of patients with operable breast cancer, who undergo loco-regional treatment
alone, will die from metastatic disease. Systemic therapy improves survival of these patients,
suggesting that micro-metastases are present at diagnosis. Systemic treatment can be
classified as chemotherapy, endocrine or targeted therapy. It may be delivered before or
after loco-regional treatment. Both chemotherapy and targeted therapy will be discussed in
brief in this chapter. Endocrine therapy will form the focus of discussion in subsequent
chapters.
1.7.1 Chemotherapy
Traditional chemotherapeutic agents specifically target cells undergoing mitosis, thereby
preferentially affecting rapidly dividing cancer cells. Some drugs cause cells to undergo
apoptosis (programmed cell death). By its very nature however, chemotherapy also harms
normal cells undergoing mitosis - with the bone marrow, digestive tract, and hair follicles
being especially susceptible, resulting in the most common side-effects of chemotherapy:
myelosuppression, mucositis and alopecia.
The benefits of chemotherapy depend largely on the biological subtype of the tumour and are
greatest in women with ER negative, HER2 positive disease and in younger women.
Adjuvant chemotherapy is widely used in the over 50's, but its efficacy appears to reduce with
increasing age and as yet there is no clear evidence of benefit in women over 70 years l178,
1891. All women under the age of 70 years with early breast cancer should be considered for
adjuvant chemotherapy I1781.
In contrast, there is little evidence to suggest chemotherapy is of additional benefit to many
women with ER positive, HER2 negative disease, already taking endocrine therapy. This is
particularly true for grade I and II tumours.
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Some of the newer therapeutic agents, for example monoclonal antibodies, are not
indiscriminately cytotoxic, but rather target proteins that are abnormally expressed in cancer
cells and that are essential for their growth. Such treatments are often referred to as targeted
therapy, as distinct from classic chemotherapy, and are often used alongside traditional
chemotherapeutic agents in treatment regimens.
Adjuvant Chemotherapy in EBC
The ability of adjuvant chemotherapy to reduce recurrence and improve survival from breast
cancer has been established by a series of meta-analyses of many clinical trials l189l Whilst it
was once believed that the benefits of chemotherapy were age related, and greatest in young
women, it is now clear that other biological factors have a strong influence. For example,
chemotherapy is known to be most effective against ER negative and/or HER2 positive
disease. Whilst these subtypes are more prevalent in young women, it does not however
preclude older women with such disease receiving appropriate treatment.
The decision to offer chemotherapy is based upon a risk benefit analysis and on the basis of
the patient's age and tumour characteristics as well as the type of therapy being considered.
The absolute benefit of chemotherapy appears to increase with an higher number of adverse
prognostic factors, including: Tumour size >2cm; Nodal involvement; Oestrogen and
progesterone receptor negativity; HER2 positivity; High grade (grade III); the presence of LVI
and younger age (<35 years). Risk/benefit considerations are important because of the
potential toxicity of these agents and so, consensus criteria have been defined to aid in
patient selection ['90'.
Chemotherapy does not appear to offer an advantage over endocrine therapy alone in
postmenopausal women with grade I or II, ER rich, HER2 negative breast cancer. However,
a key challenge is to identify a subset amongst this large subgroup in which it may confer




Whilst there is no single gold standard chemotherapy regimen in early breast cancer, an
increasing body of evidence suggests that combinations of Anthracycline with Doxorubicin or
Epirubicin achieve a significant survival advantage of 4-5% over traditional non-anthracycline
regimens containing Cyclophosphamide, Methotrexate and Fluorouracil (CMF) [178,189,191]. In
the UK, a sequential combination of Anthracyclines followed by CMF is widely used and, is
superior to CMF alone l192l The Anthracyclines are however more toxic, with higher rates of
myelodysplasia and neutropenic sepsis. They are also associated with a modest risk of
cardiac impairment [1911. Short duration regimes combining 5FU, Epirubicin and
Cyclophosphamide (FEC) provide similar benefits to the longer sequential regimen 11931.
The addition of Taxanes (Docetaxel or Taxotere), to the Anthracyclines has further improved
survival in node positive disease, especially in women with ER negative and or FIER2 positive
tumours 1194]. Again, these can be used sequentially or in combination (195'. With new
treatment regimens, five-year survival in node positive women has risen from 65% to over
85%. Currently, there is no evidence to demonstrate a benefit of the Taxanes in node
negative disease.
A frequently used regimen in the UK for high-risk node positive patients is the FEC-T
combination, which involves 3 cycles of FEC (or Anthracycline) followed by 3 of Docetaxel.
This has shown a 27% reduction in the relative risk of death in patients with a high tumour
Ki67 11961
Dose Density
There is no clear consensus on how individual chemotherapy drugs should be sequenced.
Drugs are often combined and there is some evidence to suggest that block sequential
therapy may be better[197].
Dose density therapy intensifies the chemotherapy regimen by reducing the inter-treatment
interval to two instead of three weeks and this may improve disease free survival[1981. Finding
the minimum duration for effective treatment is an important challenge.
To counter the negative effect of chemotherapy on white blood cell production, granulocyte
colony-stimulating factor (G-CSF) is administered to stimulate the production of new white
blood cells. This has been shown to reduce, though not completely prevent, the rate of
infection and low white cell count. Most adjuvant breast cancer chemotherapy regimens do
not routinely require growth factor support except for those associated with a high incidence
of bone marrow suppression and infection.
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Neoadjuvant Chemotherapy in EBC
Neoadjuvant treatment was initially given to patients with locally advanced, inoperable breast
cancers but its use has been extended to patients with early, operable breast cancer to
reduce the size of the tumour and the need for mastectomy and to allow for breast conserving
surgery11"1. Neoadjuvant therapy may also potentially treat occult micro-metastatic disease.
The clinical radiological and pathological response of the tumour can be assessed over time -
a quality that is useful in a research setting as it may lead to the identification of short-term
surrogate markers indicative of long-term disease outcomes.
Neoadjuvant chemotherapy achieves clinical regression of tumours in 70-80% of patients,
suggesting that early breast cancers are more chemo-sensitive than metastatic disease.
Complete pathological response, which equates to disappearance of the tumour from the
breast, is seen in up to 20% of patients, particularly in oestrogen receptor negative patients in
whom it is a predictor of better long-term outcome [2001. Nodal disease is cleared in
approximately 35% of patients overall, but may be as high as 50% in those with TNBC and
less than 10% in those with ER positive disease. The addition of Trastuzumab may lead to
clearance in up to 70% of HER2-positive patients [201].
Trials have shown equivalence in survival between neoadjuvant and adjuvant regimens using
similar agents [2021. There may however be an improvement in long-term outcome with
neoadjuvant therapy [2031, though this may not be the case for patients also treated with
radiotherapy but not surgery !2021.
Neoadjuvant Regimens
Neoadjuvant chemotherapy regimens are generally the same as those used in the adjuvant
setting. There is some evidence to suggest that the type of chemotherapy given may affect
the number of complete pathological responses seen, although the difference between
regimens is not always apparent[204,205].
Progressive disease, in which the tumour continues to enlarge despite treatment, is a rare
phenomenon during neoadjuvant chemotherapy and is an indication for second line




Chemotherapy prior to loco-regional treatment is standard management in LABC, with the
exception of older patients with ER+ disease, where endocrine therapy may be more
appropriate. Most trials in this disease setting have however been of relatively poor quality.
Anthracycline based schedules are the mainstay of treatment but Taxanes are increasingly
used subsequently |172! and should be considered in patients with advanced disease including
intractable residual chest wall disease [2071 as should Capecitabine or Vinorelbine [208 2091.
High rates of clinical response and complete pathological response have been noted with the
addition of cyclophosphamide to Adriamycin and Docetaxel in some studies I210].
Chemotherapy for Metastatic Disease
In the presence of metastases, a balance must be achieved between the beneficial response
and the side effects. Both survival and palliation are improved by active regimens. Response
rates of up to 60% have been achieved, with a median time to relapse of six to ten months.
The regimens used are similar to those in both the neoadjuvant and adjuvant settings.
Epirubicin is often preferred to other Anthracyclines because it has less cardiac toxicity [211).
1.7.2 Biological Therapies
Adjuvant Trastuzumab (Herceptin)
The transmembrane growth factor receptor HER2/neu (also known as c-erbB-2) is expressed
in around 20% of breast cancers and is associated with more aggressive disease and a poor
prognosis. Trastuzumab (Herceptin) is a monoclonal antibody against the external domain of
the receptor, with clinical effect against tumours expressing HER2 I212]. Trials have shown
that it reduces recurrence and improves disease free survival by 50% in patients with early
breast cancer when given after or during chemotherapy [213"21S| There is possible survival
benefit to concurrent treatmentt217].
The only significant side effect appears to be the risk of cardiac dysfunction in a small number
of cases (<2%). This may be related to concomitant treatment with the Anthracyclines and so,
the two are never given together. Cardiac function is monitored through treatment.
Importantly, Trastuzumab has also been shown to improve survival in patients with metastatic
disease when given in combination with the Taxanes and achieves higher rates of tumour
regression with other agents such as Vinorelbine [218].
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Duration of Treatment
The optimal duration of adjuvant treatment with Trastuzumab is uncertain. Most major trials
have incorporated one year, but this is on an empirical basis and by analogy with endocrine
therapy. A number of trials currently aim to compare this regimen with shorter treatment
periods and recent data suggest that two years treatment is no better than one [219'.
Neoadjuvant Trastuzumab (Herceptin)
A combination of Trastuzumab and chemotherapy given neoadjuvantly, achieves superior
response rates compared to chemotherapy alone, with improvements in pathological
complete response of 40-50% and should now be considered standard care for HER2-
positive patients. Again, there are no clear indications to date as to the optimal duration of
therapy [2181.
Other Anti-HER2 Therapies
Lapatinib, given orally, is an anti-HER2 drug that acts as a tyrosine kinase inhibitor, stopping
phosphorylation and thus activation of HER2. Its role in EBC instead of, or in combination
with Trastuzumab, is currently being investigated (www.alttotrials.com). It is occasionally
used in patients with metastatic disease who have relapsed on Trastuzumab. Its main toxic
side effect is diarrhoea.
Pertuzumab is a human monoclonal antibody with affinity for the HER 1, 2 and 3 receptors. It
has been shown to work best when given in combination with Trastuzumab without increasing
toxicity 12201 . The use of Lapatinib and Pertuzumab in the neoadjuvant setting in HER2
positive disease, may significantly improve pathological tumour response I2201. The long-term
survival outcomes from adjuvant trials are still awaited.
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Breast Cancer Endocrinology
1.8 Endocrine Dependence and the Breast
This thesis specifically relates to endocrine therapy in post-menopausal women, which will be
the subject of the remainder of the introduction.
The relationship between oestrogen and the breast is fundamental to understanding
endocrine therapy in breast cancer. Oestrogens have been implicated in the development of
breast cancer since their discovery in the 1920s, though Beatson employed oophorectomy to
induce regression of breast cancers in the 19th century [221]. A considerable body of
knowledge and evidence now exists regarding the role of oestrogen in human breast
development and tumourigenesis [116222I
1.8.1 Breast Development and Tumourigenesis
The breast begins to develop in early puberty when primitive ductal structures enlarge and
branch. After menarche, branching of the ductal system becomes more complex and lobular
structures form at the ends of the terminal ducts to produce terminal duct lobular units
(TDLUs). These become increasingly complex with successive menstrual cycles. During
early pregnancy, a further burst of activity takes place during which the ductal trees expand
further and the number of ductules within the TDLUs greatly increases. These ductules
differentiate to synthesise and secrete milk during late pregnancy and subsequent lactation
[223]
A continuous layer of luminal epithelial cells lines the breast ducts. A layer of myoepithelial
cells and then a basement membrane, in turn, surrounds these. The TDLU system as a
whole is then surrounded by delimiting fibroblasts and embedded in a specialised intralobular
stroma.
Histological studies have shown that most breast tumours appear to be derived from the
TDLUs and, have morphological characteristics in keeping with luminal epithelial cells.
Moreover, the majority of human breast cancers retain the biochemical features of luminal
cells [224> including receptors for oestrogen and progesterone that, in the normal breast, are
expressed only in the luminal epithelial compartment [222]. Luminal epithelial cells must
therefore be regarded as the primary source of malignant transformation and subsequent
tumour formation.
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The process of breast tumourigenesis is thought to result from the accumulation of multiple
genetic changes corresponding clinically to the evolution from normal breast epithelium
through benign proliferative lesions, atypical proliferative lesions, carcinoma in situ and finally,
invasive tumours I225'. Although the exact mechanism by which this occurs remains unclear,
both oestrogen and the oestrogen receptor are implicated in this process.
In the absence of normal ovarian function, there is complete failure of breast development,
such that oestradiol replacement therapy is necessary to induce breast development [226].
Furthermore excess exposure to oestrogen due to early menarche, late menopause or a late
first pregnancy, increases breast cancer risk, as does the exogenous use of hormones [22?1.
The obligate role of oestrogen has also been demonstrated in mice studies where the gene
coding for the ER protein has been rendered non functional [228]. The mammary glands in
these ER 'knock-out' mice fail to develop, even with exogenous oestrogen treatment, and are
resistant to malignant transformation following transduction with oncogenes (genes that
promote cell transformation).
Whilst there is far less evidence for the role of progesterone in human breast development,
studies on PR knock-out mice suggest that whilst oestrogen stimulates ductal elongation and
PR expression, progesterone may stimulate lobulo-alveolar development[229]. Human studies
in this area are limited due to practical difficulties of studying breast development at a young
age, it is nonetheless assumed that progesterone plays a similar role in human breast
development as well as stimulating TDLU formation and expansion during puberty and
pregnancy. With respect to tumourigenesis, there are data to suggest that progestagens,
taken in the form of HRT increase the risk of post-menopausal breast cancer to a greater
extent than the use of oestrogen only HRT l39<23°l
1.8.2 Oestrogen Production
The Oestrogens are a family of related steroid hormones that stimulate the development and
maintenance of female secondary sexual characteristics and reproduction. They occur as the
end products of a sequence of steroid transformations I2311. The most prevalent forms of
circulating oestrogen are Oestradiol and Oestrone (the highest levels in the circulation are of
oestrone sulphate) but their primary site of production differs according to menopausal status.
In pre-menopausal women, the ovaries are the primary source of oestrogen production, with
smaller amounts produced by the adrenal cortex and other organs. In postmenopausal
women however, with declining ovarian function, oestrogen production occurs predominantly
by the peripheral conversion of ovarian and adrenal androgens to oestrogen in peripheral fat,
muscle and bone as well as within breast tumours I232]. This conversion is a function of the
aromatase enzyme, a product of the CYP-19 gene on chromosome 15.
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1.8.3 The Oestrogen and Progesterone Receptors
Regardless of their source, most of the major effects of the steroid hormones on the breast
are mediated by their respective protein receptors, which function as transcription factors
within cell nuclei to activate oestrogen dependent genes Transcription and translation
constitute the two crucial steps by which functional proteins are made within cells from their
encoding genes. Transcription is the process whereby messenger RNA (mRNA) is produced
from DNA in the cell nucleus, by the action of the enzyme RNA polymerase. The mRNA
migrates to the cell's cytoplasm where a process of translation by ribosomes, converts it into
functional proteins. A transcription factor is a protein that binds to specific DNA sequences by
means of one or more DNA-binding domains (DBDs), to promote or inhibit DNA transcription
of the genes that they regulate.
Two forms of oestrogen receptor (ERa and ER(3) have been recognised and are implicated in
breast development and the pathogenesis of breast cancer. The ESR 1 and ESR 2 genes on
chromosome 6 and 14 encode these respectively. Both receptors have a modular structure
which typifies the steroid receptor family and which includes domains that mediate binding to
ligands (steroids) and to intracellular DNA and are therefore known as ligand dependent
nuclear transcription factors [233] . There are six functional domains, designated A-F (Figure
1.8A). The Amino-terminal domain, AF1, exhibits hormone independent activation function
and shows the highest variability among all steroid receptors [234 235]. The middle or C domain
is the DNA binding domain (DBD) 12361, whilst the adjacent D domain or 'hinge region', is
implicated in co-regulatory protein binding. The carboxy-terminal domains E and F contain the
ligand (steroid) binding domain (LBD). This region is also implicated in modulating the
agonist activity of anti-oestrogens to be discussed later and binding to further co-regulator
proteins [237].
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Figure 1.8A: Functional Domains of the Oestrogen Receptor
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Whilst both receptor types are homologous in their binding domains, the ER(3 gene is smaller
and encodes a shorter protein I234'238'. it is likely that ERa is the key mediator of oestrogen in
the normal mammary gland and that ER£ mediates some of the non-classical effects of the
oestrogens and may negatively modulate the activity of ERa but its activity has yet to be
further defined [2391.
Progesterone also has two receptors, PRA and PRB These are again members of the
steroid hormone receptor family but both are transcribed from the same gene Whilst PRB is
longer in its amino acid sequence, the two are otherwise identical12401. it appears that PRB is
the major activator of gene transcription and that PRA is a repressor of PRB activity, however
it is possible that both mediate differing gene transcription 12221.
1.8.4 The Biology of Oestrogen Receptor Signalling
The steroid hormones are lipophilic and they enter cells primarily by diffusing through the
plasma and nuclear membranes. Once in the cell they bind their respective receptors with
high affinity and specificity. In the absence of this highly specific binding, the receptors are
inactive and exist in a monomeric form bound to heat shock proteins such that they exert no
influence on a cell's DNA expression. On binding oestrogen however the oestrogen receptor
dissociates from the heat shock protein and undergoes a process of homo-dimerisation and
protein phosphorylation on a number of specific residues. This leads to a conformational
change in the shape of the AF2 region. Consequently, ER dimers translocate to the nucleus
and bind to specific DNA sites, known as oestrogen response elements (EREs). These
consist of palindromic nucleotide sequences and they lie upstream of oestrogen responsive
genes. The ER dimers simultaneously associate themselves with receptor co-activator
proteins and together these associations are responsible for the activation of a large number
of oestrogen dependent genes, the transcription of their messenger RNA (mRNA) and the
subsequent translation of this mRNA into proteins which invariably impact on the properties of






Figure 1.8B: Classical Oestrogen Signalling Pathway.
Since the now widely accepted description of this classical oestrogen signalling pathway',
additional pathways have been described (Figure 1.8C). Firstly, it has been suggested that
some oestrogen receptors may be located on the cell membrane; upon binding with
oestrogen these can activate an intracellular signal transduction chain ending at two further
transcription factors, jun and fos, which are capable of recognising alternative receptor
binding sites and which may perpetuate cell proliferation signalling. Secondly and most
recently it has been suggested that oestrogen receptors within the plasma membrane may
interact with growth factor receptor signalling, leading to activation of the ERK1/2 gene and
thus influencing the nearby activity of dividing cells via protein kinase signalling pathways.
Interestingly in cell lines it has been noted that the growth factors TGFa and IGF1 are
incapable of promoting proliferation in the absence of oestrogen, so clearly these
mechanisms are complex and cross talk between various signalling pathways may occur[2411.
Whilst not experimentally proven, the consensus supports the idea that oestrogens act via
one or more of these pathways to trigger uncontrolled cell growth and proliferation by
regulating the expression of key oestrogen dependent cell cycle genes. In doing so they
either directly or indirectly promote the replication of defective cells or, increase the likelihood
of spontaneous mutations and their replication, with resultant tumourigenesis. They may
even promote invasion and metastases through the production of proteases that degrade the
extracellular matrix. These along with other issues have yet to be elucidated and will be
discussed further in a later section.
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Cell Survival
Figure 1.8C: Alternative Oestrogen Signalling Pathways.
1.8.5 Quantification of ER
Measurement of ER status is generally made by immunohistochemistry (IHC) using one of a
number of monoclonal antibodies. Its interpretation and scoring however remains
contentious, with a variety of scoring systems and end-points used. This must be taken into
account when considering the evidence base for treatment protocols. There are data to
indicate that ER expression in as few as 1% of cells of a particular tumour may have
consequences for clinical outcome and that this should therefore be the threshold set for
positivity [1541. Modern ER analysis however suggests that there is generally a bimodal
distribution of ER values in which almost all tumours are found to be either strongly ER
positive or negative, with only a small proportion showing intermediate values 12421
The most commonly applied system in UK practice is the Allred scoring system. This reflects
the percentage of tumour cell nuclei staining positively and the intensity of staining:
0 = No staining 0 = No staining
1 = Staining in <1% of cells 1 = Weak
2 = 1 to 10% 2 = Intermediate
3 =10 to 33% 3 = Strong
4 = 33 to 67%
5 = 67% to 100% Total Score = 0,2-8
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Alternatively, the Histoscore multiplies the intensity of staining (absent = 0, weak = 1,
moderate = 2, strong = 3) by the percentage of positively staining cells to give a total score of
up to 300. Tumours with an Allred score of 6-8 are considered to show strong ER positivity
and those with a score of 2-5 are weakly positive.
1.9 Endocrine Therapy
The dependence of many breast cancers on oestrogen for their development and continued
growth, has naturally led to a range of therapeutic interventions that aim to reduce tumour
growth either by reducing oestrogen production or by antagonism of its action at the
oestrogen receptor l243'. Virtually all breast cancers that respond to endocrine treatment
express significant levels of ERa. However, the expression of ER is age dependent: whilst
only 60% of patients under 35 years of age will show ER positivity, 80% of women diagnosed
over 65 years have ER positive disease 12411 Indeed, the mechanistic approach by which
oestrogen deprivation therapies are applied depends largely on the primary site of oestrogen
production and thus on the age and menopausal status of the patient.
1.9.1 Limiting Oestrogen Production
Ovarian Suppression
In premenopausal women, the ovaries are the primary source of oestrogen production.
Bilateral oophorectomy was first performed by Glasgow Surgeon George Beatson over one
hundred years ago and is still an option for reducing oestrogen production in premenopausal
women. Whilst effective and technically simple, this procedure is however irreversible and is
therefore reserved for a select few [244]. The same is true of the less effective and more risky
alternative of ovarian ablation by radiotherapy [245 246]. These have now largely been
superceded by gonadotropin releasing hormone agonists (GnRH agonists), which produce an
effective and reversible medical oophorectomy and currently provide the only available
method of reversible ovarian suppression l247].
Several GnRH agonists have been developed including Goserelin, Buserelin, Leuprorelin and
Triptorelin. Whilst no direct comparative studies have been published, all show efficacy as
mono-therapy in advanced breast cancer [247 248l. Goserelin (Zoladex) is the drug of choice
currently recommended by the FDA for ovarian suppression in premenopausal women with
ER positive breast cancer.
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It is noteworthy that whilst premenopausal women often experience ovarian suppression
secondary to cytotoxic chemotherapy, this does not constitute adequate endocrine therapy in
many, since menses will resume following chemotherapy in most young women and in 10-
20% of women over the age of 40 years [249l
Inhibition of Aromatase
In post-menopausal women, where ovarian steroid biosynthesis is reduced markedly and
oestrogen levels in the circulation fall dramatically, inhibition of the aromatase enzyme, which
catalyses the last step in peripheral oestrogen biosynthesis, has long been a target for anti-
oestrogen therapy (Figure 1.9A). Aromatase converts androgens to oestrogens by creating an
aromatic ring in the steroid molecule and is present in many tissues including adipose,




Figure 1,9A: Mechanisms of Action of the Endocrine Therapies.
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Three generations of aromatase inhibitors (Als) have been developed. Whilst the first
generation Aminoglutethimide induced inhibition of the enzyme, it was not particularly potent
and lacked specificity, often producing side effects unrelated to oestrogen deprivation
including Cortisol suppression 12551 . A second generation was developed that showed greater
selectivity but their use was limited due to poor bioavailability [256l However, the current third
generation agents Letrozole, Anastrozole and Exemestane possess remarkable specificity
and potency. They may be subdivided into steroidal (Type I) and non-steroidal (Type II)
inhibitors, each exhibiting different interactions with the aromatase enzyme. Steroidal Als
(Exemestane) bind non-covalently and reversibly to aromatase, whereas the non-steroidal
Als (Letrozole and Anastrozole) bind covalently and irreversibly 1231].
All three of the current available Als switch off peripheral oestrogen biosynthesis almost
completely and are highly effective in the treatment of postmenopausal breast cancer1257 258].
Letrozole is the most potent amongst these, inhibiting peripheral aromatisation by almost 99%
[259-262] Exemestane and Anastrozole inhibit aromatase by 97% and 98% respectively,
although the clinical significance of this difference is not clear [263]. The steroidal Al
Exemestane may exert androgenic effects, but the clinical relevance of this has yet to be
determined. Whilst in pre-menopausal women the Al's can be used in combination with
oophorectomy or the GnRH agonists, they cannot be used in isolation since they do not
effectively inhibit ovarian oestrogen production.
The Als are well tolerated though not without side effects, and are rapidly becoming the
endocrine therapy of choice in postmenopausal women with ER positive disease.
1.9.2 Blocking Oestrogen Function
The 'Anti-Oestrogens'
The 'anti-oestrogens' as their name suggests do not block oestrogen biosynthesis but rather
antagonise its action by competing for binding sites on the oestrogen receptors l264]. These
agents are considered in two groups depending on their interaction with the receptor.
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The Selective Oestrogen Receptor Modulators (SERMs)
The SERMs, which include Tamoxifen, Raloxifene and Toremifene, compete with oestrogen
for binding at the ER 12641. Indeed, when given at the usual daily dose of 20mg, Tamoxifen
occupies at least 99% of ER binding sites I241]. The effects of Tamoxifen binding are similar to
that of oestrogen, with dimerisation causing a conformational change in the shape of the ER.
However rather than activating the AF2 module, the Tamoxifen bound receptor reduces or
eliminates the activity of AF2. Consequently, the association of the ER with co-activator
proteins does not take place; co-repressor proteins are not displaced and the transcription of
AF2-oestrogen-dependent genes is greatly reduced. They can be used in both pre and post¬
menopausal breast cancer patients (Figure 1.9A).
Whilst Tamoxifen is an effective antagonist in the presence of high levels of oestrogen, it can
also exhibit some agonist effects on the breast and on other oestrogen-dependent target
tissues in the absence of oestrogen [265l This is probably mediated by the activation of the
AF1 ER module. The activity of further molecules such as the steroid receptor co-activator
A1B1 and the type 1 growth factor receptor HER2 may also influence the degree of agonism.
The effects of enhanced signalling through the ER pathway are evident in the side effect
profile of Tamoxifen. The anti-oestrogenic effects have a negative impact on the bone stock
of premenopausal women in particular who incur a risk of osteoporosis following treatment
[266]. There is however a positive effect on bone in postmenopausal women through agonist
effects. Tamoxifen also exerts positive effects on blood lipid profiles and is associated with a
small increased risk of venous thromboembolism in post-menopausal women. The
proliferative effect of Tamoxifen on endometrium accounts for a small increase in the risk of
developing endometrial carcinoma also only in postmenopausal women !267"2691. Raloxifene on
the other hand, has no stimulating effect on the endometrium [264'268l
Tamoxifen was established as the primary endocrine treatment for both early and advanced
breast cancer and as an adjunct to surgery in both pre and post menopausal ER positive
groups until fairly recently. The Als with their superior efficacy and tolerability have now
superseded Tamoxifen for postmenopausal women in many centres.
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' The Pure Anti-Oestrogen'
The second group of anti-oestrogens includes only one drug, Fulvestrant, also known as a
selective oestrogen receptor down-regulator (SERD). This also competes with oestrogen for
binding to its receptor but unlike the SERMs does not demonstrate any agonist activity,
thereby avoiding some of their unwanted side effects [2701 (Figure 1.9A). Furthermore, by
destabilising the receptor it may actually reduce levels of ER. It has been tested primarily on
metastatic or locally advanced breast cancers and its efficacy in this group appears to be
similar to that of the Als t271,2721.
1.9.3 Adjuvant Endocrine Therapy
It has become clear that adjuvant endocrine therapy is generally only effective in patients with
ER positive disease with a clear correlation between the degree of ER expression and the
efficacy of therapy [1541.
Until recently Tamoxifen was the agent of choice in the adjuvant setting for both pre and post¬
menopausal women and additionally has been shown to reduce the risk of contralateral
breast cancer by 40-50% when given for five years, although it may be less effective against
HER2 positive tumours [273'274).
Postmenopausal Adjuvant Endocrine Therapy
The advent of the third generation selective Als has provoked major changes in adjuvant
therapy for post-menopausal women with early breast cancer. These Als reduce the risk of
contralateral breast cancer by a further 40-50% when compared to Tamoxifen and have been
shown to improve disease free and metastatic free survival, to a greater degree than
Tamoxifen [275 276]
Data from the first trial to compare Tamoxifen with Anastrozole alone or in combination (The
ATAC trial), demonstrated a significant disease free survival benefit with Anastrozole alone
l277]. This has remained the case at the most recent 10-year analysis of the data. Subsequent
trials have also shown beneficial effects on disease free survival and overall survival when
Letrozole is used as first line treatment over Tamoxifen l278'. The on-going FACE trial is
comparing the efficacy of Letrozole and Anastrozole in over 4000 women with node positive
disease and should demonstrate which is most clinically effective I279]. Exemestane is not
currently licenced for use as first line therapy in the adjuvant setting and results have shown
equivalence with Anastrozole [28°'.
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Data from a series of early trials led to the trend of 'sequencing' endocrine therapy, whereby
treatment was initiated with Tamoxifen and later 'switched' to an Al after two to three years. It
was hoped that this would improve the outcome compared with ongoing Tamoxifen or Al
treatment I276-281' However, two large randomised trials have since shown no benefit to this
approach in women eligible for Al treatment [278 282). The current standard of care in this
subset of patients is therefore to commence an Al and to continue this for five years, unless
contraindicated due to the side effect profiles of Als. Many women however will still be
commenced on Tamoxifen and substituted at 5 years to extended treatment.
Extended Adjuvant Therapy
Further evidence in favour of the Al's comes from the Canadian led MA17 trial. This revealed
that Letrozole, when given following five years of Tamoxifen as extended adjuvant therapy,
reduces risks of local recurrence in ER positive, node negative and positive patients and,
produces a significant survival benefit in patients with node positive disease [283'284]. Two
further trials have shown similar benefits with the other Al's [285,286]. Further follow up data
from MA17 suggest that the benefits of Letrozole increase with time, certainly up to four years
of extended therapy. A further trial is currently investigating whether treatment for up to ten
years is of continuing benefit. For some women, indefinite treatment may be appropriate
given the long natural history of the disease. Extended adjuvant therapy with Letrozole in ER
positive postmenopausal cancer has therefore become the standard of care for all but low risk
women.
Premenopausal Adjuvant Endocrine Therapy
In premenopausal women with hormone sensitive disease, the options include Tamoxifen
alone or in combination with ovarian suppression or ablation, most commonly using a GnRH
analogue such as Goserelin. The combination of Tamoxifen and Goserelin may improve
survival in women with ER positive disease [273 2871 and, is more effective than CMF
chemotherapy [288"2901 However, endocrine therapy alone has never been compared with
Anthracycline or Taxane based regimens that are now seen as standard [1781. In advanced
breast cancer the addition of Tamoxifen to an LHRH agonist improves response rate and
overall survival12901
It is not yet clear whether there is a substantial advantage or indeed a disadvantage in using
an Al instead of Tamoxifen in combination with Goserelin.
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Combinations of Adjuvant Chemotherapy and Hormonal Therapy
The use of chemotherapy and Tamoxifen in combination is more effective than either alone,
for women with high risk ER positive cancer[291]. Efficacy is greater when Tamoxifen is given
after chemotherapy, rather than concurrently. No data exist on whether the same is true of
ovarian ablation or Al's, but it would seem likely.
A recent study suggested that for those patients under the age of 40 years, who remain
amenorrhoeic following chemotherapy, prognosis is better [2921. This confirms that ovarian
suppression is beneficial after chemotherapy in patients with ER positive cancer whose
menses persist.
1.9.4 Neoadjuvant Endocrine Therapy
The use of endocrine therapy has become increasingly popular in the neoadjuvant setting.
Such treatment was initially reserved for postmenopausal patients with large ER positive
tumours who had either locally advanced operable or inoperable breast cancers. Its use has
now been extended to patients with earlier operable breast cancer. The aim in these groups
is to downstage disease to facilitate a surgical approach in otherwise inoperable tumours or to
minimise the extent of surgery in operable tumours I293].
Premenopausal Neoadjuvant Endocrine Therapy
Very few neoadjuvant endocrine studies have been conducted in pre-menopausal women.
Those reported have examined the use of Tamoxifen versus an Al in women taking a GnRH
agonist for 3-4 months, in small series. Whilst they have shown some clinical advantage in
patients taking Letrozole, no differences were reported in survival between responders and
non-responders I294,295].
Postmenopausal Neoadjuvant Endocrine Therapy
The majority of neoadjuvant endocrine studies have been carried out in the postmenopausal
population. Indeed, a number of relatively small but robust randomised neoadjuvant trials
have proven the benefits of Al's, particularly Letrozole over Tamoxifen as first line treatment
for post-menopausal women with large operable ER positive tumours. Letrozole, given for
three to four months pre-operatively, was shown to be superior to Tamoxifen in terms of
clinical response (55% versus 36%) and rates of BCS (45% versus 36%), in women who
would otherwise have required mastectomy [296'.
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The results of the IMPACT trial, which compared 3 months of neoadjuvant Anastrozole or
Tamoxifen alone or in combination, showed no difference in cancer response rates. However,
in the subpopulation of patients with large cancers initially warranting mastectomy,
Anastrozole, like Letrozole, was significantly more effective than Tamoxifen alone or in
combination in achieving BCS (46% vs. 22% vs. 26%)I297].
A second study (PROACT) compared three months of Anastrozole with Tamoxifen and again
showed similar response rates with the two drugs but a higher rate of BCS with Anastrozole
i298i. When the results of PROACT and IMPACT were combined, a significantly greater
response rate was seen with the Al's in tumours that were locally advanced or that required
mastectomy at presentation.
These results have since been backed up in a head to head trial and further in a meta
analysis of neoadjuvant Als versus Tamoxifen, in which better clinical response rates,
objective tumour shrinkage on ultrasound scanning and BCS rates were evident with the Als
[299] [3oo] |y|0S{ recently the American College of Surgeons Oncology Group (ACOSOG)
carried out a multicentre trial in which 377 patients were randomised to receive Letrozole,
Anastrozole or Exemestane for 16 weeks [3011. Clinical response rates were high in all groups
(74.8% with Letrozole, 69.1% with Anastrozole and 62.95% with Exemestane). Disease
progression rates were low in all groups but lowest with Letrozole (4.7%) and the overall rate
of BCS between groups was 82%. These results are similar to those found in previous
studies and suggest that all three agents are suitable for use in the neoadjuvant setting. In the
UK, Letrozole is most commonly used in clinical practice, as it is currently the only agent
licenced for this indication.
It was initially felt that neoadjuvant endocrine therapy might not be appropriate for all types of
ER positive cancer, in particular ILC, which may be difficult to monitor radiologically due to its
often occult nature. However, data now show that these also respond well [302!. Early data
from an Edinburgh series, which enrolled 61 patients with 63 ILCs as part of a prospective
neoadjuvant Letrozole audit, have shown encouraging results. The mean reduction in tumour
volume measured clinically at 3 months was 66% (61% ultrasonically and 54%
mammographically). Of the enrolled patients, 81% underwent BCS. With the exception of
two patients, the rest who have continued on Letrozole mono-therapy have remained
controlled at a median of 2.8 years.
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Duration of Neoadjuvant Treatment
The standard duration of neoadjuvant treatment to date has been three to four months. This
is based largely on experience with neoadjuvant chemotherapy, without due consideration of
how long endocrine therapy might be effective for and what the optimal duration should be.
Recent studies with longer durations of chemotherapy have suggested that prolonging
treatment increases response rates [303].
Initial endocrine studies examining patients treated with neoadjuvant Tamoxifen suggested
that a lack of tumour response by 3 months, indicates the need to consider alternative
treatment [3041. This idea has been recently challenged. One prospective study published
from Edinburgh included 184 women with large operable or locally advanced ER positive
breast cancers who were treated with neoadjuvant Letrozole. Of those treated 119 patients
underwent surgery at 3 months and, 63 patients continued on Letrozole beyond 3 months.
Amongst the latter group, a sustained response to Letrozole with reductions in tumour volume
was notable. In fact, prolonged treatment resulted in an increase in the number of patients
treatable with BCS from 60% at 3 months to 72 % at 3 years. Three quarters of patients
maintained disease control at 3 years on Letrozole [305l
A further multicentre study similarly found that BCS rates improved with time of neoadjuvant
treatment (25% at 5.8 months, 50% at 8.2 months and 75% at 12 months) [306!. Whilst an
initial, rapid response was seen in the first 4 months of treatment, a slower and sustained
response was seen thereafter, with a median time to BCS of 8.2 months. The results of both
of these studies suggest that the conventional treatment period of 3 to 4 months of
neoadjuvant Letrozole may need to be revised.
Sequencing the Al's
The question of whether neoadjuvant sequencing of different classes of Al is of clinical benefit
remains the subject of much debate. Results from a recent small head-to-head trial
comparing steroidal and non-steroidal Als suggest no meaningful clinical differences in
efficacy or adverse events between the two classes and therefore no conceivable benefit
from sequencing l307]. Similarly, no benefit has been found to date from the addition of an
oestrogen receptor blocker in combination with a non-steroidal Al |3081.
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Histological Response To Neoadjuvant Endocrine Therapy
One of the main features seen in response to Letrozole therapy is central scar formation
within the tumour mass, associated with a reduction in tumour volume. This discovery was
one of the first indications that the breast tissue stroma may be an important factor in the
development, proliferation and response of breast tumours [309]. This was one of the
indications to include the assessment of stromal signatures in the present study. The process
of signature selection is discussed in more detail later.
In contrast, scattered and diffuse cellular patterns are seen in response to chemotherapy [310!.
Neoadjuvant Endocrine Therapy versus Chemotherapy
As with adjuvant chemotherapy, evidence suggests that patients with hormone sensitive
disease respond better to neoadjuvant endocrine therapy than they do to neoadjuvant
chemotherapy [311]. One large retrospective study of 1731 patients receiving primary
chemotherapy showed significantly lower clinical response rates in its ER positive subset t312l
Until recently, there was only one randomised trial of neoadjuvant chemotherapy (doxorubicin
and paclitaxel) versus the Als (Anastrozole and Exemestane) [169]. Amongst the 121 women
with EBC treated for 3 months, response rates between the chemotherapy and endocrine
treated groups were similar, however there was a trend for increasing BCS rates in favour of
endocrine therapy with no significant differences in recurrence rates at 34 months. Moreover
the endocrine treatments were better tolerated and with fewer serious side effects.
Subsequent studies also suggest that endocrine therapy is a safe alternative to chemotherapy
in postmenopausal women with hormone sensitive cancers, with similar response rates but
less toxicity [313].
Response and HER 2 Status
The evidence for whether response rates to Als and Tamoxifen therapy in ER positive
tumours differs in HER2-positive patients remains equivocal. The P024 study comparing
neoadjuvant Letrozole with Tamoxifen found that clinical response rates amongst HER2
positive tumours were significantly higher for groups treated with the Al I314315) other smaller
studies have however, failed to find a significant difference and the evidence remains unclear
[316,317] overall however, HER2 positivity may predispose to resistance to endocrine therapy.
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1.10 Assessment of Response to Neoadjuvant Endocrine Therapy
There are no current recommendations regarding the method or frequency of monitoring
response to neoadjuvant endocrine therapy [318l Most studies use clinical response as an
end point. Tumour shrinkage and time to disease progression (progression free survival) are
reasonably assumed to be associated with overall survival 1319]; though the association is not
strong.
1.10.1 Clinical Response
Clinical response to therapy may be monitored by a change in tumour size using the following




Such assessments can be made at various time points although 0, 6 and 12 weeks have
been recommended [32Gl.
Clinical Response Criteria
Tumour endpoints, such as objective response and time to disease progression, are useful
only if based on widely accepted and readily applied standard criteria. Two such systems
have been published over the past two decades, the WHO classification published in 1981
[321] and subsequently a modified RECIST classification in 2000 [322_324i jhe use of these is
however aimed at the advanced disease setting. Since no system is specifically designed for
use in the neoadjuvant setting, trial centres commonly employ locally defined response




In trials of neoadjuvant chemotherapy, pathological response is consistently shown to be a
powerful determinant of long-term outcome. Patients with a complete pathological response
(pCR) have a significantly better disease free and overall survival compared to those with no
or incomplete response [325]. Neoadjuvant endocrine therapy also produces changes in
tumour morphology and histology, including a decrease in cellularity and an increase in
fibrosis, so called 'central scar formation' I309 326 327i Such pathological responses have been
reported in 60-80% of tumours after 3-4 months of treatment [328,329!. Complete pathological
responses to endocrine therapy are however rare [330l Currently the criteria defining partial or
incomplete pathological response are subjective and variable. Given the low frequency of
complete pathological response, some form of standardised assessment of partial
pathological response needs to be devised.
Endocrine treatment may also reduce histological grade; mitotic score being the most
commonly affected grading feature [32Sl.
Rates of clinical and pathological response are similar and significantly associated, but the
concordance is not exact. For example, approximately one fifth of tumours either display a
decrease in tumour volume without evidence of pathological changes, or appear unchanged
in size but display a decrease in cellularity I166l Because of this discordance, clinical
response is most often used as the primary end point for response and pathological response
reserved for secondary use or to confirm the clinical response.
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1.10.3 Proliferative Response
The predictive value of Ki67 as a marker of proliferation and response to neoadjuvant
endocrine therapy has been assessed in a number of studies. In the P024 study comparing
Letrozole to Tamoxifen, there was a significantly greater reduction in proliferation with
Letrozole (87% vs. 75%) [331] As part of the IMPACT trial Ki67 was assessed following 2
weeks of treatment with Anastrozole, Tamoxifen or a combination of the two and again at the
time of surgery (12 weeks) l332]. There was a significantly greater reduction in Ki67 in the
Anastrozole only group at both 2 and 12 weeks. Moreover, both the percentage change in
Ki67 expression and the absolute level of Ki67 expression at 2 weeks, predicted the
superiority of Anastrozole over Tamoxifen in disease free survival in IMPACT'S adjuvant
equivalent, the ATAC trial [277] Whilst no significant relationship between Ki67 changes and
clinical response was evident initially, the results of both the IMPACT and P024 trials at long-
term follow up have since shown a statistically significant correlation between the level of Ki67
after 2 weeks of treatment and relapse free survival i155'332 333i This implies that there may
be predictive value in the residual rate of proliferation after 2 weeks of treatment and that
measuring Ki67 at that time point could be a valuable tool for predicting long-term outcome.
This theory is being tested in the randomised POETIC study (Peri-Operative Endocrine
Therapy for Individualised care) which is currently underway [334].
1.10.4 Molecular Response
Clear evidence of molecular responses to aromatase inhibitors has also been elicited
following treatment.
ER loss after neoadjuvant endocrine therapy was identified as an independent prognostic
marker for relapse in both the IMPACT trial and the P024 trial. In the former, the levels of ER
following two weeks of neoadjuvant therapy were significantly associated with recurrence free
survival (66, 68). In the P024 trial, patients with post treatment ER negative tumours had
poorer relapse free and overall survival than patients with tumours that retained their ER
positive status after treatment (72).
The progesterone receptor (PR), which is regarded as a marker of oestrogenic activity, is also
reduced in 70-80% of tumours during neoadjuvant endocrine therapy, with staining
completely disappearing in about half of cases t166 33°l These changes are also encountered
as early as 14 days following initiation of treatment and are consistent with the anti-
oestrogenic effects of the Als. However, loss of PR expression may occur independently of
pathological and clinical response [166' 315l
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1.11 Molecular Mechanisms of Endocrine Resistance
Although there have been significant improvements in the efficacy of endocrine therapy since
the introduction of the Al's, drug resistance remains a major obstacle to the effective clinical
management of breast cancer. Approximately a third of patients with ER positive disease fail
to respond to endocrine therapy in the neoadjuvant setting I335 337> primary resistance occurs
when the tumour fails to respond to initial treatment. On the other hand, acquired resistance
occurs after an initial response. The latter is of particular concern, as this subset of tumours
appears to be more aggressive, difficult to treat and is therefore associated with poorer
prognosis and survival[336 338].
The oestrogen receptor and its signalling pathway play a central role in promoting cellular
proliferation, survival and invasion of ER positive cancers, through both oestrogen-dependent
and independent mechanisms 1336 339 3401 A number of potential mechanisms of tumour
resistance have been proposed and can be broadly considered as occurring within or outwith
the tumour.
The extra-tumoural mechanisms include:
(i) Patient factors such as poor compliance with treatment[341].
(ii) Adverse drug metabolism, reducing the effective dose l342].
(iii) Inaccurate assessment of the ER status I343].
(iv) Stimulation of ER by dietary or other exogenous oestrogen sources 1344 345].
(v) Reduced efficacy of Als, due for example, to polymorphisms in the aromatase gene
[346]
Intra-tumoural mechanisms are perhaps more complicated and are subject to greater
research efforts, but can be considered to occur at any point in the pathway of oestrogen
stimulated tumour growth (Figure 1.11 A).
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Figure 1.11 A: Points in the ER Stimulated Pathway during which Resistance may Develop
Within a Breast Tumour.
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More specifically, resistance to treatment may develop because of:
(i) Deregulation of various components of the ER pathway and ligand-independent
activation of ER.
(ii) Alterations in cell cycle signalling proteins [347].
(iii) Activation of escape pathways that provide tumours with alternative cell proliferation
pathways [34S1.
(iv) Alteration of cell survival proteins and signalling pathways.
Each of these will be discussed below.
1.11.1 Deregulation of Components of the Classical ER Pathway
The oestrogen bound ER complex exerts its classical effects by translocating to the nucleus
where it binds to oestrogen-response elements (ERE), altering the expression of numerous
genes involved in tumour growth, as well as normal cell function l349]. The presence of various
co-regulatory proteins such as NCoA1-4 can augment or inhibit this activity I350"352! similarly,
ER can itself modulate other transcription factors, such as AP-1, NF-Kb and MYC to effect
transcription pathways that are oestrogen independent (Figure 1.11 B(i)) [3401. Furthermore,
other growth factors receptor pathways can activate ER and its co-regulators, through
mechanisms collectively known as 'cross talk' (Figure 1.11 B(ii))[353 3541.
In this way, tumour cells may lose their dependence on the oestrogen-ER complex and
develop resistance to endocrine therapy. Alternatively, overexpression of the co-regulator
proteins may increase sensitivity to low levels of oestrogen (Figure 1.11 B(iii))[35Ql.
1.11.2 Alterations in the Cyclins and Other Cell Cycle Regulators
A number of cell cycle regulators acting downstream of the ER have been linked to endocrine
resistance [3471. The Cyclin D gene (CCND1) is amplified in about one fifth of breast cancers
[355' and its protein is overexpressed in approximately half of breast tumours (Figure 1.11 B(iv))
[356,357] gjnce cyC|jn d plays an important role in the G0-G1-S transition of the cell cycle, it
has been hypothesised that this increased activity may be associated with high proliferation
rates and poor outcome I358l Conversely however, some groups have associated
overexpression of the Cyclin D protein with ER positivity and a favourable prognosis [356'.
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This discrepancy may be explained by the fact that the CCND1 gene is a known ER target
I3591. Therefore, high expression of the gene in ER+ disease, in the absence of gene
amplification, may be indicative of oestrogen-dependent growth, which is likely to respond to
endocrine treatment and to have a good prognosis. In contrast, CCND1 gene amplification is
associated with activity of the autonomous ER-independent Cyclin D1, which may contribute
to endocrine resistance [360] and is linked to a poor response to endocrine treatment and poor
prognosis i361362i
Other examples include the overexpression of Cyclin E (CCNE1), downstream of CCND1,
which can cause endocrine resistance by bypassing the cell cycle arrest induced by
endocrine treatment [363"366i
1.11.3 Activation of Escape Pathways
As well as the classical ER pathways, the receptor can also function outwith the nucleus and
is capable of indirectly regulating the activity of genes through interaction or 'cross talk' with
other growth factor pathways [353, 354, 367~3711. These pathways can stimulate each other
through phosphorylation by cell cycle kinases (Figure 1.11 B(v)).
A number of growth factor pathways have been implicated. Prominent among these are the
tyrosine kinase growth factors HER1/HER2, IGF-1R, FGFR and their associated downstream
pathways. The HER2/EGRF pathway is among the most avidly studied. HER2 is a member
of the tyrosine kinase family, regulating many processes that can promote tumour cell
proliferation and survival [3721. FIER2 does not directly bind with oestrogen but is a common
dimerisation partner for the other FIER family members t373]. Upon binding to their respective
ligands, dimerisation of the FIER receptor occurs, followed by phosphorylation of its
intracellular tyrosine kinase domain leading in turn, to the activation of downstream signalling
pathways such as PI3K-AKT-mTOR and RAS-ERK (MAPK) [3741. The former is a key
mediator of growth factor receptor signalling and is important in the regulation of cell
metabolism, growth, survival and angiogenesis. The latter is important in mediating the
transcription of genes related to cell proliferation and differentiation.
HER2 amplification in ER positive tumours is associated with resistance to endocrine
treatmentl375,3761. This can be explained by:
(i) The direct effect of HER2 on proliferation via the downstream signalling pathways.
(ii) The cross-talk stimulation between ER and HER2 I339. 3771 r ,v ' nc^
, for example through
ligand-independent phosphorylation of ER.
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1.11.4 Alteration of Cell Survival Proteins and Signalling Pathways
A number of other molecular mechanisms have also been implicated in endocrine resistance.
These involve certain proteins associated with apoptosis (e.g. P53, BCL2 and CASP8) 1378 3791
and also micro-RNAs (e.g. mir9, 221, and 222) [38a381l The latter are short RNA sequences
that have been recognised as important regulators of gene expression through their ability to
cause degradation of mRNAs and repress translation
It is increasingly clear that the mechanisms of endocrine resistance, which are complex in
themselves, are rendered ever more so by the fact that they closely interact with each other.
For example, micro-RNAs exert control over the ER and cell cycle regulators whilst apoptosis
is in part regulated by oestrogen signalling pathways. The combination of mechanisms at play
may differ between individual tumours.
In order to understand the mechanisms of tumourigenesis, proliferation and resistance, it is
necessary to consider them within the context of the hallmarks of cancer development.
Cell Survival
Figure 1.11B: Mechanisms of Resistance to Endocrine Therapy
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The Molecular Biology of Breast Cancer
1.12 The Molecular Basis of Tumourigenesis
Multiple events are implicated in tumourigenesis (Figure 1.12A)1382 383)
Figure 1.12A: Mechanisms of Tumourigenesis.
These are:
(i) Sustained proliferative signalling
(ii) Evasion of growth suppression
(iii) Resisted cell death
(iv) Replicative immortality
(v) Induction of angiogenesis
(vi) Activation of invasion and metastasis
(vii) The involvement of the tumour microenvironment or stroma
(viii) Evasion of immune destruction and,
(ix) Re-programming of energy metabolism
These provide a framework by which the complexities of tumourigenesis may be considered
and each will be discussed briefly.
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1.12.1 Sustained Proliferative Signalling
Uncontrolled cell growth and the ability to sustain proliferation are arguably the most
fundamental traits of the cancer cell. Entry into the cell cycle is usually highly controlled by
the production and release of growth promoting signals, which ensure a homeostasis of cell
number and maintenance of normal tissue architecture and function. In order to understand
this better, it is necessary to have an overview of the cell cycle and its regulation.
An Overview of the Cell Cycle
The cell cycle comprises two principle stages: Interphase and Mitosis. Cells continually cycle
between these two phases, occasionally entering a quiescent or 'resting' phase known as
GapO (GO). During interphase, the cell grows, replicates its chromosomes and prepares for
cell division. Through mitosis, the cell divides its chromosomes and cytoplasm to form two
daughter cells. Entry into each phase of the cycle is dependent on the proper progression and
completion of the previous one. The majority of the time is spent in interphase, which is
subdivided into three components: G1, S and G2 (Figure 1.12B)
Figure 1.12B: The Cell Cycle.
(i) G1 is the period between cell division and further chromosomal duplication During
this time the cell functions normally whilst checks take place to ensure its readiness
for further division. At this point the cell may either:
Exit the cell cycle and enter into GO.






Continue to grow and to synthesise the proteins and enzymes required for
chromosomal duplication during the next stage.
(ii) The 'S' or Synthesis phase represents the period of chromosomal replication
following G1 during which the cell is particularly vulnerable to the influence of
mutagens. A doubling of chromosomal number marks the end of this phase.
(iii) G2 follows immediately on from the S phase. The cell continues to grow, in
preparation for division. Further checks are made to ensure a full complement of
DNA and other cellular components prior to mitosis.
Regulation of the Cell Cycle
Regulation of the cell cycle includes processes crucial to cell survival, mainly the prevention
of uncontrolled proliferation and the detection and repair of damaged DNA. At least two types
of cell cycle control mechanism are recognised. The first involves a cascade of protein
phosphorylations that trigger the cell to move from one stage to the next. The second is a
series of checkpoints that monitor the completion of critical events and delay progression to
the next stage if necessary, for example to allow time for DNA repair. Mutations in many
cancer promoting genes known as oncogenes, with resultant altered expression of their
protein products, are primarily responsible for these changes [384 385]. The regulation is
governed by positive and negative modulators of the cell cycle Figure 1.12C.
) Negative Modulators
o Positive Modulators
Figure 1.12C: Modulators of the Cell Cycle.
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Positive Modulators of the Cell Cycle
The Cyclins
These are a highly regulated family of proteins that are transiently expressed in a cyclical
manner, at appropriate times in the cell cycle, in response to growth signals and are
subsequently degraded. They play a pivotal role in the activity of another group of proteins
known as the Cyclin dependant kinases (CDK's). Several classes of Cyclins are recognised
to be active at various stages of the cell cycle. The D and E Cyclins are critically associated
with the G1-S phase and the B Cyclins with G2-M transition [384 3851
The Cyclin Dependent Kinases
The Cyclin dependent kinases (CDKs) are an intracellular group of enzymes that form
complexes with the Cyclins and are dependent upon them for their ability to phosphorylate
other proteins. Active Cyclin-CDK complexes have unique substrate specificity and
orchestrate signalling pathways that enable a cell to pass into the next phase of the cycle,
whilst also influencing other biological processes (Figure 1.12C). Cyclins and CDKs are
therefore positive modulators of the cell cycle. When a cell ceases to divide, the Cyclins are
degraded, with consequent deactivation of the CDKs and arrest of the cell cycle.
Negative Modulators of the Cell Cycle
The CDK Inhibitors
In contrast to the Cyclins and CDKs, another group of proteins, the CDK inhibitors, negatively
modulate the cell cycle by disabling the phosphorylating activity of the Cyclin-CDK complexes
[386). Two classes of CDK inhibitors are known to exist:
(i) Class 1 specifically bind to CDK 4 and 6 and inhibit their association with the D-type
Cyclins.
(ii) Class 2 are inhibitors of the Cyclin A-CDK, D-CDK and E-CDK complexes. These
are otherwise known as kinase inhibitor proteins (KIPs) and include the proteins
products of the p21, p27 and p57 genes.
Whilst many CDK inhibitors are known, the above are prominent amongst them and are
known to play a pivotal role in breast cancer development1384 3851
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Deregulation of the Cell Cycle
Since the production of the Cyclins, which promote progression through the cell cycle, is
dependent upon stimulation by growth factors and in the case of breast cancer, upon steroid
hormones, it has been hypothesised that cancerous cells may induce and sustain their
proliferative signalling by:
(i) Up-regulating / changing the configuration of their receptors rendering them hyper-
responsive to low levels of stimulation 1374 38?l.
(ii) Producing and responding to their own growth factors in an autocrine fashion [374-388
389]
(iii) Activating neighbouring stromal cells to produce growth factors, which act in a
paracrine manner1390 391).
(iv) Loss of the intracellular negative feedback mechanisms that ordinarily act to
attenuate proliferative signalling [392]
(v) Achieving growth factor independence via the activation of downstream pathways
directly.
The latter may occur as a result of 'cross talk', whereby activation of the intracellular kinases
or other proteins, not only promote entry into the cell cycle but also result in the activation of
multiple other intra and inter cellular signalling pathways, which intercommunicate resulting in
complex biological consequences [383'.
1.12.2 Evasion of Growth Suppression
Cancers are capable of circumventing the signals that negatively regulate cell proliferation.
Many of these signals are dependent on the actions of tumour suppressor genes, whose
protein products such as the CDK inhibitors have an inhibitory effect on the cell cycle.
Dozens of tumour suppressors operate in this way and have been discovered through their
characteristic inactivity in various types of cancer. Two prototypical tumour suppressor genes
encode the RB (retinoblastoma associated) and TP53 proteins; they operate as central
controls within two key complementary circuits that govern the decisions of cells to proliferate,
rest or undergo apoptosis [383 3931
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Malignant cells do not exhibit 'contact inhibition', whereby cell-to-cell contact inhibits further
cell replication. The mechanisms underlying this probably relate to the defective actions of
intracellular proteins that ordinarily orchestrate growth inhibition through the coupling of cell
surface adhesion molecules (e.g. E-cadherin) to trans-membrane tyrosine kinases I394].
1.12.3 Resisted Cell Death
Programmed cell death or apoptosis, serves as a natural barrier to tumour development I395,
396'. Apoptosis is triggered in response to various physiological stimuli including:
(i) Signalling imbalances resulting from elevated levels of oncogene expression.
(ii) DNA damage associated with hyper-proliferation or otherwise.
Yet, apoptosis is attenuated in high-grade malignancy and in cancers that are resistant to
therapy l395'396]
The apoptotic machinery is composed of pathways that are either extrinsic or intrinsic to the
cells, each ultimately culminating in the activation of a normally latent protease. Proteolysis,
disassembly and consumption of the cell by phagocytosis then follows l395'. Autophagy, an
intracellular catabolic process by which redundant or dysfunctional cellular components are
degraded by lysosomes may mediate both tumour cell survival and death [3971.
Tumour cells evolve a variety of strategies to limit or circumvent apoptosis. Most common is
the loss of TP53 tumour suppressor function that eliminates this critical element from the
apoptotic circuitry. Resistance to apoptosis may also be achieved by:
(i) Increased tumour expression of anti-apoptotic proteins.
(ii) Increased expression of survival signals.
(iii) Decreased expression of pro-apoptotic proteins.
(iv) Short-circuiting the extrinsic pathway.
These strategies reflect the diversity of apoptotic signals within each tumour [383i
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1.12.4 Replicative Immortality
Cancer cells require unlimited replicative potential in order to form macroscopic tumour whilst
normal cells are limited to a defined number of successive cell cycles. With each cycle the
protective terminal sequences of the chromosomes (telomeres) shorten, eventually allowing
fusion to their neighbouring chromosomes. The resultant DNA is unstable and the cell
becomes senescent or undergoes apoptosis. Cancer cells employ the enzyme telomerase to
lengthen their telomeres and thus become immortalised [398'.
1.12.5 Induction of Angiogenesis
Tumours, like any tissue, are dependent on a blood supply to survive and grow. During
tumour progression, an imbalance in certain regulatory proteins, which bind to endothelial cell
surface receptors, promotes continuous angiogenesis at an early stage [39Sl. Vascular
endothelial growth factor (VEGF) and Thrombospondin (TSP-1) are central regulators in this
process 1400 4011. A variety of bone marrow derived cells also contribute to tumour
angiogenesis 1402].
1.12.6 Activation of Invasion and Metastasis
The process of tumour propagation involves several stages beginning with local invasion and
followed by intravasation of cancer cells into blood and lymphatic vessels from where they are
dispersed and subsequently extravasate into the parenchyma of distant tissues. Small
micrometastases form and eventually become macroscopic tumours I403l
Recently a normal developmental pathway known as the 'epithelial-mesenchymal transition'
(EMT) has been implicated in tumour invasion and spread [404'. Epithelial cells lose their
polarity and cell-cell adhesion and instead acquire the ability to migrate and invade other
tissues. This process is essential for numerous normal developmental and wound healing
pathways but appears to be exploited by tumours. EMT is dependant on a number of key
transcriptional proteins that evoke changes in cellular biology including:
(i) Conversion from an epithelial to a fibroblastic morphology
(ii) Loss of cell-cell and cell-ECM adhesion
(iii) Expression of ECM degrading enzymes
(iv) Increased motility
(v) Resistance to apoptosis
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Current evidence suggests that these transcription factors regulate each other and share
regulation of other genes. Little is known about these interactions although cross talk between
the cancer cells and the surrounding stroma may induce and promote these changes I405].
1.12.7 Involvement of the Tumour Microenvironment
In recent years, the tumour stroma has been recognised to play a critical role in tumour
development [406,4071. There is now a growing appreciation that tumours are not simply an
independent mass of proliferating cells but rather a complex collection of multiple different cell
types including stromal cells, which participate in complex interactions with one another.
In the breast, the stromal system is composed of the connective tissue matrix and fibres and
supporting cells that surround the parenchyma including fibroblasts, immune cells, adipocytes
and endothelial cells [406, 408]. Each of these may contribute individually or collectively to
tumourigenesis via mechanical and biochemical regulatory signalling pathways [409'. In this
way, the stroma may be activated by the tumour epithelium to encourage and support tumour
growth through secretion of growth factors, stimulation of angiogenesis, or by facilitating cell
migration and metastasis [4091.
Cancer Associated Fibroblasts (CAFs) and Collagen Re-Alignment
One of the earliest indicators of a link between stromal biology and tumour progression was
made by Boyd et al, who found that women who had mammographically dense breasts also
had a two to fourfold increase in their susceptibility to breast cancer [4101. This appears to
relate to an increase in collagen density I411]. Furthermore in breasts of variable density,
tumours most commonly arise within the densest areas [412 413i
Three-dimensional optical imaging of breast tumours in mice suggested that collagen
changes at the tumour-stromal boundary might be important. Certainly, the invasion of the
collagen-based basement membrane in humans appears to correlate with exponential tumour
growth and invasion 1414 4151. Three patterns or 'tumour associated collagen signatures'
(TACS) were identified which reflect tumour progression as follows:
(i) TAC1 - Tumours exhibit a localised increase in the deposition of surrounding stromal
collagen.
(ii) TAC2 - With an increase in tumour size, the collagen fibres straightened and aligned
themselves parallel to the tumour boundary.
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(iii) TAC3 - Remodelling of the stroma occurs with re-orientation of the collagen fibres
perpendicular to the tumour boundary, the preferred orientation for tumour cell
invasion I4151.
TAC-3 has subsequently been associated with poor disease free survival in human breast
cancer1416!.
The mechanisms contributing to re-alignment of the collagen matrix remain unclear, however
recent evidence points to the role of cancer associated fibroblasts (CAFs) and syndecan
signalling '417 4181 CAFs comprise at least two cell types; those like fibroblasts and those like
myofibroblasts. It is unclear whether CAFs are normally resident within the stroma or arise
from mesenchymal stem cells in response to tumour-secreted growth factors and thence
recruited into the stroma or by the conversion of adipocytes in response to other tumour
derived factors '419!.
The syndecans comprise a family of transmembrane cell surface proteins, expressed on
fibroblasts and epithelial cells. Syndecan-1 is normally expressed on mammary epithelial
cells but not in the stroma. In three quarters of breast cancers however, this pattern is
reversed [420l it has been hypothesised that growth factors secreted by malignant cells
activate stromal syndecan associated with CAFs to promote collagen re-alignment via
unknown mechanisms [421]. In addition, Syndecan-1 appears to stimulate the proliferation of
tumour epithelium and angiogenesis, and may be closely correlated with patient outcome [422~
424l The full spectrum of activity of the CAFs has yet to be elucidated.
Stromal Re-Modelling, Inflammation and the Immune Cells
The normal breast undergoes extensive cell death and remodelling on cessation of breast¬
feeding in an attempt to restore normal architecture [4251. The associated inflammatory
changes of the stroma are similar to that seen in aggressive breast cancers t426). Indeed,
pregnancy associated breast cancer (PABC) has been associated with a particularly poor
survival I427'4281, suggesting that inflammatory stroma may be in part responsible for invasion
and metastases.
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The involution of breast stroma is linked to the activity of cyclooxygenase-2 (COX-2), an
enzyme that catalyses the synthesis of the prostaglandin mediators of inflammation.
Moreover, a positive feedback loop exists as denatured collagen binds to the receptors of
epithelial cells stimulating the production of COX-2 and prostaglandin signalling which in turn,
increases the inflammatory response, resulting in further collagen deposition [426]. Inhibition of
COX-2 in animal models results in stroma with severely diminished tumour-sustaining ability
I4291. Given the link between breast density and survival, this signalling cascade may explain
the decreased survival in PABC. The role that COX-2 plays in breast tumour progression
appears to be significant [430]. In human breast cancer patients, moderate to strong
expression of the COX-2 protein occurs in 40 % of patients and is associated with a poor
disease free survival [4311. Agents like Aspirin, that inhibit COX-1 and COX-2, may inhibit
breast cancer development.
The process of breast involution is also known to release pro-inflammatory colony stimulating
factor (CSF-1) into the tumour micro-environment, which attracts inflammatory cells and in
particular stromal macrophages [432l The presence of large numbers of macrophages is
associated with angiogenesis, tumour invasion and the stimulation of matrix degradation
enzymes known as matrix metalloproteinases I407,433,4341 whose presence is also correlated
with poor outcome [435].
The matrix metalloproteinases (MMPs) are a family of nine or more highly homologous Zinc-
endopeptidases that collectively cleave most if not all of the constituents of the extracellular
matrix. Their specific role in tumour progression is still highly debated yet clinical studies
have firmly established a correlation between survival and MMP expression 1436-4391 The
hypothesis however is that these enzymes contribute to the breakdown of the basement
membrane and degrade stromal collagen to facilitate migration of tumour epithelial cells.
This strong indication of stromal involvement in breast cancer led to the decision to include
multi-gene stromal signatures in this study.
1.12.8 Immune Destruction
The ability of cancer cells to evade the immune system highlights the dichotomous role of this
system in tumour formation, at once trying to eliminate the tumour through various
mechanisms whilst enhancing tumour development and progression through others 13821.
Both B cell and T cell lymphocytes are likely to influence tumour progression and have been
linked to overall survival in some studies 1440 441]. As yet however, their role is not clearly
defined.
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1.12.9 Re-Programming of Energy Metabolism
Another attribute that is currently under investigation is the ability of tumours to instigate a
major re-programming of cellular energy metabolism in order to support continuous cell
growth and proliferation [3821. These are beyond the scope of this thesis.
The very many and complex biological pathways and signalling mechanisms that occur within
and between the tumour parenchyma and associated stroma, are yet to be fully elucidated.
However, it appears that the acquisition of each hallmark of malignancy is dependant on a
combination of many processes and most importantly, the development of genomic change
and instability. Molecular features have therefore been extensively applied to classify breast
cancer and to design new biomarkers. In the breast cancer field the main focus of
translational molecular profiling has been directed toward the development of multi-gene
transcriptional signatures. This will be explored in the following section.
1.13 The Molecular Classification of Breast Cancer
1.13.1 The Limitations of Current Classifications
The ultimate goal of breast cancer management is to provide a perfect classification, to give
an exact prognosis and to predict the best treatment regimen for each individual with
precision. However, our current inability to consistently and accurately predict tumour
behaviour and response to therapy indicates that the classification and prognostication
systems currently in use are far from perfect.
The standard prognostic variables such as tumour size, grade and lymph node status
combined with the predictive indicators of receptor status and Ki67 may direct treatment, but
the response to that treatment can be remarkably variable.
There are several likely reasons for these inconsistencies:
(i) Breast cancers are comprised of a mosaic of heterogeneous cell lines, such that the
behaviour and response to treatment of the tumour as a whole is a reflection of all the
cell lines within it.
(ii) Inter-observer variation in the sampling and interpretation of clinical and pathological
findings can result in misclassification.
(iii) The mechanisms underlying cancer development, progression and response to
treatment are more complex than the current classification systems allow for.
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The main reason however for the shortcomings of the current classification systems, is that
none of them fully incorporate our understanding of breast cancer at the molecular or genetic
level.
1.13.2 The Genetic Basis of Cancer
Each of the hallmarks of cancer development discussed in the previous chapter, are
ultimately regulated through complex mechanisms, under genetic control. When mutations
occur in the genes responsible for this regulation or when their products are over or under
expressed, tumourigenesis can occur.
There are several means by which cancer-enabling genes can malfunction. An abnormal
variation in the number of whole or parts of chromosomes within the cell nucleus, known as
aneuploidy, may arise through errors in mitosis. This results is an increase or decrease in the
number of copies of specific genes within the nucleus (copy number alterations or CNA),
increasing the potential for the over expression of their gene products.
Gene expression may also be altered by mutations within the genes themselves. These
include point mutations, insertions, deletions and translocations of DNA sequences, as well
as epigenetic events. The latter are defined as heritable changes in gene expression or
cellular phenotype caused by mechanisms other than changes in the underlying DNA
sequence - for example, changes in DNA methylation and histone modification, both of which
are involved in the regulation of gene expression, without altering the underlying DNA
sequence.
Whilst DNA repair mechanisms exist and may in some cases correct these mutations before
they become phenotypically apparent, this is not always achieved successfully. In addition,
genetic mutations may similarly arise in the very genes responsible for DNA repair.
In the majority of cases, the genetic changes that lead to malignant transformation are
acquired over a lifetime and are present only in certain cells. These 'somatic' mutations are
not inherited. Less commonly, 'germ line' gene mutations are inherited resulting in
susceptibility to cancer from birth. Most often however, cancers only develop following the
acquisition of additional somatic mutations, as part of the multistep process of
tumourigenesis.
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Our understanding of the molecular biology of breast cancer and of the alterations in
chromosomal and genetic structure underlying it, is rapidly improving. In time, the accuracy
of classification systems, prognostication and prediction of individual treatment response will
become more sophisticated and accurate. An enormous amount of research is currently
focusing on this objective, employing new techniques of gene expression analysis.
1.13.3 Gene Expression Profiling and the Intrinsic Subtypes
The advent of microarray technology has for the first time, allowed a rapid assessment of the
activity of many thousands of genes from small tissue samples.
The concept behind this technology is that thousands of different short segments of nucleic
acids or 'probes' are bonded in an organised pattern to a solid surface (microarray). These
hybridise with mRNA-derived genetic material extracted from a tumour / tissue sample and
this is then detected and quantified by means of chromogenic or luminescent markers. The
process is known as gene expression profiling and the patterns of selected gene expressions
thus derived are known as 'signatures'.
Microarrays can be used to assess gene expression in any type of breast cancer and
changes in the signatures obtained before, during or after treatment can help us to
understand the mechanism and efficacy of any particular therapy as well as guiding the
development of new therapeutic approaches. This technology has already promoted the
concept of breast cancer not as a single disease with variations in behaviour and treatment
response, but rather a collection of different cancers affecting the breast, each with distinct
patterns of gene expression, behaviour and histopathological features, whose response to
treatment is determined by molecular characteristics as opposed to anatomical ones [442"445i
One approach to microarray analysis in breast cancer has been to look empirically at a large
range of genes to determine which are expressed in breast cancers and how their expression
changes with tumour progression and treatment, in order to identify prognostic and predictive
markers. Some of the earliest studies by Perou et al. demonstrated marked differences in the
expression of many hundreds of genes between ER positive and ER negative tumours [446'
44?l. Surprisingly, it appears that a relatively small proportion of these are directly oestrogen
regulated. In the majority of cases the co-expression of ER exists by virtue of common cell
lineages during the evolution of an ER positive or negative tumour I446"448!
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Analysis of the genes whose expression varied more between tumours as opposed to
between repeated samples from the same tumour, suggested at least five subtypes of
tumours: Luminal; HER2 enriched; Basal-like; Normal breast like and Claudin-low. The
luminal subtypes (A and B) are characterised by high ER gene expression, the remaining
subtypes are ER negative 1446 447l All of these subgroups exhibit marked differences in
biology, survival and recurrence rates [446 447 449l More recent studies have varied in their
number and definition of molecular subtypes as well as their prognostic and predictive value
[450-455] |3ut the patterns 0f molecular classification are remarkably similar and confirm that ER
status is a dominant molecular feature [44®.447 449-456-457l |n addition, the normal breast like
subtype may be due to a mix of normal breast and cancer within the same sample.
One empirical study identified a 70-gene prognostic signature in systemically untreated,
node-negative breast cancer patients [1581, which was subsequently validated in treated and
node positive breast cancers l157]. Another 76-gene signature was later identified and
validated, with prognostic implication for metastatic spread [458l Only three genes are
common to both signatures [459 4601 Impressively, both signatures outperformed the St Gallen
and NIH clinical risk classification systems, particularly in low risk patients [15° 4611.
Nevertheless, the fact that half of the patients classified as high risk did not develop disease
recurrence demonstrates that these signatures are still imperfect predictors.
An alternative approach to microarray analysis has been to consider which genes are
involved with a particular cellular pathway and to specifically study expression of these genes
[462]. This 'hypothesis led' approach was used to demonstrate that a 'wound response' gene
expression signature is associated with poorer clinical outcome in breast cancer patients and
is able to supplement the NIH and St Gallen classifications by identifying relatively low risk
patients within the clinically high risk groups i463-464'
Similarly, Glinsky et at. used microarray analysis to demonstrate the activation of 'self-
renewal pathways' in malignant cells. These pathways are associated with normal stem cells
and might contribute to the survival of cancer cells as well as promoting tumour progression.
This investigation was based on the hypothesis that the presence of rare stem cell like
populations of cancer cells amongst the heterogeneous mix of cells within a tumour is
essential for tumour progression and metastasis of epithelial malignancies. An 11-gene
signature was identified whose presence in primary tumours is a consistently significant
predictor of rapid disease recurrence, distant metastasis, and death after treatment in a
variety of cancers including those of the breast[465]. The genes associated with this signature
have been shown to be involved in cell cycle control[4661
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Desmedt et al. studied the expression signatures associated with breast cancer grading to
determine if these could be used to refine the histopathological grading system 14671 This
concept followed from the increasingly accepted views that high and low grade tumours are
distinct diseases with differing clinical outcomes; that tumour progression is independent of
grade [468, 4691 and that intermediate grade tumours (30-60% of all breast cancers), display
intermediate behaviour for which prognostication and prediction are difficult. A 97-gene
signature, known as the Genomic Grade Index, was identified consisting of genes that are
expressed to different extents in high and low grade tumours and which are associated with
cell cycle progression and proliferation [4671. It was also confirmed that intermediate grade
tumours are composed of a mixture of high and low-grade tumours. Not surprisingly, a
significant overlap is evident between these genes and those of the separate 70 and 76 gene
signatures !470].
Dai et al. demonstrated that the occurrence of metastases within a subset of patients with
high ER is strongly predicted by a signature largely consisting of cell cycle genes, the
overexpression of which is associated with an extremely poor outcome [471l The Dai signature
was selected for assessment in this study, but was found to be significantly less well
correlated with the outcome of neo-adjuvant treatment in other patient subpopulations (see
results section).
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Many other studies have identified different gene signatures that are of prognostic value in
breast cancer. These share several characteristics:
(i) They mainly identify the same group of patients with poor prognosis, i472"474l
corresponding to high expression of genes involved with proliferation [442, 473' 475]i
which have been shown in meta-analysis to have the highest predictive value (4731.
(ii) The level of expression of proliferation genes is the strongest prognostic indicator in
ER positive tumours (442'473'475- 476>.
(iii) They mostly identify ER negative tumours as having poor prognosis due to high
levels of proliferative gene expression [442,473'475'4761.
(iv) Most correlate with response to traditional therapeutic agents, which is not surprising
as these target proliferation [442,445- 476).
(v) Meta-analysis suggests that clinical and pathological criteria provide prognostic
information distinct from these signatures [443,444.473,477]
(vi) Prognostic accuracy is time dependent with predictions at 5 years being more
accurate than at 10 years I459 478l
(vii) Prognostic information above and beyond that provided by ER, PR, HER2 and Ki67
is currently limited 1156 4551
It seems likely that the prognostic and predictive power of various signatures would be
increased if they were carefully combined with one another or indeed with other non-genetic
factors. Recently, some benefit has been demonstrated by combining both empirical and
hypothesis driven signatures, for example in the Sensitivity to Endocrine Therapy (SET) index
[479]. In this way, a 165-gene signature was identified and validated on ER positive patients
who received either adjuvant Tamoxifen for 5 years or neoadjuvant chemotherapy followed by
Tamoxifen or an Al as well as patients receiving no adjuvant therapy. The signature was
predictive for patients receiving either of the endocrine treatments but not in untreated
patients. The signature may therefore help to determine which patients should receive
endocrine treatment.
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1.13.4 Clinical Application of Microarray Technology
Despite all these findings, molecular classification is still in its infancy and processing
specimens is both expensive and time consuming. Classification is further hindered by the
fact that most breast cancers contain multiple cell lines with different pheno- and genotypes
which, in part, explains the variability in response to therapy in these cancers l480]. Therefore,
the clinical use of molecular classification is currently limited despite the promise it holds.
There are however, several clinically available kits for identifying molecular signatures in
breast cancers including MammaPrint® 1157,158], Oncofype DX® [481"485', the Veridex 76-gene
signature [458l Mapquant DX ™ 14671 and the Breast Cancer Index ™1486'. Only the first two are
currently supported by level II and level I evidence respectively and approved by the FDA 1459
4601. Many more are sure to be developed.
1.13.5 Prognostic Signatures
MammaPrint® (Agendia, Amsterdam) is a microarray based gene expression profiling assay
and is the same 70-gene signature described above 1157 158). It relies on RNA from fresh tissue
samples and can be used for patients with stage 1 or 2, node negative breast cancer of less
than 5cm, irrespective of oestrogen receptor (ER) status 1157 459 487l MammaPrint®
categorises tumours as either high or low risk and provides independent prognostic
information beyond standard clinico-pathological variables I4591.
Oncofype DX® (Genomic Health, California) is a 21-gene signature (16 cancer-related genes
and 5 normal comparator reference genes) based on quantitative reverse transcription PCR
analysis of formalin fixed, paraffin embedded tumour samples 1481 482 4851. The result is
reported as a Recurrence Score (RS) score that classifies patients as high, intermediate or
low risk of recurrence at 10 years in ER positive, node negative disease as well as having
predictive relevance when these tumours are treated with Tamoxifen. Oncofype DX® may
also be applicable to ER positive tumours treated with aromatase inhibitors 14881 and those
with positive nodes 14891 The ability to retrospectively apply this test to stored fixed tumour
samples has enabled further validation and resulted in level I evidence leading to the
incorporation of Oncofype DX® into several national guidelines in concert with standard
anatomical and pathological staging 1485,49°-493i
Sotiriou described the currently available signatures as adding "modest prognostic
information for patients with HER2-positive and triple-negative tumours", but added that
"when measures of clinical risk are equivocal (e.g., intermediate expression of ER and
intermediate histologic grade), these assays "could guide clinical decisions"[443].
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The promise of the future is to develop more specific, clinically applicable signatures that can
identify the most significant molecular prognostic and predictive markers in breast cancer and
guide the most appropriate therapy. However, it is likely that histopathological classification
will remain the baseline standard for some time, with the gradual introduction of molecular
tests which may be useful only in specific histopathological subtypes.
1.13.6 Second-Generation Prognostic Signatures
The first generation prognostic signatures are useful in patients with ER positive disease and
have pointed to genes largely associated with proliferation. Therefore, proliferation
signatures were selected for assessment in this study. The hope is that the next generation of
signatures will provide both prognostic and predictive information for ER positive and negative
disease. The principal difficulty with ER negative disease is in identifying a population of
patients with significantly good prognosis to justify withholding chemotherapy, since the
incidence of disease relapse within 5 years exceeds 20%. Whilst many genes related to the
cell cycle and proliferation have been shown to predict outcome in ER positive disease,
significantly fewer such genes have been identified in ER negative disease. The latter include
genes relating to immune response [445,475,477.494]
Stromal gene signatures are also of increasing interest and several of these have been
identified [495"498li although as yet, their usefulness in clinical practice has not been
determined. An appreciation of the importance of stromal rearrangement in the biology of
breast cancers treated with neo-adjuvant endocrine therapy influenced the selection of these
signatures for evaluation in the present study.
1.13.7 Predictive Signatures
Clinically useful gene signatures should also be able to predict response to treatments
including endocrine and chemotherapy. Indeed, the first generation signatures, by identifying
poor prognosis tumours with high expression of proliferation genes have proved useful in
predicting response to combination therapy that targets proliferation 1442-445 476] prec|jctj0n of
response to specific agents has been less successful 1499 5041 and there are currently no
commercially available signatures for this purpose. The search for such signatures may be
confounded by the fact that the mosaic of cell lines within a particular tumour confounds
microarray analysis. For example, a cell line within a tumour may express genes that confer
resistance whilst the remaining cell lines could be relatively sensitive. Microarrays are not
capable of distinguishing between the different cell lines within a tumour and instead present
the 'average' pattern of expression for the tumour as a whole.
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Many of the molecular sub-classifications of breast cancer whether based on the tumour
epithelium or stroma or both, are essentially descriptive of the cell type rather than the
underlying biological changes associated with tumour progression or response to treatment.
As a result, despite being predictors of survival, they are not yet clinically useful predictors of
treatment.
Efforts are now underway, to categorise gene expression signatures based upon their
responsiveness to adjuvant or neoadjuvant therapy [50S1. In this way, the signatures can be
used to determine the optimally effective treatment plan for individual patients.
1.13.8 Predictive Signatures in ER Positive Tumours
To date, no multi-gene test predicting response to neo-adjuvant endocrine therapy in
advanced ER positive tumours has been validated for clinical use. Recently however a
number of exploratory studies have applied pre-operative and advanced disease protocols to
examine the relationship between endocrine response and gene expression profiles [506"5101.
Jansen et al. evaluated clinical response to Tamoxifen in advanced breast cancers and found
that genes associated with clinical response included classical oestrogen related genes and
elements of 'stromal signature' including genes associated with extracellular matrix
production and immune response I506!.
A series of studies undertaken in Edinburgh have looked at molecular response to aromatase
inhibitors. Miller et al. studied sequential core biopsies taken before and after two weeks of
neoadjuvant treatment with Letrozole and related the early changes in gene expression to the
clinical response observed at the time of tumour excision [5081. At present this is the largest
study to report a predictive signature for neo-adjuvant endocrine treatment. However as yet
this signature lacks independent validation. Assessment of the performance of this signature
was therefore a major aim of this study (see Aims and Objectives).
Similarly, Mackay et al. studied gene expression profiles in sequential biopsies taken before
and after two weeks of neo-adjuvant treatment with either Anastrozole or Letrozole and
followed immediately with surgery I5071. However, they developed a signature that used Ki67
as a response surrogate to evaluate changes in proliferation.
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The molecular responses observed in both Miller's and Mackay's studies were generally
consistent. Aromatase Inhibitors suppressed classical oestrogen dependent and proliferation
associated genes. On the other hand, the most consistently up-regulated genes were
enriched by the stromal signature, including genes encoding specific types of collagens and
genes associated with cell adhesion, immune response and turnover of the intercellular
matrix. Significantly, these molecular changes were observed as early as two weeks post
treatment, before morphological changes were evident.
1.13.9 Stromal Gene Signatures
Breast stroma is increasingly recognised to play an important role in tumour progression and
invasion, and possibly initiation. The mechanisms by which this may occur are unclear but are
certainly complex and are the subject of a comprehensive review by Muschler and Streuli(5111.
These mechanisms are again influenced at the genetic level and significant effort is being
focused in this area.
Early gene expression studies used tissue derived from whole tumours composed of both the
tumour epithelium and stromal cells, making it impossible to distinguish the gene expression
profiles of each i157 158-446'447i Given that the tumour epithelium often only comprises about
half of the total tumour volume, this was a significant shortcoming l5121. The relevance of this
was reflected in the observation that the gene signature profile from the same tumour differs
when the biopsy is performed using FNA (stroma poor) or core biopsy (stroma rich) [495].
Furthermore, comparison of the gene expression profiles of stroma and epithelium from
normal breast and breast cancers, demonstrated that the stroma plays a role in tumour
progression even before invasion with 90% of the alterations occurring during the transition
from normal breast tissue to in situ carcinoma |5131.
The importance of the stroma is confirmed by a number of other studies [495'514'515]. One of
these looked at the expression of stromal genes in aggressive breast cancer and found that
genes encoding Syndecan (Sdc-1), Fibronectin and some Collagens were significantly up-
regulated compared with less aggressive tumours 1516].
In fact, stromal gene expression signatures may prove to be better predictors of patient
outcome because the stroma and not the epithelium may be the primary target of
carcinogens. When isolated normal mammary stroma was exposed to a carcinogen and
recombined with normal epithelium, a tumour developed. The same did not occur when
isolated carcinogen-exposed epithelium was recombined with normal stroma [517].
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Recently, microarray analysis was used to compare gene expression profiles of normal breast
tissue and breast tumours and these were correlated with patient outcomes [497]. A 26-gene
stromal signature (Stroma Derived Prognostic Predictor, SDPP) was identified and
subsequently trained to a 23-gene signature that stratified disease outcome independently of
standard clinical prognostic factors including lymph node status. The signature was also
found to be a better predictor of survival than whole tumour signatures from amongst patients
with multiple clinical subtypes of breast cancer, having even greater accuracy than predictors
that were derived from whole tumour samples. Five and later six, categories of altered
stromal gene expression were identified: matrix remodelling, hypoxia, fibroblast signalling, ER
signalling, angiogenesis and the immune response. Each category exhibits distinct molecular
and biological phenotypes, carrying prognostic information that is independent of existing
therapeutic biomarkers and tumour subtypes. The presence of a defined stromal signature
such as this, allows whole tumours to be analysed for predictive purposes, bypassing the
need to isolate stromal cells [497 518]. Another gene expression study of stroma tissue has
identified a wound response signature that predicts poor survival in whole tumours [463 4971
In terms of predicting therapeutic responses, Farmer et at. developed a stromal gene
expression signature that predicts resistance to pre-operative FEC chemotherapy for patients
with ER negative tumours. The genes expressed in this signature are associated with
reactive stroma and this was taken to indicate that anti-stromal agents could be useful in
mitigating tumour resistance to chemotherapy [496].
Since the complex communication between the stroma and the tumour epithelium underlies
tumour progression and metastasis, better understanding of stromal gene expression
patterns may lead to novel strategies for improving patient outcome.
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2. Aims and Objectives
2.1 Aims
Approximately 75% of all breast cancers are ER positive and the vast majority of these occur
in postmenopausal women. Amongst this group of patients, neoadjuvant endocrine therapy is
used widely in an attempt to reduce tumour size prior to surgery. For some patients, this will
permit breast-conserving surgery to be performed instead of mastectomy, whilst for others it
can make an inoperable cancer operable. A further group of patients with advanced
inoperable disease may be palliated with endocrine therapy.
It is clear however that not all patients respond to endocrine therapy and for those that do, the
response may vary in magnitude and longevity. It is therefore essential to find an accurate
and consistent means of predicting which subset of ER positive patients will respond well to
endocrine treatment, so that the others can be spared unnecessary delays in receiving more
appropriate forms of treatment.
Molecular classifications of breast cancers using microarray technology and other means
show great potential to refine the current clinical classification systems. Gene expression
signatures have been largely derived from whole tumour specimens and have focused
primarily on tumour epithelium. More recently, the importance of peri-tumoural stroma has
been demonstrated and several stromal signatures derived. Not only do these signatures help
with the sub-classification of breast cancers into clinically useful groups, but they may also be
used to provide a prognosis and help predict which patients will respond to specific
treatments. Furthermore ontological assessment of the genes comprising these signatures
may help elucidate the control mechanisms underlying the development, progression and
response or resistance to treatment for breast cancer.
Nonetheless, at the time when the present study was conducted, the clinical utility of only one
of the published gene expression signatures had been tested in the neo-adjuvant endocrine
setting 15101 and this had yet to be validated in an independent dataset. Since then however,
several published studies have investigated response prediction to Als in this setting I519"521!
The aim of this study therefore was to validate the efficacy of the published neo-adjuvant
endocrine response predictive signature and to compare it to other potentially informative
signatures.
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Gene expression signatures reflective of proliferation and stromal rearrangement were
selected for comparison. Proliferation signatures were chosen because they reflect the
principle component of the majority of previously described adjuvant signatures'522'.
Additionally, they represent the main gene cluster change following two weeks of neo¬
adjuvant treatment with Letrozole'508' 523'. Stromal rearrangement signatures on the other
hand, were selected for their important biological role in response to endocrine treatment'168
309 3261 and for their potential to predict neoadjuvant response to cytotoxic chemotherapy. To
ensure that the results were pathway related, rather than being related to a specific signature,
two signatures were reported for each pathway.
In light of the strong preliminary evidence supporting the clinical relevance of proliferation, the
following were investigated further:
(i) Shifts in mRNA expression of selected Cyclins and CDKs during neo-adjuvant
treatment with Letrozole using real-time quantitative PCR.
(ii) The association of proliferation with long-term outcomes in a sub-group of Al
treated patients, using immunohistochemical measurements of Ki67 as a
surrogate marker of tumour proliferation.
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2.2 Objectives
The objectives of the study were therefore as follows:
(i) Identification and enrolment of patients.
(ii) Collection of response and survival data.
(iii) Assay of tumour samples by microarray analysis.
(iv) Validation of the 205-covariables signature published by Miller et al. [510] against a
new and independent dataset.
(v) Identification of four relevant published signatures for comparison: Two proliferative
and two stromal ^1,496,508,524,525]
(vi) Comparison of the predictive capacity of each signature using all available datasets
derived from this and previous studies based on the Edinburgh Letrozole Audit
series.
(vii) Measurement of changes in the expression of mRNA of Cyclins B1, A2, D1, CDKs
1,2 and 4 and the NUSAP1 gene (a mitotic spindle associated protein) by real-time
PCR in a sub-group of cases. Then to relate these changes in expression of the
Cyclins/CDKs to changes in Ki67 (measured by ICH) and clinical response to
neoadjuvant therapy.
(viii) Relate neoadjuvant changes in Ki67 within a subgroup of patients, to breast cancer
specific survival and to compare Ki67's prognostic capacity with classical clinical
parameters, such as tumour size and lymph node status.
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3. Methods and Results
3.1 Study Design
The study design is summarised in Figure 3.1A-C below. In brief, enrolled patients were
treated with neoadjuvant Letrozole whilst sequential tumour biopsies were taken before and
early in the course of treatment. Tumour response was assessed during treatment using 3D
ultrasound and whole genome mRNA expression profiles were obtained using high-density
microarrays. The performance of the published gene expression signatures was assessed
using the microarray and clinical response data. Two focused sub-analyses were performed
using real-time qPCR and IHC data. Each of the study elements will be described in more
detail in the subsequent sections.
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Focused Assessment of mRNA Expressions of Cyclins and CDKs
During Neo-Adjuvant Treatment with Letrozole (qPCR)
Sub-analysis 2:
Evaluating Long-Term Prognostic Capacity of Early Changes of Ki67
During Neo-Adjuvant Treatment with Letrozole (IHC)
92
3.2 Patient Selection and Enrolment
This study involved the prospective enrolment of postmenopausal patients presenting with
locally advanced or large yet operable, ER positive breast cancer for whom the current
clinical guidelines indicated neoadjuvant treatment with the aromatase inhibitor Letrozole.
All patients included in this study were diagnosed and treated at the Edinburgh Breast Unit of
the Western General Hospital. Those who met the eligibility criteria were discussed at a
weekly multi disciplinary meeting (MDM) and referred to the author or to one of the other
medical and research staff involved.
The inclusion criteria required that patients had:
(i) Previously untreated, biopsy proven invasive breast cancer.
(ii) Oestrogen receptor (ER) rich tumours (Allred score 5-8).
(iii) No evidence of metastatic spread.
(iv) Tumours that were amenable to clinical examination, mammography and ultrasound
scan.
(v) Ceased hormone therapy, such as HRT, at least four weeks prior to commencement
of Letrozole.
(vi) Capability to give written, informed consent.
Patients excluded from this audit included those:
(i) With premenopausal disease.
(ii) With Oestrogen receptor negative (or ER poor) tumours.
(iii) Having had prior treatment with endocrine therapy or treatment with another
investigational drug within 30 days of commencing Letrozole.
(iv) With transmissible disease (e.g. HIV, Hepatitis C).
(v) With severe renal or hepatic impairment or other co-morbidities.
(vi) Unable to give informed consent
(vii) Deemed unlikely or unable to maintain compliance with the treatment or follow-up
regimen.
Following the MDT, the author met with the patients to explain the purpose and aims of the
study, to provide details of the nature and timings of additional investigations that they would
be subject to, should they agree to participate and to determine their willingness to
participate. Written documentation was provided with the same information (Appendix III) and
follow-up appointments were arranged for further discussion and to obtain consent. A detailed
consent form was signed for each participant (Appendix II). Information about the study and
patient enrolment was sent to each patient's GP for their records.
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Letrozole has been established as a front-line neoadjuvant treatment within this population of
patients since 2001. In the present study, a standard daily dose of 2.5mg oral Letrozole was
prescribed for a period of three months. The duration of treatment was based upon previous
clinical experience and allows sufficient time to effect meaningful tumour response in most
cases, whilst avoiding prolonged, ineffective treatment and tumour progression in patients
that do not respond.
The use of the neoadjuvant setting allows for the in vivo and ex vivo assessment of the
clinical, pathological and molecular response to Letrozole at multiple time points, which are
independent of surgery or other treatments. Clinical and radiological assessments of the
tumours were made using callipers, USS and mammography and serial core biopsies were
taken at the time of diagnosis and repeated after two weeks and after three months of
treatment, the latter generally corresponding to the time of surgery (Figure 3.2A). The core
biopsies were fresh frozen or formalin-fixed for further analysis.
Long-term clinical outcome measures were recorded as part of an ongoing audit - the
Letrozole Audit series.
A sub-group of patients treated with various neo-adjuvant Als which included Letrozole,
Exemestane and Anastrozole for whom long term follow-up was also available, was used in a
sub-analysis which related neo-adjuvant Ki67 changes to breast cancer specific survival.
It is important to note that several studies were being undertaken simultaneously to maximise
the research potential of the information and tissue samples collected from these patients.
Whilst the author was involved in many of these, their purpose, conduct and findings are
outwith the scope of this thesis and are therefore not described.
These Studies were undertaken in accordance with the ethical principles of the declaration of
Helsinki and approved, in advance, by the Lothian Research and Ethics committee (LREC
06/S1103/65, 2001/W/BU/09, 07/S1103/26, 07/S1104/23 and 2001/W/BU/10) and the NHS
Trust Research and Development Department. Patients gave their written informed consent

































Ongoing Clinical Follow-Up |
Figure 3.2A: Summary of Study Chronology
Note: Additional ultrasound measurements were taken when possible
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3.3 Assessing Tumour Response and Clinical Follow-up
A variety of complimentary methods were utilised to evaluate initial tumour characteristics and
subsequent response to Letrozole treatment These included clinical, radiological and
pathological measures. In addition, patients were asked to confirm their compliance with the
treatment and report any side effects. Outwith the follow-up appointments, all patients in the
study were given contact details for the investigators with whom they could discuss side
effects or any other complications or concerns.
3.3.1 Clinical Examination
The maximum diameter of the tumour was measured in two perpendicular planes using
callipers. Based on the assumption that a tumour is approximately spherical, its volume (V)
can be related to its diameter (D) by the equation V=(ttD3)/6. Tumour volumes were recorded
at each time period. Any change in the overlying skin was also documented.
Measurements taken in this way are subject to intra and inter-observer variability and are
notoriously inaccurate, nonetheless they remain in common clinical use and it was therefore
considered to be an important variable to document in the present study.
3.3.2 Ultrasound
Ultrasound offers the potential to more accurately measure tumour volume by utilising the
third dimension of tumour thickness as measured from superficial to deep. In addition, the
tumour dimensions taken by USS do not include those of the skin and subcutaneous fat and
are therefore subject to less intra and inter-observer variability than calliper measurements.
The USS measurements for this study were undertaken using a Honda Convex scanner (HS-
2000) with a linear array probe. Tumour volume was calculated according to the formula
V=(dTTD2)/6, where d is the tumour thickness and D is the mean of the tumour width and
height. The results were recorded as above.
3.3.3 Mammography
Oblique and cranio-caudal mammographs were taken at the time of diagnosis and prior to
surgery. The diameter of the tumour was measured and used to calculate the tumour volume
in the same way as that described for calliper measurements above. This technique suffers
from some distortion associated with compression of the breast and tumour between the
mammographic plates.
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All three methods of volumetric assessment were applied at the time of diagnosis and
surgery. Additional USS and Calliper measurements were taken whenever possible, and at
least at 6 weeks to assess tumour response to Letrozole. Where these measurements
suggested a lack of response or indeed expansion of the tumour, consideration was made to
changing treatment as appropriate. Responsive patients however, were scheduled for surgery
at around three months. Dynamic changes in tumour volume measured by 3D ultrasound
were considered as the primary measure for response assessment as described later.
3.3.4 Pathological Assessment
At the time of tumour extirpation, the examining pathologist determined the exact invasive
tumour dimension both macro and microscopically, for comparison with those taken by the
pre-operative clinical methods (callipers, USS and mammography).
In addition, the tumour was assessed histologically by Haematoxylin and Eosin staining.
Changes in cellularity and fibrosis, known as central scar formation were assessed by
comparison with the biopsies taken at the time of diagnosis and after two weeks of treatment.
Such pathological responses have been reported in 60-80% of tumours after 3-4 months of
treatment 1328 3291 Response may also be indicated by a reduction of histological grade;
mitotic score being the most commonly affected grading feature [3281.
3.3.5 Classification of Tumour Response
Tumour endpoints, such as objective response and time to disease progression, are useful
only if based on widely accepted and readily applied standard criteria, which are in turn,
based upon assessment of anatomical tumour burden. Two such systems have been
published over the past two decades: the WHO classification, published in 1981 13211 and
subsequently a modified version known as the RECIST classification in 2000 I322-324] These
are however designed for use in the advanced disease setting.
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Since no defined classification systems currently exist for measuring response in the
neoadjuvant setting, trial centres commonly employ locally defined criteria. The following
modified WHO classification is routinely used in Edinburgh for clinical purposes [320].
• Complete Response (CR): No measurable tumour.
• Partial Response (PR): Reduction in tumour size of 50% or more.
• Minor Response (MR): Reduction in tumour size of 25% to 50%.
• No Change (NC): Less than 25% reduction or increase in size.
• Progressive Disease (PD): Increase in size over 25%.
Minor response and no change are also regarded as being indicative of stable disease.
The present experimental analysis used a highly selective approach based on several
sequential ultrasound measurements. Essentially, only tumours exhibiting extreme
responses (i.e.- rapid and stable responders or long-term non-responders) were selected.
Tumours with intermediate response were excluded from further analysis, to ensure true
biological comparison between responders and non-responders.
3.3.6 Outcome Monitoring
Patients were, and continue to be, monitored for disease recurrence (local and/ or distant)
and survival (disease-free, distant disease free and overall). Local recurrence was classified
as that occurring in the ipsilateral breast, adjacent chest wall or ipsilateral axillary nodal basin.
A sub-group of patients for whom long-term outcome data was available at the time of the
present analysis was used to relate breast-cancer specific survival to changes in Ki67
observed during neo-adjuvant treatment.
3.4 Tissue Collection and Storage
Core biopsies were taken under ultrasound guidance at the time of diagnosis and again
approximately two weeks later, following initiation of Letrozole treatment. This second biopsy
was optional although the majority of patients agreed to it. The final tumour specimen was
taken at the time of surgical excision, usually at three months following initiation of treatment.
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When taking a core biopsy, local anaesthetic solution (10-20mls of Lignocaine 1% with
1:200,000 adrenaline) was infiltrated around the tumour to minimise discomfort and bleeding.
Next, the skin overlying the tumour was prepared with Betadine antiseptic solution and a
fenestrated disposable drape applied to the chest to minimise the risk of infection. A small
incision was made over the palpable tumour through which a single use 14-gauge Bard Max
core biopsy cannula was inserted into the tumour substance. Several passes (approximately
8) were made to obtain sufficient and representative samples of the tumour. Pressure was
then applied to the biopsy site to minimise bruising and bleeding and a dressing applied.
On several occasions, tumour biopsies were taken by the lead clinician, using the ultrasound
guided Mammatome ™ biopsy device. This device employed a larger 8 or 11-gauge biopsy
cannula and suction to permit harvest of larger specimens than those from conventional core
biopsy.
The final (three month) tissue specimens were collected from the operating theatre at the time
of wide local excision or mastectomy, either by core biopsy on the excised specimen or direct
excision from the specimen performed by the surgeon or pathologist.
Each specimen was labelled with a unique, anonymised identifier. A part of the sample was
immediately fixed in Formalin and sent to the pathology department at the Western General
Hospital to be embedded in paraffin and undergo further histological analysis. The remaining
cores were immediately snap frozen in liquid nitrogen to preserve nucleic acids and
maintained in liquid nitrogen in the on-site tissue bank for later genetic analysis.
A spreadsheet was kept of patient and sample details to allow identification for later analysis.
3.5 Tumour Processing and RNA Extraction
Prior to molecular analysis, unit pathologists assessed frozen sections for tumour content.
Samples in which the malignant component exceeded 20% of the cross-sectional area were
chosen for RNA analysis. Tissue samples were not enriched for their malignant component
only, because the intention was to include stromal tissue for analysis in the belief that the
latter may also produce relevant genetic information.
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3.5.1 Extraction of Specimens from OCT and Stabilising RNA
The frozen-section specimens were returned from the pathology department embedded in
frozen OCT (Optimal Cutting Temperature buffer) and transferred on dry ice (Figure 3.5A).
The volume of OCT significantly exceeded the volume of tissue embedded within it by a
factor of 10 and therefore, the OCT had to be removed prior to RNA extraction so that the
appropriate ratio of reagents to tissue could be maintained throughout, to optimise the
extraction process.
This was achieved by placing the OCT-tissue blocks in pre-chilled (-20°C) RNA/afer®ICE
solution and storing them overnight at -20°C. The now stabilised tissues were defrosted to
room temperature immediately prior to use. Once the OCT had melted, the tissue biopsies
were collected using forceps.
Figure 3.5A: OCT Embedded Tissue.
RNA/afer®-ICE (Ambion, Texas, US) is a reagent used in the transitioning of frozen tissue to
room temperature in order to preserve high quality RNA for further extraction.
3.5.2 Procedure for RNA Extraction using Qiagen RNeasy Mini-kits
RNA extraction was performed by the author for a subset of tumour samples collected
between 2005-2008 and used in this study. The remaining samples were extracted by trained
laboratory personnel employed in the unit at the time.
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Weighing and Homogenising the Tissue
1. The defrosted tissue was weighed and 100mg used for RNA extraction, the
remainder was stored in RNA/afert8)-ICE according to the manufacturer's
recommendations.
2. The tissue was then disrupted by finely cutting into small pieces and
3. Transferred to a tube containing 2ml RLT buffer (Qiagen) and 2-Mercaptoethanol
4. This was then homogenised using a hand-held rotor-stator homogeniser (Qiagen
TissueRuptor or Silverson) for 45 seconds.
5. The homogenate was cleared by centrifugation for 3 min at room temperature.
6. 2 ml of the supernatant was then dispensed into pre-labelled tubes for RNA
extraction on Qiagen RNAEasy mini columns according to the manufacturer's
recommendations as described below.
RNA Extraction and Purification with RNeasy Mini Columns (Qiagen)
7. The lysates were mixed with 2ml of 70% ethanol by vortex for 2 minutes.
8. 700(tl aliquots were transferred into the pre-labelled RNeasy-mini columns, which
were centrifuged for 15 seconds and the flow-through discarded. This process was
repeated until the entire sample had been applied to the column.
9. 700i.il of Buffer RW1 (Qiagen) was applied to the column, which was centrifuged for
15 seconds, and the flow-through discharged.
10. 500pl of Buffer RPE (Qiagen) was applied to the column, which was centrifuged for
15 seconds, and the flow-through discharged.
11. Another 500(tl of RPE was applied to the column, which was centrifuged for 2
minutes, and the flow-through discharged.
12. The mini columns were left open and centrifuged for a further minute to dry them.
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Elution of RNA
13. 30^1 of RNase-free water was added to the mini columns and centrifuged for 1
minute to elute the RNA, which was then placed on dry ice for transfer and storage in
a freezer at -80°C.
After purification, the quantity and quality of the RNA was evaluated on an Agilent
Bioanalyser (Agilent Technologies UK Ltd, Berkshire) and on a Nanodrop-1000
spectrophotometer.
3.6 Microarray Analysis
Following RNA extraction, the tissue samples were subjected to whole-genome gene
expression microarray analysis in order to identify which genes, of many thousands, were
expressed and either up or down-regulated by Letrozole treatment. Qualified personnel at the
local Genetic Core Facility carried out both the labelling and amplification of the RNA samples
and microarray hybridisation.
3.6.1 Microarray Platforms
In principal, microarray analysis depends upon the hybridisation of thousands of specific DNA
probes on a microarray chip to fragments of DNA or RNA within the sample being analysed.
Prior to hybridisation, the RNA is amplified and labelled as recommended by the array
manufacturer.
The probes are short oligonucleotide sequences that correspond to a known gene or other
DNA element. These are synthesised and bound to a solid substrate surface such as glass,
known as a chip or array (Figure 3.6A). The surface of the array comprises thousands of
spots or 'features', typically measuring less than 10 microns in diameter and each containing
millions of copies of a single probe sequence in a specific position on the array.
When the tissue sample extract is added to the surface of the array under specific conditions,
the probes hybridise to their complementary sequences within the sample. Unbound
sequences are washed off the chip and the remaining hybridised sequences are detected by
the addition of a fluorescent tag, which adheres to biotin, attached to the fragments during the
amplification and labelling process, prior to hybridisation. The fluorescent features,
representing expressed genes, are detected using a microarray scanner and their signal
strength can be quantified by computer analysis.
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Various microarray platforms are commercially available. The Affymetrix® (Santa Clara,
California) and lllumina® (San Diego, California) systems are leaders in this field and both
were used in this study.
Affymetrix Arrays
The Affymetrix® HG-U133A (22283 features) system was used to analyse tissue samples
collected from the first 137 patients enrolled in this study (L2 series, see Section 3.8 for
details). The Affymetrix® chips contain a high density of multiple short probes, each of
approximately 25 nucleic acids. These are synthesised in-situ directly onto specific pre¬
defined locations on the chip by a process of photolithography and can hybridise to
complimentary aRNA (amplified, labelled RNA) within tissue extracts. Because the probes
are short, it is possible for several different probes to hybridise with the same sequence of
target RNA. To improve specificity, multiple 'perfect match' probes are used for each gene
along with multiple 'single-base mismatch' probes. The chips were scanned using the
Affymetrix 3000 laser scanner.
Figure 3.6A: Affymetrix Microarray Chip.
Ilumina® Arrays
The newer lllumina® array system (HT-12 chip) became available at the genomics laboratory
of the Roslin Institute at Edinburgh University and was therefore used for gene expression
analysis on all subsequent tumour samples (L3 series). This system uses pre-synthesised
probes that are attached to microbeads of 2-3 microns in diameter to a density of 800,000
probes per bead. The beads are randomly applied to micro-wells etched on a silica array
surface, each 5.7 microns apart (Figure 3.6B). These locations are 'decoded' after
manufacture and a unique 'bead map' is supplied with each array. The probes are longer
than those of Affymetrix at around 50 nucleotides each and approximately 30 beads at
different sites on each array contain the same probe to improve the quality of the data. In
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general, the lllumina HT-12 system allows for higher density analysis than the Affymetrix HG-
U133A system and can therefore produce even more reliable results.
lllumina Array Silicone Wafer
Photo Resistant Surface
Plasma Etched 1
Surface Cleaned & Glass





3um Beads in Wells
Figure 3.6B: lllumina Microarray System.
The present study used data generated using HG_U133A Affymetrix arrays (L2 dataset [508
5io, 523,525]^ anc) (-|uman hT-12 V3 expression Beadarrays (L3 dataset[526]).
3.6.2 Microarray Data Processing
Microarrays scans produce fluorescence intensity measurements for each probe spot, with
the intensities corresponding to the levels of hybridisation.
By their very nature this produces vast amounts of raw data, which needs to be processed
carefully in order to yield useful information. This process is highly complex and belongs to
the realm of bio-informatics and computer analysis but in essence involves a series of stages
described below. These are specific to the array technology used. The microarray data
processing for this study was carried out with the support of local bioinformaticians.
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Pre-Processing
There are several potential causes of variation in the intensity of an individual spot or feature
on a microarray. Whilst this may be due to an actual difference in gene expression, it is often
influenced by background 'noise', which needs to be eliminated or reduced, prior to final data
analysis.
'Noise' may be caused by non-specific hybridisation or other fluorescent artefacts. The initial
steps of pre-processing are usually carried out by computer software, which is provided with
the commercial microarray scanning equipment. Later steps may be carried out using
multiple third-party tools, for example the R-statistical software environment. In general, pre¬
processing aims to extract background intensity caused by non-specific gene probe
hybridisation. It also permits the comparison of data from multiple arrays. Microarrays
processed at the same time and in the same environment to minimise the variability in
analysis conditions, are referred to as a 'batch'. However, it is often necessary to process
samples at different times, in different batches. In order to negate or minimise the effect this
can have on data quality, some form of 'batch correction' processing must be applied. This
was performed by computer software.
Normalisation
A further source of noise relates to labelling and detection inefficiencies. Normalisation aims
to correct for differences that do not represent true biological variation between samples. It
also aims to remove systemic or technical variations in the relative intensities of each feature
and to correct for differences in intensities between samples, whether on the same or
different arrays. For example, with Affymetrix, the intensity of the probes on a given array can
be consistently higher or lower than those on other arrays. This is referred to, as array bias
and failure to correct for such bias would lead to serious errors in data interpretation.
Normalisation often makes use of genes that are constitutively expressed in all samples at a
constant rate (e.g. housekeeping genes) to act as intensity controls. Alternatively, the
summed intensity values of each whole array can be compared and used to normalise the
difference between them, based on the assumption that most genes are equivalently
expressed between different arrays and, the remainder, which are either up or down-
regulated, will balance each other out.
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The following pre-processing was used for each dataset:
L2 dataset
Raw expression values were read from Affymetrix' CEL files and normalised using the Robust
Multichip Average (RMA) algorithm, including background correction, normalizing, log-2
transformation and summarisation, as implemented in the Affymetrix R Bioconductor package
(http://www.bioconductor.org/). Doctor A. Krause, the Novartis bioinformatician responsible
for the Letrozole audit project at that time, performed this pre-processing. Further detail and
references can be found in the papers [508,510' 523l
L3 dataset
The background subtracted, non-normalised data were exported from lllumina Genome
Studio for downstream processing in Lumi R-package !527]. Seven arrays were excluded
because of their low global detection rate (<10%) or low mean intensity (<6.5). After applying
force-positive background correction, the data were log-transformed and quantile-normalised.
Low-expression probes were removed (detected with p<0.01 in less than 25% of cases).
Only probes classified as 'Perfect' or 'Good' according to the ReMOAT probe annotation were
used for the analysis l528!. This reduced the number of probes from approximately 47,000 to
11,000. Batch correction was performed using SVA R-package: ComBat correction
accounting for treatment response and sample type (baseline, 2 weeks or 3 months) without
interaction [529'530]. This pre-processing was performed by Dr. A. Larionov specifically for this
MD project in 2013.
L23 dataset
This dataset was produced by Dr. A. Turnbull through merging of the L2 and L3 datasets at
signal level. The detailed data processing is available in Turnbull et al (2012) 15261. Briefly,
prior to the integration, the L2 raw data were pre-processed using RMA from Affymetrix R
package and the L3 raw data were quantile normalised using lumi R package. A
sophisticated in-house bioinformatics algorithm was used to map compatible Affymetrix and
lllumina probes [5261. Only 7000 probes were found to be compatible out of 24,000 Affymetrix
and 43,000 if lllumina probes. Pre-processed expression values for the compatible probes




Filtering allows the identification and removal of non-informative genes, such as those either
not expressed in any studied sample or uniformly expressed in all samples. It also corrects
for poor quality or empty spots, outliers and control probes. Data are also processed by three
different means to determine which genes are significantly up or down regulated. These are:
i) Direction of change.
ii) Magnitude of change.
iii) Statistical significance of the change.
The function of these genes can later be ascertained by comparison with previously identified
biological pathways or gene ontology.
Downstream Analyses
Multiple methods of downstream analysis can be applied to the microarray data depending on
the specific study aims, for instance to detect differentially expressed genes or to visualise the
results. The present study calculated multi-gene expression scores and evaluated their
association with clinical response using Receiver Operating Characteristic Curve Analysis.
Details of these study-specific analyses are described later in section 3.11.
3.7 Reverse-Transcription and Quantitative Real-Time PCR for Selected Genes
The microarray analyses indicate the pattern of expression of genes within a tissue sample.
Changes in expression can be determined by analysis of the tissue samples collected at
different time points during treatment with Letrozole. However, microarray probes can
become saturated by target sequences and are not necessarily a reliable means by which to
quantify gene expression. In order to validate and quantify gene expression based on the
microarray results, quantitative polymerase chain reaction (qPCR) also known as real time
PCR was performed for selected genes (Section 3.16). The same technique was also
employed for the focused sub-analysis of the cell-cycle associated genes (Section 3.17).
Standard PCR can be used to target and amplify any specific nucleic acid sequence within a
tissue sample, which can also be quantified by different means. PCR comprises a series of
steps (Figure 3.7A):
1) The target gene for amplification is identified and used to design primers. These are
short nucleic acid sequences that are complementary to sequences flanking the
target of interest.
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2) The primers, buffer, a supply of nucleotides and the enzyme Taq polymerase are
mixed in appropriate quantities within a 'thermocycler'.
3) The thermocycler controls a cyclical variation in temperature to facilitate the
replication of the target gene. Each cycle consists of the following:
(i) The solution is raised to a high temperature (95°C), causing complementary
DNA strands to separate.
(ii) The temperature is then lowered to 50-60°C to promote hybridisation or
'annealing' of the synthetic primers to the separated DNA strands.
(iii) Finally, at a temperature of 68-72°C, the polymerase enzyme replicates the
DNA strand commencing at the annealed primer sequence.
At the end of each round, the number of target gene DNA strands is theoretically doubled.
Typically 25-50 cycles are performed to achieve amplification of the order of 1,000,000 fold
1 Double Stranded DNA
2 Gene of Interest Identified
& Paired Primers Designed
3. Primers, Nucleotides &
Taq Polymerase Added to
PCR Mix
4 Complementary DNA Strands
Heated to Separate
5. DNA Cooled & Primers Anneal
6 Each DNA Strand Replicated
from Primer by Polymerase
Enzyme
7. DNA Strands Containing
Target Gene Doubled.












Figure 3.7A: Amplification of Specific DNA Sequences by PCR.
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Standard PCR does not however allow for quantification of the amplified DNA. Real Time or
quantitative qPCR does permit relative or absolute quantification of the DNA by means of
either double-stranded DNA intercalating-dyes such as SYBR green, or by the use of
fluorescently labelled oligonucleotide probes which can be quantified during the PCR
process. The latter technique is more specific: the bases at either end of the probe are
labelled with a fluorescent reporter tag and a 'quencher', which serves to absorb the
fluorescent energy from the tag when in close proximity to it. As the polymerase reaction
proceeds, the fluorescent probe is cleaved off the DNA strand as is it replicated. The tag and
quencher are therefore separated and the resulting fluorescence can be detected with a
fluorometer. The SYBR green technique used in the present study does not require the
synthesis of specific labelled probes and can still be used for reliable quantification of PCR
targets.
The relative quantity of target within a sample can be measured by comparison to one of
several standard, constitutive genes that are considered to be expressed at consistent rates.
In breast cancers undergoing endocrine treatment, the TBP, KIAA0674 and PUM1 genes
show low variation in expression and can be used as references. Alternatively, an absolute
quantification can be obtained by comparison with DNA standards, using an absolute
calibration curve.
Whilst DNA is the natural substrate for PCR, the samples obtained in this study were of
mRNA. It was therefore necessary to convert them to cDNA using the enzyme reverse
transcriptase, prior to the application of a PCR technique similar to that described above.
Reverse transcription and qPCR were performed by the author for a subset of tumour
samples collected between 2005-2008 and used in this study. The remaining samples were
processed by trained laboratory personnel employed in the unit at the time.
3.7.1 Reverse Transcription Protocol
The following protocol for the superscript® VILO™ cDNA synthesis kit (Invitrogen) was used
to convert the RNA specimens to cDNA for use on PCR, according to the manufacturer's
recommendations:
1) The RNA samples were treated with DNase enzyme to degrade all DNA
contaminants within the samples.
2) The pre-measured concentration of each RNA sample (Nanodrop 1000) was used to
calculate the appropriate dilution with RNase-free water to achieve a concentration of
125ng/pl.
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3) A mastermix was prepared comprising:
6pl of RNase-free water
4pl of 5X VILO ™ reaction mix
2pl of 10X superscript ® enzyme mix.
4) The mastermix was vortexed, briefly spun and aliquots of 12pl were dispensed into
0.5ml Eppendorf tubes for each reaction
5) 8pl of diluted RNA specimen was added to the tube of mastermix solution to achieve
a total of 1pg of RNA in a final reaction volume of 20pl, which was gently mixed.
6) A PCR thermal cycler (Thermo Hybaid, Ashford, England) was used to control the
following incubation sequence:
25°C for 10 minutes.
42°C for 60 minutes.
85°C at 5 minutes to terminate the reaction.
7) The resultant cDNA solutions were diluted ten fold by adding 180pl of RNase-free
water, which was then mixed by vortex and divided into four 50pl aliquots which were
stored at -20°C for later use.
Control samples were also required for the PCR assays. One type of control was prepared
using RNA from one of the most abundant tumour samples in which the Reverse
Transcriptase component was substituted with DNase-free water prior to the PCR reactions.
The second series of controls (Non-template, NTC) were processed using water instead of
cDNA samples.
3.7.2 Selection and Design of Primers
PCR primers were designed using the Primer-3 software (open-source online software),
avoiding known SNPs. Since the PCR was run on cDNA samples prepared from RNA, only
expressed sequences (Exons) could be used in the PCR primers. At least one primer in each
pair spanned exon boundaries or the primers were each located in different exons, preferably
co-located on the gene with the sequences detected by the microarray probes. The primer
sequences were then validated on the public database RTPrimer DB (www.rtprimerdb.org)
and the National Centre for Biotechnology Information's e-PCR tools
(www.ncbi.nlm.nih.gov/projects/e-pcr/reverse.cgi). Once validated, they were ordered and
supplied by Sigma Genosys (Dorset, England).
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Finally, the primers were validated using gradient PCR, which essentially completes PCR
cycles at a range of different annealing temperatures (50-64°C) in order to determine the
optimal annealing temperature.
The Primers sequences are shown below in Table 3.7A
Gene Forward Primer Reverse Primer Function
CCND1 TGTCCTACTACCGCCTCACA CCAGGTCCACCTCCTCCT Proliferation/Cell cycle
CCNA2 ACAAAGCTGGCCTGAATCAT ACTGTTGTGCATGCTGTGGT Proliferation/Cell cycle
CCNE1 ACAGCTTGGATTTGCTGGAC GCTCTGCTTCTTACCGCTCT Proliferation/Cell cycle
CCNB1 CATGGTGCACTTTCCTCCTT CAGGTGCTGCATAACTGGAA Proliferation/Cell cycle
CDK2 GTGGTGTGGCCAGGAGTTAC CAGCATTTGCGATAACAAGC Proliferation/Cell cycle
CDK4 ACTGGCCTCGAGATGTATCC AGGCAGAGATTCGCTTGTGT Proliferation/Cell cycle
CDK1/
CDC2
TGGCCAGAAGTGGAATCTTT AAATTCGTTTGGCTGGATCA Proliferation/Cell cycle
NUSAP1 AGTTTGTCTCGTCCCCTCAA CGTTTCTTCCGTTGCTCTTC Proliferation/Cell cycle
DCN GGGCTGGCAGAGCATAAGTA CAGAGCGCACGTAGACACAT Stromal
adhesion/rearrangement
COLEC12 TGGAACGATTTCCAATGTGA TTTGGGTAATGACGGATGGT Stromal
adhesion/rearrangement
MMP2 TGCTGGAGACAAATTCTGGA TGATGCTTCCAAACTTCACG Stromal
adhesion/rearrangement
KIAA0674 GGGCAACTCTGAAAGCTCTG CTTCATCCCAGCCAGTCAAT Reference
PUM1 CGTGGTCCAGAAGATGATTG TACGAAGAGTTGCGATGTGG Reference
TBP GGGGAGCTGTGATGTGAAGT CCAGGAAATAACTCTGGCTC Reference
Table 3.7A: Primer Sequences for all PCR Analyses.
3.7.3 Quantitative PCR Protocol
Quantitative PCR was undertaken using the QuantiTect SYBR Green® qPCR kit (Qiagen)
and 96x PCR plates on an Opticon™2 DNA engine thermal cycler (MJ Research, Bio-Rad).
This kit utilises SYBR Green fluorescent dye to bind to double stranded DNA and enable
quantification of PCR targets without the need to synthesise specific probes. All work was
undertaken in a safety cabinet to prevent contamination.
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The following protocol was applied:
1) The prepared cDNA samples, primers and SYBR Green PCR mastermix were
thawed and placed on ice.
2) All the reagents were spun briefly to ensure collection of the content in the bottom of
each tube.
3) Thirty-two 0.6ml tubes were pre-labelled and placed in a tray on ice.
4) The PCR mix containing RNase-free water, SYBR green and 2 primers was prepared
as follows:
2x QuantiTect SYBR Green PCR mastermix 25 pi
Primer A: Variable volume to achieve a final concentration of 0.3pM
Primer B: Variable volume to achieve a final concentration of 0.3pM
RNase-free water to make total volume up to 45pl in each pre-labelled vial.
5) 45 pi of the PCR mix was pipetted into each of the 32 pre-labelled tubes.
6) 5 pi of cDNA preparation was then added to each tube.
7) The tubes were mixed by vortex and spun briefly to collect the content in the bottom
of the tube.
8) 15 pi of each PCR/cDNA mix was pipetted into 3 cells on a white 96x PCR plate to
ensure the optimal reflection of the fluorescent signal.
9) The plates were centrifuged briefly (3000 rpm, 1 min, room temperature).
10) PCR was carried out on the Opticon™2 thermal cycler set with the following
parameters:
- Once only activation of Taq DNA Polymerase, 15 minutes at 95°C
- Denaturation, 15 seconds at 94°C
- Annealing, 30 seconds at 56°C
- Extension, 30 seconds at 72°C
- Fluorescence data collected at 72°C
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11) The PCR cycle was repeated 50 times.
12) PCR cycling was followed by once only 5' elongation at 72°C.
13) A melting curve analysis was performed on the thermal cycler following the DNA
amplification cycles to verify the specificity of PCR products, based on the binding of
SYBR green to double-stranded DNA. During this analysis, the product of qPCR was
gradually heated until the DNA strands were dissociated and released the SYBR
green dye with a corresponding drop in measurable fluorescence. This allowed
detection of the melting temperature of the formed PCR product(s).
14) PCR results were normalised by geometric averaging of three housekeeping genes:
KIAA0674 (FKBP15), PUM1 and TBP The genes and primers used for their
detection are presented in Table 3.7A These housekeeping reference genes were
validated in previous studies from our unit and found to be expressed stably in clinical
breast cancer biopsies undergoing endocrine treatment [532l
3.8 Datasets
The datasets used in the present work have been generated during a Letrozole Audit initiative
in the Edinburgh Breast Unit between 1999 and 2010. The relationship between each
dataset and their allocation within the Letrozole Audit series as a whole, are illustrated in
Figure 3.8A. The initial small set of subjects known as LETMA-1 (LETrozole MicroArray) or
'L1', was used for methodology and logistics optimisation and was not used in the present
analysis. The author personally participated in enrolment of patients between 2005 and
2008. Qualified personnel employed in the Unit at the time have enrolled other patients used
in the present analysis.
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Allocation of Patients into Datasets within
Letrozole Audit Series in Edinburgh Breast Unit
2000 2001 2004 2010
L23
Figure 3.8A: Overview of Datasets.
3.8.1 Letma 2 (L2)
The first 137 patients enrolled into the Letrozole audit between 2001 and 2004 were
incorporated into the L2 dataset used in the present study (52 of these were reported by
Miller et al. earlier '508 510 523l) Tumour sample microarray analysis was performed using the
Affymetrix HG-U133A platform. Doctor A. Krause performed the microarray pre-processing
using Robust Multichip Average methodology 1533 5341
Of these 137 patients, only those with a complete set of measurements taken at baseline
(pre-treatment), two weeks and three months and high quality RNA samples were included in
the final analysis. Sixty-eight paired samples (Baseline and 2-weeks) from 34 subjects were
therefore selected for present analysis based on the tumours' response to treatment (see
Tablel in Datasets and Signature Translation, Appendix V)
After this period, the llumina HT-12 assay replaced Affymetrix HG-U133A because it became
locally available and additionally includes a greater number of features. Furthermore, the use
of an alternative platform permitted platform-independent validation of the L2 series results in
the subsequent L3 series of tumour samples.
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3.8.2 Letma 3 (L3)
Continued recruitment into the Letrozole Audit after 2004, produced a second dataset, the L3
series. This group was recruited in exactly the same way as the L2 series and treated
according to the same protocol, although fewer patients consented to a two-week biopsy or
had clearly documented USS measurements at three months. The main difference between
L2 and L3 related to the microarray platform used in their analysis. Microarray was performed
on Human HT-12 V3 expression BeadArrays (lllumina, Cambridge, UK). Overall, the L3
series recruited a further 257 patients of which 44 had complete, high quality data and tissue
samples for inclusion at the time of this study.
Doctor A. Larionov performed the microarray pre-processing for this series. The background
subtracted non-normalised data were exported from lllumina Genome Studio for downstream
processing in Lumi R-package. Some arrays were excluded because of a low detection rate
(<10%) or low mean intensity (<6.5). After applying force positive background correction, the
data were log-transformed and quantile-normalised. Low-expressed probes were removed
(detected with p<0.01 in less than 25% of cases). Only probes qualified as "Perfect" or
"Good" according to ReMoat probe annotation were used for the analysis [528' This reduced
number of probes from the initial ~47k to ~11k probes. Batch correction was performed
using SVA R-package: ComBat correction accounting for treatment response and sample
type (baseline, 2 weeks or 3 months) without interaction [529 530] Finally, sixty paired samples
(baseline and 2 weeks) from thirty subjects were selected for the analysis basing on their
response to treatment (see Table2 in Datasets and Signature Translation, Appendix V).
3.8.3 Letma 2 and 3 (L23)
Whilst the L2 and L3 series were identical in terms of recruitment and inclusion / exclusion
criteria, the microarray analysis was performed using different platforms as above. Combining
the data from both series therefore has the potential to improve statistical power of
subsequent analyses, however direct integration of expression data is complicated by the fact
that different platforms were utilised. Even the scanner used in data collection and the day on
which samples are analysed can introduce inter-platform bias. In order to combine these
datasets, the microarray data from lllumina and Affymetrix analyses was first translated into a
'common language' using the pipeline for Affymetrix and lllumina integration described by
Turnbull et al. [526l This cross platform integration was mediated using gene ID's from the
Ensembl genome browser (www.ensembl.org), which was shown to significantly out perform
other methods of cross platform integration I526].
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In the present study the combined dataset was used to improve statistical power when
comparing the signatures that had not been derived from either L2 or L3. However, this
dataset could not be used for assessment of the Edinburgh signature because the signature
was partially derived from these samples. A total of 99 patients were included in the L23
dataset.
The method of data integration has been previously described in detail in Turnbull 2012 [526'.
In summary, the data from different platforms were first pre-processed separately, using tools
specific for each platform (i.e. Affymetrix and lumi R packages - see section 3.6.2). Genes
with low detection rates were removed Batch-effect correction was performed using ComBat
R script [529' |_2 probes were re-annotated to Ensembl Gene IDs using the custom Chip
Definition File (CDF[4711). L3 probes were re-annotated to Ensembl Gene IDs using
ReMOAT15281 and a custom BLAST and BioMart search. This strict methodology ensured that
only comparable probes were taken for the downstream data integration; numerically
reducing the dataset to only 7000 compatible probes out of 24,000 Affymetrix and 43,000
lllumina probes. Pre-processed, batch-corrected and re-annotated data for the compatible
probes were integrated using the XPN (cross-platform normalisation algorithm described in
Shabalin et at. 2008 |531]. Finally, 126 paired samples (baseline and 2 weeks) from 63
subjects were selected for the current analysis based on their response to treatment (see
Table3 in Datasets and Signature Translation, Appendix V) .
3.9 Tumour Response
Tumour response was assessed by measuring any change in tumour size between the initial
assessment at the time of diagnosis, and following two and 12 weeks of Letrozole therapy.
Although calliper, mammography and three-dimensional USS measurements were all
recorded, the latter is known to be the most accurate and reproducible and was therefore
used as the primary determinant of tumour response in the present study [53S|.
In order to classify tumours by response, the change in tumour volume by three-dimensional
USS was plotted against time, for each dataset (Figures 3.9A-C). For the purpose of this
study, responders were classified as those whose tumour volume reduced by 50% or more at
60 days and 75% or more at three months. Non-responders were classified as those who
failed to reach a reduction in tumour volume of at least 50% by the time of tumour excision at
3 months. All remaining patients were classified as intermediate responders and excluded
from subsequent analysis in this study with the purpose of separating clear responders from
clear non-responders
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Of the 57 patients included in the L2 dataset, 24 (42%) were classified as responders and 10
(18%) as non-responders. Twenty-three patients (40%) were classified as intermediate
responders and excluded from further analysis (Figure 3.9A).












Similarly, in the L3 dataset 18 patients (41%) were clear responders and 12 (27%) non-
responders. Fourteen intermediate response patients (32%) were excluded from further
analysis (Figure 3.9B).
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Figure 3.9.B: Tumour Response by USS in L3 Series
0 20 40 60 w
Day of treatment
-P029 P040 P051 P064 P150 P171 —P179 —P200 -—P203
P208 P209 P214 P215 P226 P264 P269 —P288 —P291
-P299 P300 P309 P311 P322 P328 P329 ——P331 P332
-P333 P334 —P340 P341 —P343 P346 —P350 —P353 —P354
P355 P357 P363 P364 P367 P369 P373R P374
When the combined datasets were considered (L23), there were 42 (42%) responders, 21
(22%) non-responders and 36 intermediates (Figure 3.9C). The discrepancy in the count for
intermediate and non-responders (where L23 t L2+L3), is due to the patients P103 (L2 non-
responder) and P117 (L2 intermediate responder) who were included in L2 dataset (Miller
2007, Miller 2009 and Miller 2012) but eliminated from the L23 dataset (Turnbull 2012). This
is illustrated in Figures 3.9A and 3.9C.
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3.10 Selection of Gene Signatures
The microarray analyses were used to validate established breast cancer signatures for their
predictive power in these datasets. Other groups have published a large number of breast
cancer signatures, though none were specifically designed in the neo-adjuvant setting at the
time that the present study was undertaken. Therefore, after an extensive literature search, a
few of these 'adjuvant' signatures were selected for evaluation in the present study on the
basis of their anticipated relevance to the neo-adjuvant setting. Two signatures were selected
for proliferation and two for stromal rearrangement, to ensure that the results related to the
pathway rather than to any one specific signature.
In order to extend the basis for comparison, the efficacy of these signatures was also
compared to that of the Edinburgh signature on an extended series of patients. This included
the initial dataset published by Miller et at. (2009) and the subsequent L3 dataset.
The overlap of genes within the various signatures in represented in the Venn diagram in














Figure 3.1 OA Representation of the numbers of overlapping genes within each of the
signatures used in the present study. See Appendix IV for gene lists.
Beck Beck Dai Nagalla Dai
Miller Farmer Nagalla Miller Miller
1 24 7 5 1
























Table 3.10A: Table showing number and lists of genes common to paired signatures.
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3.10.1 Signature Translation
When assessing the efficacy of any particular gene expression signature within a population
of samples, consideration has to be given to the microarray platform used to design the
signature and that used to process the samples.
Affymetrix and lllumina microarrays differ in the selection, design and length of their
oligonucleotide probes, which therefore may have variable affinity for different regions of any
particular gene. In this way, probes intended to hybridise with the same gene may not do so
equally effectively on either platform. In addition, the one-base mismatch probes of Affymetrix
arrays act as a competitive hybridisation control, whereas the lllumina uses multiple copies of
the same probe on each array to provide an internal non-competitive hybridisation control.
Other differences such as the probe layout and the ability to process multiple arrays in
parallel using lllumina, contribute to the potential difficulty in comparing data derived from
either platform. For these reasons, some form of signature translation is necessary.
Nevertheless the correlation between these two platforms in particular has been shown to be
surprisingly good'536'.
Human genome sequence data are held in a number of open access online databases. The
following are part of an international collaboration and exchange data on a daily basis:
- European Molecular Biology Laboratory (EMBL) Ensembl database.
- American National Centre for Biotechnology Information (NCBI) GenBank database.
- Japanese DNA DataBank of Japan (DDBJ).
The HUGO (Human Genome Organisation) Gene Nomenclature Committee is the only global
authority assigning standardised nomenclature to human genes including unique gene
identifiers (gene IDs) and short codenames or 'symbols' for each.
Database interrogation can be made directly but recent applications such as BioMart
(www.biomart.org) can be used as a single online interface to access these multiple sources.
In the present study, the genes within each signature were translated into a "common
language" using the databases described above and some further optimisation procedures
summarised in Turnbull et al. [526]. In doing so, some genes from the original signatures
chosen for use in this study, were excluded on account of their low cross-platform correlation
and reliability. The methods used for the translation of each signature are described below,
together with a description of the signature itself.
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No translation was needed to apply the Nagalla and Miller signatures to L2 dataset as all
were derived with the Affymetrix platform. However, signatures, which reported HGNC Gene
Symbols were translated to the required namespaces using the Ensembl Biomart web
interface (www.ensembl.org/biomart). In several cases, the initially reported gene
symbols/IDs had to be manually verified to account for the nomenclature change since the
date of publication. To convert Affymetrix signatures to lllumina and ENSG name-spaces we
used the optimised translation table developed by Dr.A.Turnbull[5261.
Translation always affected the number of features in the signature. Ensembl Biomart
translation from HGNC to Affymetrix or lllumina namespaces usually increased the numbers
of features, because of the multiple probes associated with the individual genes. Conversion
from Affymetrix to lllumina namespace using Dr.TurnbuH's translation tables usually reduced
the size of signature because it included only probes directly comparable between Affymetrix
and lllumina platforms. Of note, the effective number of features might be further reduced if
some of the features were not available in the dataset. A summary of the signature




















Optimised translation Ensemble Biomart
Key: No translation needed (Turnbull 2012) Translation
Figure 3.10B: Overview of Signature Translation. Signatures used for this analysis had
different feature IDs: Miller's and Nagalla's signatures reported Affymetrix probe IDs, whilst
the remaining signatures - Dai, Farmer and Beck - reported HGNC gene symbols. For the
downstream analysis the signatures first had to be translated into the datasets' namespaces
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3.10.2 The Edinburgh Signature - Miller 2009 [51°)
The Edinburgh signature, which is the only signature generated from patients treated with
endocrine therapy in the neoadjuvant setting, was chosen as a benchmark for validation and
for further comparison with pathway focused signatures previously described and validated in
the adjuvant setting
Miller's signature included genes both positively and negatively associated with response.
The association with response for the current analysis was obtained from Supplementary
Figure 3 of the original publication. The signature was derived using the Affymetrix arrays
and translated into Ensembl and lllumina IDs using an optimised procedure described by
Turnbull et al. [5261. The noticeable loss of genes during translation reflects the exclusion of







AFFY 205 182 201 Original namespace
ENSG 74 67 64
LUMI 143 67 70
3.10.3 Proliferation Signature - Dai 2005 [471]
The first proliferative signature chosen for this study was that derived by Dai et al. The
signature composition is illustrated in Figure 2 and in Supplementary Table 3 of the original
publication. It includes a series of 50 genes that were highly correlated with outcome in a
population of 311 patients with relatively high ER positivity for their age (all were under 55
years). Almost all of these genes were found to relate to the cell cycle and their over-
expression correlated with very poor outcome (471'. The 50 genes were presented as HGNC
Gene symbols and Gene-bank IDs.
A manual search for each symbol and ID was conducted using Ensembl and NCBI databases
online. Only 40 of the 50 genes could be identified. The genes that could not be identified
had been described in the initial signature in a non-conventional way (Contig57584_RC,
Contig38901_RC, Contig41413_RC, Contig31288_RC, Contig64688, Contig44289_RC,
Contig28552_RC, Contig46218_RC, Contig28947_RC and Contig38288_RC). Two of the
remaining 40 probes described the same gene and were therefore combined (AURKA:
STK15/ STK6 = NM_003600/ NM_003158). The resulting 39 HGNC gene symbols, all of
which were associated with cellular proliferation (35 positively, 4 negatively) were translated
to Ensembl, lllumina (HT12) and Affymetrix (HG U133A) gene IDs using the Ensembl BioMart
online interface.
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Namespace Total Unique NGNC
symbols
Notes




3.10.4 Proliferation Signature - Nagalla 20 1 3 15251
Nagalla et at. analysed gene expression profiles from almost 2000 breast tumours to identify
three gene signatures (termed metagenes) associated with distant metastasis-free survival,
each of which related to different immunological functions. Among this subset, tumours were
stratified into high, medium and low proliferation groups by a further proliferative signature.
The prognostic strength of each immune metagene was dependent on proliferation and
greatest amongst highly proliferative tumours, where increased levels of expression were
associated with a markedly reduced risk of metastasis; suggesting that a subset of immune
responders exists among highly proliferative tumours, with potential prognostic ramifications
[525]
The metagene used in this study was obtained from supplementary Table 6 of the original
publication, and consists of 61 paired Affymetrix IDs, accompanied by 54 corresponding
unique gene symbols. The noticeable loss of genes during translation reflects the exclusion of
"non-reliable" probes and IDs, which had not passed the strict translation procedure. All
genes were positively associated with proliferation. Translation to lllumina IDs was performed








AFFY 61 61 54 Original namespace
ENSG 26 26 26
LUMI 39 26 26
3.10.5 Stromal Signature - Farmer 2009 [496]
Farmer et at. identified a stromal gene expression signature that predicted resistance to
neoadjuvant chemotherapy using FEC. The predictive value of this signature was
subsequently validated in two independent cohorts of patients who received chemotherapy,
but not in an untreated control group, which was taken to indicate that the signature was
predictive rather than prognostic. These 50 genes were all associated with a reactive stroma,
which is rich in activated fibroblasts, or CAF's I496]. Again, all genes were considered positively
associated with the stromal component.
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The stromal metagene used in this study was obtained from Supplementary Table 4 in the
original publication and includes 50 HGNC gene IDs that were translated to Ensembl, lllumina
(HT12) and Affymetrix (HG U133A) gene IDs using the Ensembl online interface.
Namespace Total Unique NGNC
symbols
Notes




3.10.6 Stromal Signature - Beck 2008 [524]
Beck et al. developed the second stromal signature selected. This group initially
demonstrated that the gene expression patterns in two types of soft tissue tumour, Desmoid
Type Fibromatosis (DTF) and solitary fibrous tumours, could be used to identify distinct
stromal reaction patterns in a subset of breast tumours |537'. They have since identified 66
DTF associated genes, consistently expressed in 25-35% of breast tumours, among a
population of 561 tumours, the expression of which is associated with low grade, ER positivity
and improved survival. After validation on a separate subset of tumours, this signature has
been recognised as a robust predictor of clinical response associated with improved survival
outcome l524'.
The DTF Core Gene Set was obtained from Supplementary Table 1 in the original publication
and includes 66 HGNC gene IDs. All were identified on the Ensembl or NCBI web sites and
subsequently translated to Ensembl, lllumina (HT12) and Affymetrix (HG U133A) gene IDs
using the Ensembl online interface. All genes were considered as positively associated with
the stromal phenotype.
Namespace Total Unique NGNC
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In order to assess the possible existence of proliferation genes within the stromal signatures,
Gene Ontology (GO) analysis was performed using the online tool at
www.omicslab.genetics.ac.cn/GOEAST [53S|. The results indicate that neither of the stromal
signatures was enriched by any GO term associated with promotion of cell division or
proliferation, suggesting that interference between the proliferation and stromal signatures
studied here is unlikely.
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The full list of detected GO terms is tabulated in Excel and attached in Appendix V. No GO
terms associated with proliferation were detected in Beck's stromal signature. On the other
hand, the Farmer signature may be enriched by genes associated with the negative
regulation of proliferation in the prostate ( G0:0060770, G0:0008285).
3.11 Signature Interpretation
3.11.1 Incorporating Dynamic Measurements
The datasets from the present study include pre-treatment tumour profiles as well as those
from early treatment samples taken at two weeks. This allows analysis of the signatures'
performance in three ways:
(i) On pre-treatment (baseline) data only.
(ii) On early-treatment (two week) data only.
(iii) On the change between these time points.
Such an approach was not necessary for the Miller signature, because it is comprised of
separate gene-lists for all three of the above.
3.11.2 Sign of Association
Most of the selected signatures included only genes "positively" associated with the
phenotypic feature. For example, the expression of all of the genes included in the Nagalla
signature increased in high-proliferation cases. Some other signatures however, included
genes both positively and negatively associated with the phenotypic feature. For example,
the Dai signature includes some genes whose expression is increased and others decreased
in highly proliferative tumours. The sign of association was therefore taken into account when
calculating the multigene scores as described in the next section.
3.11.3 Heat Maps
Following pre-processing of the microarray raw data, 'heat maps' were generated as visual
representations of gene expression. The intensity of the colours on each spot of the map
reflects the quantity of RNA hybridisation and therefore the level of gene expression (Figure
3.11 A).
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On these heat maps, the x-axis corresponds to the samples within the studied dataset and
the y-axis to the genes within the signature being assessed. The colour and intensity of each
spot on the matrix represents the sign of association and level of gene expression
respectively. Green represents down-regulated genes and red represents up-regulated
genes. When assessing the expression of a whole signature for a particular sample, the
intensity data, as represented in the heat map, can be converted into a single score for each
sample.
3.11.4 Multi-Gene Expression Scores
Signature performance was evaluated using a multi-gene expression score adapted from
Bedard l539'. This effectively represents the average gene expression within the signature,
taking into account the sign of association. In order to equalise the relative contribution of
each gene within the signatures and to minimise platform-specific biases, each gene
expression was Z-scaled before summation. The following formula summarises the
calculation:
EiWiXi
Gene Expression Score =
Where W, is the total expression value of each gene within the signature, X, is either +1 for
up-regulated expression or -1 for down-regulated expression and |Wj| is the absolute value of
W,
When the resultant scores are plotted in order of increasing value, a graph such as that in
Figure 3.11B is produced, with individual tumour samples on the x-axis and the multi-gene
expression score on the y-axis. The points on the graph are colour coded into clear
responders (green) and long-term non-responders (red) based on their USS measurements
(see section 3.9).
Gene expression scores were calculated in this way for each of the signatures against each
of the three datasets (L2, L3 and L23). The heat maps and graphs are available in the
relevant sections below.
127









Figure 3.11A (top) & B (below): Corresponding Heat Map and Multi-gene
Expression Score Chart for the Edinburgh Signature and Response for Samples
from the L2 series.
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3.11.5 Receiver Operating Characteristic (ROC) Curve Analysis
In a ROC curve the sensitivity (true positive rate) of a test is plotted as a function of one
minus the specificity (false positive rate) for different cut-off points of a parameter. Thus each
point on a ROC curve represents a sensitivity/specificity pairing which corresponds to a
particular threshold setting. ROC analysis is commonly used as a statistical test of
association between the signature and response which alleviates the potential 'over-fitting' of
results which can occur when vast amounts of data are generated from relatively few
samples.
As illustrated in Figure 3.11C below, the best possible predictive signature would yield a point
in the top left corner of the ROC curve, representing perfect sensitivity (no false negatives)
and perfect specificity (no false positives). On the other hand, a completely random signature
would give a point along a diagonal line from the bottom left to top right corners of the ROC
curve, known as the line of no discrimination. This line divides the ROC space into two equal
triangles. Points above this line represent a positive correlation of each signature to tumour
response (better than random), i.e. a signature with good predictive value. Points below the
line represent the opposite association or signatures with negative predictive value.
However, it should be noted that consistently negative predictors could be inverted to obtain a
positive predictor. Thus only an AUC of 0.5 indicates to a lack of association.
In the present study, calculations were performed using the pROC R package. 95%
confidence intervals (CI) of the AUC were computed with 2000 stratified bootstrap replicates
[540] ass0Cjatj0n was considered significant if the AUC CI did not include the value 0.5.
The combination of multi-gene scores with ROC analysis has been successfully used in
several studies of gene expression signatures in breast cancer[496 539l jhe advantage of this
approach is its simplicity and transparency whilst preserving an equivalent performance to
that of many alternative and more complex methods [541'. Furthermore, this approach
circumvents the need to select a specific threshold for signature comparison because the
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Figure 3.11C: Model of the Receiver Operating Characteristic Curve.
The area under the ROC curve (AUC) reflects how well the parameter, in this case the given
gene signature, functions to distinguish between the two groups - responders and non-
responders.
3.12 Validation of the Edinburgh Signature
The predictive capacity of the Edinburgh signature has been evaluated in all three datasets
using multi-gene scoring and ROC curves as described above. The results are shown on
Figure 3.12A.
Using the L3 series, it was confirmed, for the first time, that this signature has significant
association with neo-adjuvant response to Letrozole on an independent dataset. However,
the assessment of the Edinburgh signature on the L2 (and L23) datasets is not informative in
terms of prediction because the signature was derived from samples within this series and
would therefore be expected to perform well. Nevertheless, it is a useful benchmark for
comparison of the performance of the other signatures in this regard.
The results show that the ability of the Edinburgh signature to predict response to
neoadjuvant Letrozole therapy is statistically significant in all of the datasets. This is the first
time that this signature has been validated on independent (L3) and extended (L23) datasets.
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Figure 3.12A: Performance of Miller Signature on L2, L3 and L23 Datasets
L2: Miller-205, BL+W2+CH L3: Mlller-143, BL+W2+CH
L2: Miller-205. BL*W2*CH LS: Miller-143. BL*W2+CH L23: Miller-74. BL»W2*CH
i!f liiiplliillililf llllllilliligl lilliiillliiiliillgliilllil ill
i 3 Miliar ?n«; m «wnr.H L3 Millpr 141 Rl <wl.ru I 31- Miller.74 Rl +\M3»CM
Key: Dataset: Signature-Number of useable genes for each dataset: Time point
(BL=Baseline, W2= Week 2, CH = change between BL and W2). Note that the Miller
signature incorporates all three timepoints whereas the other signatures were assesed at
each time point as shown in the figures below. The number shown after the signature name
indicates the number of genes remaining in the signature after translation to the appropriate
namespace. For example, Miller-143 indicates that 143 genes have been retained in the
signature after the translation to the L3 namespace. However some genes were then lost
through pre-processing (e.g. poorly performing or annotated probes) and so the number of
genes shown on the heatmaps corresponds to those actually used. An overview of the
signature translation is shown on Figure 3.10B and discussed in the section 3.10.2 above.
The exact composition of translated signatures is shown in tables 4-18 of the Datasets and
Signature Translation file, Appendix V.
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In Figure 3.12A, the heatmaps (top panels), multigene expression scores (middle panels) and
ROC curve analyses (lower panels) are shown, indicating the performance of the Edinburgh
signature in each of the three datasets. In each case, the AUC CIs do not include 0.5,
indicating a significant association. Not surprisingly, the signature performed very well against
the L2 dataset from which it was derived and the extended L23 dataset. The reproducibility of
the result with the L3 dataset however, represents the first time this signature has been
validated against an entirely new dataset. Note that separate analyses for baseline, two-
weeks and change were not carried out as for the other signatures below because the Miller
signature incorporates these already.
3.13 Performance of Proliferative Signatures
Both of the independent proliferative signatures chosen for this study were designed for use
in response prediction to endocrine therapy in the adjuvant setting. The results of this study
nevertheless confirm their significant predictive application in the neoadjuvant setting for the
first time.
Significance was demonstrated at the two-week time point, but not at baseline for both
signatures on all three datasets (Figures 3.13A-F). In addition, the Nagalla signature alone,
demonstrated significant predictive power, comparable to that of the Edinburgh signature,
when changes in gene expression between baseline and two weeks were considered in the
L3 and L23 datasets.
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Figure 3.13A: Performance of Nagalla Signature on L2 Dataset
Baseline 2 Weeks Change










Key: Dataset (L2 or L3 or L23): Signature Name-Number of genes left in signature after
translation: Time point (Baseline, Week 2, Change between Baseline and Week 2). The
number shown after the signature name indicates the number of genes remaining in the
signature after translation to the appropriate namespace. Some genes were then lost through
pre-processing (e.g. poorly performing or annotated probes) and so the number of genes
shown on the heatmaps corresponds to those actually used. See section 3.10.4.
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Figure 3.13B Performance of Nagalla Signature on L3 Dataset
Baseline
L3: Nagalla 39, Baseline
2 Weeks
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Change
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Key: Dataset (L2 or L3 or L23): Signature Name-Number of genes left in signature after
translation: Time point (Baseline, Week 2, Change between Baseline and Week 2). The
number shown after the signature name indicates the number of genes remaining in the
signature after translation to the appropriate namespace. Some genes were then lost through
pre-processing (e.g. poorly performing or annotated probes) and so the number of genes
shown on the heatmaps corresponds to those actually used. See section 3.10.4
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Figure 3.13C: Performance of Nagalla Signature on L23 Dataset
Baseline 2 Weeks Change
L23: Nagalla 26. Baseline L23: Nagalla 26. Week-2 L23 Nagalla_26, Change
L23: Nagalla 26 Baseline L23: Nagalla_26, Week-2 L23: Nagalla_26, Change
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Key: Dataset (L2 or L3 or L23): Signature Name-Number of genes left in signature after
translation: Time point (Baseline, Week 2, Change between Baseline and Week 2). The
number shown after the signature name indicates the number of genes remaining in the
signature after translation to the appropriate namespace. Some genes were then lost through
pre-processing (e.g. poorly performing or annotated probes) and so the number of genes
shown on the heatmaps corresponds to those actually used. See section 3.10.4.
The three figures above (3.13A-C) show the heatmaps, multigene expression scores and
ROC curve analyses indicating the performance of the Nagalla (proliferative) signature in
each of the three datasets. In each case, the AUC CIs indicate a significant association at the
two-week time point and in the case of the L3 and L23 datasets there is an also a significant
association in relation to the change between baseline and two-week gene expression.
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Key: Dataset (L2 or L3 or L23): Signature Name-Number of genes left in signature after
translation: Time point (Baseline, Week 2, Change between Baseline and Week 2). The
number shown after the signature name indicates the number of genes remaining in the
signature after translation to the appropriate namespace. Some genes were then lost through
pre-processing (e.g. poorly performing or annotated probes) and so the number of genes
shown on the heatmaps corresponds to those actually used. See section 3.10.3.
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Figure 3.13E: Performance of Dai Signature on L3 Dataset
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Key: Dataset (L2 or L3 or L23): Signature Name-Number of genes left in signature after
translation: Time point (Baseline, Week 2, Change between Baseline and Week 2). The
number shown after the signature name indicates the number of genes remaining in the
signature after translation to the appropriate namespace. Some genes were then lost through
pre-processing (e.g. poorly performing or annotated probes) and so the number of genes
shown on the heatmaps corresponds to those actually used. See section 3.10.3.
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Figure 3.13F: Performance of Dai Signature on L23 Dataset
Baseline 2 Weeks Change
L23: Dai_40, Baseline L23: Dai_40, Week-2 L23: Dai_40, Change




Key: Dataset (L2 or L3 or L23): Signature Name-Number of genes left in signature after
translation: Time point (Baseline, Week 2, Change between Baseline and Week 2). The
number shown after the signature name indicates the number of genes remaining in the
signature after translation to the appropriate namespace. Some genes were then lost through
pre-processing (e.g. poorly performing or annotated probes) and so the number of genes
shown on the heatmaps corresponds to those actually used. See section 3.10.3.
Figures 3.13D-F above, show the heatmaps, multigene expression scores and ROC curve
analyses, indicating the performance of the second proliferative signature used in this study
(Dai) against each of the three datasets. As was seen with the Nagalla signature, the Dai
signature AUC analyses also indicate a significant association at the two-week time point.
However this association is not seen in relation to the change in gene expression levels
between baseline and two weeks, which was not significant.
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|3.14 Performance of Stromal Signatures
In contrast to the performance of the proliferative signatures, neither stromal signature was
significantly informative of response to neoadjuvant Letrozole in the baseline or two-week
samples Both however showed significant predictive power with respect to changes in gene
expression between baseline and two weeks in the L3 dataset only. The figures below show
the results for the Beck (Figures 3.14A-C) and Farmer (Figures 3.14D-F) signatures.







L2: Beck_124, Baseline L2: Beck_124, Week-2 L2: Beck_124 Change
?8i§8§!?U!S8f t8i§fliil!lt?!?f?f f §







Key: Dataset (L2 or L3 or L23): Signature Name-Number of genes left in signature after
translation: Time point (Baseline, Week 2, Change between Baseline and Week 2). The
number shown after the signature name indicates the number of genes remaining in the
signature after translation to the appropriate namespace. Some genes were then lost through
pre-processing (e.g. poorly performing or annotated probes) and so the number of genes
shown on the heatmaps corresponds to those actually used. See section 3.10.6.
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Figure 3.14B: Performance of Beck Signature on L3 Dataset
Baseline 2 Weeks Change
L3: Beck_101, Baseline 13: Beck 101, Week-2 L3: Beck_101, Change











Key: Dataset (L2 or L3 or L23): Signature Name-Number of genes left in signature after
translation: Time point (Baseline, Week 2, Change between Baseline and Week 2). The
number shown after the signature name indicates the number of genes remaining in the
signature after translation to the appropriate namespace. Some genes were then lost through
pre-processing (e.g. poorly performing or annotated probes) and so the number of genes
shown on the heatmaps corresponds to those actually used. See section 3.10.6.
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Figure 3.14C: Performance of Beck Signature on L23 Dataset
Baseline 2 Weeks Change
L23: Beck 68, Baseline L23: Beck 68. Week-2 L23: Beck_68, Change
L23: Beck 68, Baseline
L23: Beck_68, Week-2
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Key: Dataset (L2 or L3 or L23): Signature Name-Number of genes left in signature after
translation: Time point (Baseline, Week 2, Change between Baseline and Week 2). The
number shown after the signature name indicates the number of genes remaining in the
signature after translation to the appropriate namespace. Some genes were then lost through
pre-processing (e.g. poorly performing or annotated probes) and so the number of genes
shown on the heatmaps corresponds to those actually used. See section 3.10.6.
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Figure 3.14D: Performance of Farmer Signature on L2 Dataset
Baseline 2 Weeks Change
L2: Farmer_100, Baseline L2: Farmer_100, Week-2 L2: Farmer_100, Change
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Key: Dataset (L2 or L3 or L23): Signature Name-Number of genes left in signature after
translation: Time point (Baseline, Week 2, Change between Baseline and Week 2). The
number shown after the signature name indicates the number of genes remaining in the
signature after translation to the appropriate namespace. Some genes were then lost through
pre-processing (e.g. poorly performing or annotated probes) and so the number of genes
shown on the heatmaps corresponds to those actually used. See section 3.10.5.
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Figure 3.14E: Performance of Farmer Signature on L3 Dataset
Baseline
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Key: Dataset (L2 or L3 or L23): Signature Name-Number of genes left in signature after
translation: Time point (Baseline, Week 2, Change between Baseline and Week 2). The
number shown after the signature name indicates the number of genes remaining in the
signature after translation to the appropriate namespace. Some genes were then lost through
pre-processing (e.g. poorly performing or annotated probes) and so the number of genes
shown on the heatmaps corresponds to those actually used. See section 3.10.5.
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Figure 3.14F: Performance of Farmer Signature on L23 Dataset









Key: Dataset (L2 or L3 or L23): Signature Name-Number of genes left in signature after
translation: Time point (Baseline, Week 2, Change between Baseline and Week 2). The
number shown after the signature name indicates the number of genes remaining in the
signature after translation to the appropriate namespace. Some genes were then lost through
pre-processing (e.g. poorly performing or annotated probes) and so the number of genes
shown on the heatmaps corresponds to those actually used. See section 3.10.5.
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3.15 Signature Comparison
The area under the curve was calculated for each ROC curve with 95% confidence intervals
and plotted into bar charts. These are shown in Figures 3.15A-C below which correspond to
the data derived from the L2, L3 and L23 datasets respectively. These summarise the main
results from this study. In each chart, the significant results are highlighted in red and the non
significant in blue.
Figure 3.15A represents the signature comparison in the L2 dataset. Not surprisingly the
Edinburgh signature shows extremely high predictive power on the L2 dataset with the ROC
AUC confidence interval reaching 1. This reflects the fact that this signature was derived
from this dataset and this association had to be confirmed within an independent dataset.
With respect to the other signatures, only the proliferation signatures showed significant
association with response and only at the two-week time point. Their performance at two
weeks nonetheless approximated that of the Edinburgh signature.
Figure 3.15A: AUC Results for L2 Series
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Figure 3.15B illustrates the performance of the studied signatures on the L3 series and
confirms the above findings with respect to the Edinburgh signature in a new and
independent dataset. Both proliferative signatures were similarly informative at the two-week
time point but only the Nagalla signature was significantly informative with respect to change
in gene expression. Interestingly, these results also demonstrate that stromal signatures may
be informative with respect to change in gene expression.
Figure 3.15B: AUC Results for L3 Series
Figure 3.15C compares signature performance on the extended L23 series. As this includes
the L2 dataset, it would be anticipated that the Edinburgh signature remains highly
informative of treatment response, whilst the proliferative signatures perform similarly to that
seen in the L2 and L3 datasets. However, in this larger series, the significance of the stromal
signatures is lost.
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3.16 Quantitative PCR Validation of Microarray Data
Quantitative PCR was used for the validation of microarray results using genes selected from
samples of the L2 dataset, as previously published |508]. When gene expression changes
between baseline and the two-week samples were stratified for their magnitude of change
(>1.5 fold), consistent direction of change and the statistical significance of that change, a
total of 143 genes were identified of which 91 were down-regulated and 52 up-regulated by
the Letrozole therapy. Only nine genes were common to all three stratifications.
For validation purposes, three up-regulated and three down-regulated genes were selected
for qPCR analysis based on their presence in at least two of the three stratifications described
above. These were COLEC12, MMP2 and DCN (up-regulated) and CCNB1, CDC2 and
NUSAP1 (down-regulated). Primer sequences for the qPCR analysis were designed for each
gene as described in Section 3.7.2.
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The results of these comparative analyses are shown in Table 3.16A (and were published in
Miller et a/.[5081). The data show that the direction, amplitude and significance of the changes
were comparable between qPCR and microarray. The latter was measured using the
Wilcoxon signed rank test, a non-parametric analysis of repeated measurements on a single
sample; the P-values are given in the table. The correlation between the microarray and
qPCR quantification of gene expression changes was positive and highly significant when
compared using Spearman's rank test. The p value represents the correlation coefficient
where a value of 1 reflects maximal correlation and zero represents no correlation. P-values
for the significance of the correlation are also given. These results therefore validated the use
of microarray analysis for the quantitative evaluation of gene expression in this dataset This
additional verification step is not often undertaken or reported in other publications of this
nature.

























































2x10"® t 3.0(1.4-4.6) 5x10-® 0.44 5x10"4
Table 3.16A: Comparative Analysis of Microarray and qPCR on Selected Genes.
3.17 Changes in Cyclin and CDK Expression during Neoadjuvant Letrozole Treatment
The Als are known to reduce cellular proliferation in the majority of breast cancers and this
reduction is associated with a clinical response to treatment. For this reason, a focused sub-
analysis was carried out to investigate the molecular events underlying the anti-proliferative
effect of Als, specifically Letrozole, in the neoadjuvant setting. The expression of selected
genes representative of the main phases of the cell cycle was measured using qPCR, as
described above, in the L2 dataset samples, collected at baseline and at 2-weeks and 3-
months of treatment.
148
The selected genes included Cyclins D1, A2, B1, CDKs 1, 2, 4 and the NUSAP1 gene (a
mitotic spindle associated protein). In addition, proliferation was assessed by
immunohistochemical staining for Ki67 and expressed as a percentage of cells staining
positively. Changes in the expression of the Cyclins/CDKs were compared to changes in Ki67
positivity and to clinical response, classified as tumour shrinkage >50% at 3 months.
At the time of this sub-analysis, sequential biopsies were available for 62 tumours of the L2
series (42 for the CDK4 assay), clinical response was available in 56 of these cases and Ki67
change was assessed in 53 cases. The results of this analysis are summarised in Table
3.17A and in Figure 3.17A









(47-74,43) (63-83, 53) (29 / 9) (32/11)
46% 49% <0.001 <0.001 0.007 0.01
(30-63, 56) (30-69, 55) (0.75, 38) (0.50, 48) (32/14) (32 /11)
42% 51% 0.004 <0.001 0.001 0.03
(32-52, 55) (39-64, 56) (0.46, 38) (0.55, 48) (32/13) (32 /12)
42% 51% <0.001 <0.001 0.01 0.01
(27-58, 56) (37-65, 56) (0.69, 38) (0.56, 48) (32/14) (32/12)
35% 45% 0.101 0.015 0.10 0.47
(26-44, 56) (35-54, 55) (0.27, 38) (0.35, 47) (32/14) (31 / 12)
48% 50% <0.001 <0.001 0.01 0.03
(34-61,55) (32-68, 56) (0,64, 38) (0.51, 48) (31 / 14) (32 /12)
16% 14% 0.006 0.019 0.006 0.02
(5-27, 56) (3-25, 56) (0.44, 38) (0.34, 48) (32/14) (32 /12)
6% 16% 0.796 0.118 0.08 0.45
I (1-41-16, 41) (5-26, 42) (-0.05, 29) (0.26, 37) (27 / 8) (27 / 7)
Table 3.17A: Changes in Selected Cell-cycle Associated Genes During Treatment with
Letrozole
Values in the table show the following:
• % of reduction: mean reduction (CI of mean, n);
• Correlation to Ki67: Pearson product-moment correlation, p (r, n);
• Association with response: t-test for difference between responders and non-











Figure 3.17A: Associations of the Change in Selected Genes with Clinical Response. The y-
axes in each plot show the percentage change in mRNA expression after 14 days of
treatment (red for responders, blue for non-responders); p-values show the significance of the
t-test for the difference between the responders and non-responders.
These results demonstrate that two weeks of Letrozole therapy strongly decreased mRNA
expression of Cyclins B1, A2, D1, CDK1 and NUSAP1 but not CDK 2 and 4 where the
changes observed were only modest (or even non significant). The mean expression levels
decreased by the two week time point and were maintained at a similar level after 3 months
of treatment. Significant correlations between the change in Ki67 and changes in Cyclins
B1/CDK1 and Cyclin A2/CDK2 were observed, demonstrating the importance of
transcriptional regulation of the S and G2-M Cyclins/CDKs for the anti-proliferative effect of
neoadjuvant Letrozole. The lack of correlation between Cyclin D/CDK4 and Ki67 or clinical
response could reflect the importance of post-transcriptional steps in Cyclin D/CDK4
activation.
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Changes in the expression of NUSAP1 and Cyclin B1 significantly correlated with clinical
response and Ki67 positivity, especially after two weeks of treatment. This sub-analysis
therefore highlights the potential utility of NUSAP1 and Cyclin B1 as anti-proliferative
response markers during neo-adjuvant treatment with Letrozole, although they do not
completely separate responders from non-responders, indicating the need for other additional
markers.
3.18 Ki67 and Other Factors Predicting Survival after Neoadjuvant Endocrine Therapy
This sub-analysis aimed to determine which factors, including pre and post treatment Ki67,
are independent predictors of breast cancer specific survival (BCSS), defined as the time
from diagnosis to death from a breast cancer related cause, following neoadjuvant Al
treatment. To this end all patients with large operable or locally advanced oestrogen receptor
positive (ER+) breast cancer who were treated with 3 months of Letrozole, Anastrozole or
Exemestane were included. In contrast, the dataset for the microarray studies incorporated
only those patients treated with Letrozole in order to eliminate possible variation in gene
expression related to treatment with the three different third-generation Als.
The major effect of the Al's is through inhibition of tumour cell proliferation i297 331-333 542l ^
follows therefore that the evaluation of tumour proliferation through measurement of Ki67 may
allow an early and reliable evaluation of response and long-term outcome following treatment
[332,542,543] Qe|| CyC|e complete response (CCCR), defined as Ki67 values of <1% 13311 [544' is
indicative of maximal cell cycle response. It is achieved more commonly than complete
pathological response in patients treated with neoadjuvant endocrine therapy. Two-week
Ki67 levels have been shown to predict disease free recurrence but there are no accurate
data correlating Ki67 with breast cancer specific survival1545].
3.18.1 Patients and Study Design
The study population consisted of 201 women. After surgery, all responding patients
continued on an adjuvant Al for five years. Inclusion criteria were as described above for the
Letrozole audit series.
All core biopsy specimens taken pre-treatment (baseline) or following three months of Al
therapy were fixed in 10% neutral buffered formalin for 24 to 48 hours prior to processing and
embedding by the local pathologist in paraffin wax blocks. Wax sections of 3-4 pM were
prepared for Ki67 staining, Ki-67 was determined by measuring the percentage of cells
stained using the MIB-1 antibody.
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In each case, the tumour size, T stage, pathological node status, grade, ER level (Allred
Score), Ki67 at baseline and at three months were recorded as was tumour response, based
on 3D ultrasound measurements. The pathology department at the Western General
Hospital performed the oestrogen receptor immunohistochemical analysis using the
Novocastra 6F11 antibody.
Objective clinical tumour response was calculated based on WHO criteria (Section 3.3.5).
Patients were followed annually in clinic throughout the course of their adjuvant treatment. All
follow up data for breast cancer relapse, all cause mortality and, breast cancer specific
mortality was recorded.
3.18.2 Statistical Analysis
Logistic regression was performed to determine whether any of the variables recorded were
predictive of tumour response, whether or not a patient underwent surgery and, if so the
nature of their surgery. Survival rates were estimated by the Kaplan-Meier technique and
compared using the log-rank test. All survival rates quoted are breast cancer specific unless
otherwise stated. Proportional hazards analysis was performed to determine any independent
prognostic factors.
3.18.3 Results
Although 201 patients were recruited to the study, not all data points were collected for each
patient and therefore analysis was carried out for those 153 patients for whom all data
collection was complete. The mean age of the patient population was 74.9 years (range 52-
93). The demographics of the study population and the details of tumour pathology are
shown in Table 3.18A.
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Table 3.18A: Patient Demographics & Tumour Pathology

















Surgical treatment to breast
Breast conserving surgery 116 (75.8)
Mastectomy 26 (17.0)
No surgery 11 (7.2)
Pathological Node Status
Node negative 68 (44.4)
1-3 nodes involved 43 (28.1)
4+ nodes involved 19 (12.4)
No nodal surgery 23 (15.0)
Response
The percentage reduction in tumour volume as measured by 3D ultrasound following 3
months of neoadjuvant Al treatment is shown in Table 3.18B. 103 patients (66.7%) had a
partial response (at least 50% reduction in tumour volume) whilst only 4 patients had
progressive disease (no response). Logistic regression shows that ER (p < 0.0001) was the
main predictor of whether or not the patient achieved a partial response, with a higher ER
correlating to better response.
Table3.18B: Tumour Response at 3 months According to Percentage Reduction in
Tumour Volume on Ultrasound.
Response Number of Patients (%)
>75% 53 (35)
>50 - <75% 50 (32)
>25% - <50% 33 (22)




Logistic regression analysis showed that tumour Grade (p=0.0014) and US response
(p=0.0180) were the only predictors of whether or not a patient received surgery for their
breast tumour. Age (p<0.0001) was the main predictor of whether a mastectomy or wide
local excision was performed.
Survival
Survival was measured from the date of initiation of Al therapy. One patient was lost to follow
up at 35 months and another two at 42 months. For the remainder, the median follow-up was
59 months with a minimum of 38 months. Fifty-eight patients died, 35 with breast cancer
present. Overall survival in this predominantly elderly population was 68.7%.
In the univariate analysis, survival was significantly associated with T stage (p=0.0315) and
the number of involved nodes (p=0.0005) but not tumour size, grade or ER level.
Patients with T1-3 breast cancers had better a survival rate than those with locally advanced
T4 tumours (p=0.0315). The five-year survival rate for patients with T1-3 tumours was 86.6%
compared with 60.5% for those with T4 tumours.
Node negative patients did well following surgery with a 5-year survival rate of 97.2%. As
expected, increasing nodal involvement equated to poorer survival; 70.5% for those with 1-3
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Figure 3.18A: Cause Specific Survival by Node Status at Surgery
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Ki67 expression at diagnosis (p=0.0355), at 3 months (p=0.0318) and the percentage change
in Ki67 between these two time points (p-0.0027), were also significantly associated with
breast cancer mortality whereas US measured tumour response was not.
For the analysis of Ki67 measured at diagnosis, three months and in terms of change in Ki67
over the 3 months, patients were divided into three groups of approximately equal sizes,
rather than using quartiles, due to the small numbers. Patients with a Ki67 of less than 10.5%
had similar survival in the first 5 years to those with a Ki67 of between 10.5% and 21% whilst
those with a Ki67 of 21% or more had a poorer survival (Table 3.18C, Figure 3.18B).
Table3.18C: Ki67 at Diagnosis
Ki67 at Diagnosis Number 5-year Survival (%)
<10.5% 50 89.7
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Figure 3.18B: Cause Specific Survival by Ki67 at Diagnosis
Values of Ki67 at 3 months were divided into residual proliferating values of greater than 5 %,
1-5% or less than 1 %. The 1% value has been widely used to define complete cell cycle
response (CCCR). Two thirds of treated patients had residual tumour proliferation of less
than 5% at three months and one half of these had values of less than 1% (CCCR) (Table
3.18D). Figure 3.18C shows that those patients with low rates of residual proliferation (<1%)
following treatment had better survival outcomes, particularly compared to those with > 5%
residual proliferation (p= 0.0318).
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Table3.18D: Ki67 at 3 Months
Ki67 at 3 months No of Patients (%) 5-year survival (%)
<1 47 ( 30.7) 86.9
>=1-<5 47 ( 30.7) 86.7







Figure 3.18C: Ki67 at 3 Months and Cause Specific Survival
The percentage fall in Ki67 observed in patients at three months was stratified according to
predetermined cut-offs considered to represent significant changes in proliferation. The
results in Table 3.18E show that around two thirds of patients had a greater than 40%
reduction in Ki67 following 3 months of treatment and more than half of these showed an over
80% fall in proliferation. A third had lesser reduction (<40%), no change or an increase in
Ki67 at 3 months. Those patients with falls in proliferation (>80%) following Al treatment were
found to have a better breast cancer specific survival than those with lesser reductions (40-
80%) and, those with the least change (<40%) had the poorest survival outcomes p=0.0027
(Figure 3.18D).
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Table 3.18E: Percentage Reduction in Ki67 at 3 Months:
% Reduction in Ki67 No of Patients (%) 5-year survival (%)
>=80 51 (35.3) 86.8
>=40-<80 45 (29.4) 80.9








Figure 3.18D: Percentage Change in Ki67 and Cause Specific Survival
10
Multivariate Analysis
Proportional hazards analysis was initially performed using only those variables available at
diagnosis, i.e. year of treatment, age, clinical size, T stage, ER, grade, Ki67 and which Al was
used. Data on all these variables was available for 152 patients. The analysis showed that T
stage (p=0.0188) and baseline Ki67 (p = 0.0205) were significant independent prognostic
factors for survival.
When adding in those variables not available until later, including US response, type of
surgery, number of involved nodes, Ki67 at 3 months, percentage reduction in Ki67 and
whether radiotherapy was given post-operatively, only 126 patients were left for analysis.
The number of involved nodes (p=0.0007), percentage reduction in Ki67 (p=0.0029) and
grade (p=0.0383) were the only significant independent prognostic factors for BCSS
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4. Discussion - PART 1
The Present Study
The over-riding purpose of any cancer classification system is to help plan effective treatment
and provide an accurate prognosis for each patient. In addition, classification can help to
standardise cancer descriptions for research purposes and communication. Furthermore it
provides an important starting point for the investigation of the mechanisms underlying cancer
development, metastasis and response or resistance to therapeutic intervention.
The current histopathological classifications of breast cancer, including hormone receptor
status and proliferative markers, such as Ki67, do not adequately reflect its diversity;
consequently patients may be given inaccurate prognoses and may be subjected to
ineffective and unnecessary treatment. For example, up to 60% of breast cancer patients will
receive chemotherapy during the course of their treatment and yet only a minority, those with
actual systemic disease (2-15%) will stand to benefit I455 546'547i Similarly, approximately 40%
of patients treated with endocrine therapy will not benefit. Many patients are therefore
exposed to the toxicity of these agents without a survival advantage. The implications for the
healthcare economy of such unnecessary treatments are also evident, with an average cost
of approximately £35,000 for each breast cancer patient. More importantly, the use of
inappropriate or ineffective therapy can only serve to delay the institution of alternative, more
effective treatments or surgery. In order to target treatment specifically to those who stand to
benefit, better predictors of response need to be developed. This is especially true for
intermediate grade tumours whose phenotype, classification and treatment are particularly
challenging.
The advent of microarray technology has allowed researchers to rapidly measure the
expression of many thousands of genes in a tumour sample at multiple time points before,
during and after treatment and to assess changes in gene expression over time. The results
have been used to derive new molecular classification systems and genetic signatures that
can potentially be used for prognostic and predictive purposes.
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The work described in this thesis was designed to validate the efficacy of the only published
signature that is predictive for neo-adjuvant endocrine response in breast cancer. To place
this signature in context, its performance has been compared to that of four other signatures
that are potentially associated with neo-adjuvant response: two proliferative and two stromal
gene expression signatures. Despite there being a large number of genetic signatures
published for adjuvant breast cancer treatment, to date, very little has been published for
neoadjuvant endocrine response prediction. The validation and comparison of the signatures
has been carried out on a previously published dataset, a newly generated dataset and an
extended dataset incorporating both of these
The work carried out directly by the author included: the recruitment of patients into the
Edinburgh Letrozole audit series and the processing and design of ethical applications and
patient consent forms; core biopsy sampling; clinical measurement of tumour response;
documentation of patient outcomes and side-effects and establishment and maintenance of a
revised database for recording this information. In the laboratory setting, the author also
performed RNA extraction and quality control prior to microarray analysis. Subsequently, the
author ran quantitative PCR analyses to validate the gene expression profiles identified on
microarray and carried out a focused sub-analysis of genes associated with different phases
of the cell cycle. In addition, the author collected patient and tumour demographics including
Ki67 staining and compared these to the available long-term outcome data. Ki67
immunohistochemistry was performed by the pathology department. RNA microarray was
performed at specialised core facilities and analysis of the microarray data was carried out
with the help of a bioinformatician using complex algorithms, the principles of which were
discussed in the methods section.
Several other original research projects have utilised the data and samples collected by the
author, but these are beyond the scope of this thesis.
4.1 Findings of the Present Study
4.1.1 Validation of the Edinburgh Signature
The Letrozole audit series (L2) was previously used to assess gene expression changes
following two weeks of neoadjuvant Letrozole therapy and identified 143 genes whose
expression was altered during treatment in one of four different patterns. The ontology of the
down-regulated genes reflected cell cycle progression and mitosis in particular, whilst up-
regulated genes were associated with organ development, ECM regulation and inflammatory
response [508i
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A follow-up study from our unit correlated the changes in gene expression profiles of patients
treated with two weeks of neoadjuvant Letrozole to the clinical response measured after three
months of treatment and thereby derived the predictive signature validated in the present
study.
Here, for the first time, the Edinburgh signature has been validated against an independent
(L3) and an extended (L23) dataset. Furthermore, the L3 validation set demonstrates that the
predictive power of the signature is still present when different microarray platforms are used.
The validation also legitimises the use of this signature as a benchmark for comparison with
the proliferative and stromal signatures used.
The AUC analysis of the Edinburgh signature on the L2 dataset demonstrates a very high
sensitivity and specificity, as would be expected from a signature being tested on the dataset
from which it was derived. Nevertheless good predictive power is maintained across all three
datasets.
Ontological analysis of the genes within the signature previously indicated that ribosomal
proteins showed higher baseline expression levels that then fell significantly on treatment in
responsive tumours. In non-responding cases, increased expression during early treatment
was observed. This is likely to reflect the suppression of protein synthesis in responsive
tumours and the escape from such suppression in resistant tumours [510l
4.1.2 Performance of the Proliferative Signatures
The decision to use two proliferative signatures in the present study was made because
proliferation genes constitute a major part of adjuvant prognostic signatures 15221 and also
because we have shown earlier that cell cycle genes were the most down-regulated genes
early during neo-adjuvant endocrine treatment t508]. Due to the lack of published predictive
signatures in the neoadjuvant setting, both of the chosen signatures had been derived in the
adjuvant setting. Both were independently validated and contained only genes associated
with proliferation.
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In this study, whilst neither proliferation signature is predictive of response at baseline, both
are significantly predictive at the two-week time point across all datasets and to a similar
degree to the Edinburgh signature. This indicates that the level of expression of proliferation-
associated genes, whilst not sufficiently discriminating between responders and non-
responders at baseline, becomes so after two weeks of Letrozole treatment. This observation
is important because it demonstrates the potential to identify non-responders early during the
course of their treatment, so that alternative therapy can be considered. The predictive power
of the proliferation signatures is consistent with other methods of measuring tumour
proliferation [5391. Since the levels of cellular proliferation in responsive tumours should drop
significantly in responders but less so, or not at all, in non-responders, it follows that the
difference in proliferation gene levels at two weeks is likely to be more informative.
On the other hand, it might then be expected that measurement of the change in proliferative
gene expression levels over the two weeks would also be significantly informative of
response. In the present study however, only the Nagalla signature demonstrates that the
degree of change in proliferative gene expression between baseline and two weeks is
significantly predictive of response to treatment and only in the L3 and L23 datasets. The
reasons for the lack of significance in the L2 dataset are not entirely clear, but may possibly
relate to differences in signature translation for the Affymetrix platform or to the statistical
power of the study.
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4.1.3 Performance of the Stromal Signatures
The stromal signatures used here, were selected for similar reasons to the two proliferative
ones mentioned above: firstly, stromal rearrangement has been associated with the biology of
neo-adjuvant endocrine treatment l309 326-3271 and secondly, we previously demonstrated that
stromal rearrangement genes were amongst those most up-regulated after short-term
treatment with Letrozole [508].
Contrary to our expectations, stromal signatures showed only a modest association with
response. The results from the present study demonstrate that neither stromal signature was
informative at baseline or at two weeks when these time-points were considered in isolation.
However, when considering the change in gene expression between these two time points,
both signatures are significantly informative on the L3 dataset only, where the predictive
power is similar to that of the proliferative and Edinburgh signatures. Once again, the reason
why this finding should only be significant on the L3 dataset and not the L2 dataset is not
clear. Nevertheless, this result does suggest that the change in stromal gene expression
during the course of treatment is more relevant to response prediction than the absolute
levels of stromal gene expression. This fact may reflect the complexity of stromal
rearrangement and the delayed timescale of events when compared to proliferation.
In contrast to studies on tumour epithelial cells, the majority of published data suggest that
gene expression and functional changes observed in the tumour stroma are not due to
genetically abnormal stromal cells in breast cancer.
Using laser capture micro-dissection to separate tumour stroma from epithelium, Ma et at.
also demonstrated the importance of change in levels of stromal gene expression in breast
cancers. Specifically, the most dramatic changes in gene expression in the stromal
component were observed during the transition from normal breast tissue to DCIS, as
opposed to the transition from DCIS to invasive carcinoma. The latter was nonetheless
associated with up-regulation of several ECM degrading proteases [5131. These observations
appear to be compatible with those of the present study in that they both suggest that change
in stromal gene expression is most informative. No other studies have specifically looked at
the stromal response to aromatase inhibitors in the neoadjuvant setting.
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When interpreting the stromal signatures' expression it is important to recognise that such
signatures may be quite diverse. Specifically, the Farmer signature includes different types of
collagens, including types 1 and 3, which would be consistent with "Desmoid Type" or "scar
formation" as described by Beck et at. [524l In contrast, Beck describes their signature, which
includes genes associated with epithelial-stromal interaction and basal membrane etc. as a
"Fibromatosis Type". Biologically, the stromal microenvironment may include many and varied
functions, such as mechanical support (e.g. collagens and extracellular matrix), adhesion
(e.g. decorin, fibronectin), local immune response and nutrition etc. Thus biologically different
sets of genes could be reported as "stromal signatures" and the specific gene composition
must be taken into account when comparing different stromal signatures.
4.1.4 Expression of the Cyclins
Aberrations in cell cycle machinery are amongst the most common mechanisms underlying
cancer development, as described in the introduction. Thus far however, most of the
research in this area has focused on the G0-G1-S transition. For instance, Cyclin D is
amplified in up to 15% of breast cancers [548] and the expression of aberrant forms of Cyclin E
is strongly associated with poor outcome [549'. In contrast, the results from the present study
have highlighted the importance of transcriptional changes in the S2-M phase regulators -
Cyclin B and CDK1. One possible interpretation of this finding is that mutations affecting cell
cycle regulation at the G0-G1 level may act through changes to the downstream expression
of G2 and M phase genes.
4.1.5 Changes in Ki67 Expression as a Predictor of Breast Cancer-Specific Survival
During Neoadjuvant Al Treatment.
This sub-analysis looked at potential clinical, pathological and, biological predictors of
outcome in breast cancer patients treated with neoadjuvant Al endocrine therapy.
The clinical factors found to bear prognostic significance in relation to breast cancer specific
survival (BCSS), were pathological node status (p= 0.0007) and tumour grade (p= 0.0336).
Previous studies in patients receiving neoadjuvant chemotherapy 15501 or endocrine therapy
[551-553] for |oca||y advanced breast cancer have shown that tumour grade and surgical node
status were significantly predictive of disease free and overall survival in multivariate
analyses.
Furthermore, it has been suggested that a poor early clinical response to neoadjuvant Als
may be predictive of early breast cancer recurrence in the long-term and could be used as an
indicator for alternative adjuvant therapy [554l Whilst this may be true, there is a lack of
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precision in clinical measurements, which may also lack the sensitivity and rapidity of change
needed to detect a response to treatment at an early stage. In this sub-analysis, clinical
response was not found to be an important predictor of breast cancer specific survival.
With respect to biological markers that allow earlier and more accurate evaluation of long-
term outcome, the IMPACT study produced convincing evidence that a change in Ki67 value
after neoadjuvant Al treatment was predictive of disease free survival [555l That study
investigated 158 patients randomised to three months of neo-adjuvant treatment with either
Anastrozole or Tamoxifen or both in combination. The findings were that: (i) Suppression of
Ki67 at 2 and 12 weeks was significantly greater with Anastrozole than Tamoxifen (p=0.004
and p<0.001 respectively) and, (ii) Ki67 predicted the recurrence free survival of the much
larger but equivalent adjuvant ATAC trial (p= 0.004) l556"558! Further analyses have since
suggested that the absolute values of Ki67 following short-term neoadjuvant Al therapy (2
weeks) are similarly predictive of recurrence free survival (p=0.004) whereas baseline Ki67
values are not[542!.
Ellis has further explored the importance of the absolute post treatment Ki67 values in
patients treated with sixteen weeks of neoadjuvant Tamoxifen or Letrozole. Cell Cycle
Complete Response (CCCR, or Ki67 <1%) was an independent prognostic factor for both
relapse free and overall survival [5591, suggesting that patients who have effectively switched
off tumour proliferation at 16 weeks will do better in the long-term.
The present study differs from those discussed in two regards. Firstly, breast cancer specific
survival has been used as an outcome measure to give a more accurate reflection of deaths
from the disease. Secondly, proliferation was measured following three months of treatment,
as opposed to two weeks. Previous studies have indicated that whilst the majority of ER
positive breast tumours treated with an Al reduce proliferation by 2 weeks and maintain this
up to the 3 month time point, a few patients will demonstrate a secondary rise in proliferation
after 2 weeks, possibly indicating early resistance [555]. Three-month values were therefore
considered to be more reflective of actual response to neoadjuvant treatment.
This present sub-analysis though small, furthers our knowledge with regard to molecular
prognostication. Firstly, the data support the concept that Ki67 expression after three months
of endocrine treatment predicts long-term outcome and in particular death from breast cancer.
Secondly, three-month Ki67 values might better reflect survival outcome compared to the
values at two weeks, since some tumours will develop resistance between these time points.
Thirdly, the findings may help in the management of individual patients receiving adjuvant
endocrine therapy by indicating the need for alternative therapy when the Al fails to switch off
or significantly reduce tumour proliferation.
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If confirmed, the quantification of changes in Ki67 during endocrine therapy potentially has
major implications for molecular prognostication by allowing the biological detection of
response or resistance earlier than clinical indicators. It could therefore inform decisions on
future treatment for individual patients and may aid in the evaluation of novel therapies used
in combination with the Al's to circumvent resistance. The use of an mTOR inhibitor
Everolimus in combination with Als is currently the subject of investigation in to the
management of endocrine resistant breast cancers in the BOLERO trial and other studies
[560]. Specifically BOLERO 4 is looking at the safety and efficacy of combining Everolimus with
Letrozole in ER positive, HER 2 negative metastatic breast cancer patients (see
http://clinicaltrials.gov/show/NCT01698918).
4.2 Comments on Methodology
4.2.1 Use of the Neoadjuvant Treatment Setting
The mechanisms of tumour response and resistance to endocrine therapy need to be
elucidated so that they can be targeted or bypassed respectively. To this end, researchers
can focus their investigations either on patients with early disease treated with surgery and
adjuvant therapy, patients with metastatic disease, or on those treated with neoadjuvant
therapy.
The principle drawback of adjuvant studies is that the primary tumour has already been
excised and cannot therefore be used to assess response directly. Instead, other measures
of response such as disease free and overall survival must be employed, necessitating
lengthy follow-up in large cohorts of patients. Adjuvant studies may also be confounded by
occult spread of disease at the time of diagnosis and must therefore incorporate untreated
control groups, which in many circumstances may be unethical. In addition, the markers of
response are usually measured in the excised primary tumour whilst the study end points are
dependant upon the behaviour and progression of micro-metastatic disease.
The neoadjuvant setting on the other hand, lends itself to the investigation of various breast
cancer therapies for a number of reasons. Firstly, it relates to whole tumours in their natural
biological environment. Secondly, the primary tumour under investigation has not yet been
excised and so multiple, sequential tissue samples can be obtained from the same primary
tumour before, during and after treatment. Thirdly, the findings regarding tumour response in
the neoadjuvant setting can be extrapolated to inform treatment decisions in the adjuvant
setting. Overall, many fewer cases and shorter follow up are required for neoadjuvant studies.
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Whilst it is possible to use in vitro cell culture or animal models to study tumour biology
directly, both have obvious and significant limitations and the results obtained from such
studies may not be clinically applicable. Attempts have been made to identify chemotherapy
predictive signatures using in-vitro models 14621 but the validity of these has subsequently been
disputed on a number of levels; some have been withdrawn and such studies are no longer
considered to be reliable l561-565]. The possible reasons for this include the fact that cell lines
represent only one component of the original tumour cell population, specifically selected for
growth in culture. It is unlikely that the gene expression profiles of such cultures adequately
reflect those of whole tumours. Additionally, since the mechanisms of tumour proliferation and
resistance may involve interactions between different cell types within the tumour, data
derived from a single cell line are likely to be fundamentally flawed and not clinically relevant
[562l Animal studies have several advantages but the results are rarely borne out in humans.
Patients undergoing neoadjuvant treatments for breast cancer are therefore the perfect
subjects for direct studies of tumour biology and response.
4.2.2 Timings of Treatment and Sample Acquisition
It has been shown that neoadjuvant Tamoxifen can reduce tumour size as early as one
month after initiation of treatment, although the majority of patients respond at 2-3 months
and a further few show a delayed response at 3-6 months. During the latter time frame
however, a few of the earlier responding tumours become resistant to treatment and increase
in size l566]. In terms of proliferative response, which is significantly correlated with both
clinical and pathological responses !1661, a decrease in Ki67 occurs in the majority of tumours
treated with Letrozole at 10-14 days and up to 80% by 3 months [166'33°i On this basis and
borrowing from experience with cytotoxic neoadjuvant therapy, three months of neoadjuvant
Letrozole had been chosen as standard treatment for the Edinburgh patients and is widely
accepted practice because it allows sufficient time for tumour response whilst avoiding
prolonged treatment in non-responders, thereby minimising potential delays in prescribing
surgery or alternative drug therapies. The collection of core biopsy samples pre-treatment
and at two weeks, allows time for the gene expression changes to occur whilst still permitting
detection of these changes as early as possible so that appropriate treatment decisions can
be made. These time points were therefore chosen in this study.
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4.2.3 Tumour Response Assessment
Three-dimensional ultrasound was used as the principal clinical marker of response because
this modality has previously been shown to correlate with actual tumour size on excision
better than calliper measurement or mammography 153S1. Additionally, since neoadjuvant
therapy is primarily used to shrink tumours prior to surgical excision, it was felt to be a more
significant end point than the assessment of pathological or proliferative responses.
For the purposes of the present study, it was necessary to define and separate patients who
clearly responded to Letrozole from those who clearly did not. This was achieved by
excluding an intermediate response group as defined in the methods section. The criteria for
defining each of these groups was deliberately very stringent to minimise the risk of cross-
contamination of the responder / non-responder groups.
4.2.4 Sample Collection
The use of core biopsies in this study provided sufficient high quality tissue for RNA analysis
without significantly reducing the size of the tumour. This was important since tumour volume
was measured as the primary end-point. Multiple samples were taken to ensure sufficient
material for analysis and the samples were also confirmed to contain at least 20% malignant
cells. Nevertheless, the actual tumour content may have varied from one sample to the next
and this could have influenced subsequent analyses. Furthermore, core biopsies taken from
tumours with marked heterogeneity may not necessarily have collected sample material
representative of the tumour as a whole. To minimise these variables, ultrasound guided
biopsies were performed whenever tumour size and location made accurate localisation
difficult.
Micro-dissection of the tissue samples in order to enrich the tumour content and maximise
RNA yields was not performed, because of our wish to include the stroma and any other non-
malignant components that might effect gene expression, in their natural proportions.
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4.2.5 Signature Selection
Since there is only one published predictive signature for use in the neoadjuvant endocrine
setting, it was necessary to select suitable prognostic and predictive signatures from the
adjuvant setting for comparison in this study. The selection of these signatures was
somewhat arbitrary but attempted to include those that clearly reflected the biology of
endocrine therapy. The signatures were also selected for their 'purity' in terms of proliferative
or stromal genes so that biological interpretation of the results could be made more easily.
The Edinburgh signature, which was derived from the L2 dataset and is the only published
neoadjuvant endocrine response signature, was validated against the independent L3 and the
extended L23 datasets. In this way, the performance of the other signatures could be
compared to that of a signature that was optimised for this treatment modality.
4.2.6 Microarray Analysis
Unlike other forms of gene expression profiling, such as quantitative PCR, microarray
technology allows the rapid assessment of thousands of genes, equating to the entire human
genome on a single array. Such technology has identified genes whose expression levels are
altered by neoadjuvant endocrine therapy [507 5091 Despite some concerns, the general
reliability and reproducibility as well as the quantitative nature of microarray technology have
been clearly established [5671. The present study included validation of gene expression by
quantitative PCR, which confirmed that microarray data correlates well with gene expression
levels as measured by alternative means.
Microarray can be performed on formalin-fixed, paraffin embedded or fresh frozen samples.
The latter are associated with less nucleic acid degradation and were therefore used in this
study to provide good quality RNA for qPCR and microarray analysis. The facilities for the
proper handling and processing of fresh frozen tissue are readily available at the Edinburgh
Breast Unit.
The Affymetrix HG-U133A system was used for the first 137 patients of the Edinburgh
Letrozole Audit series, following which the llumina® HT-12 system was used. The latter not
only became locally available but is also considered to be technically superior for a number of
reasons that have already been discussed. Nonetheless both platforms are widely used in
microarray research making comparisons relatively straightforward.
168
The interpretation of the vast amount of data produced by microarray is extremely challenging
and attempts must be made to remove all background 'noise' without discarding any of the
important and relevant information. All necessary means of data pre-processing and
elimination of bias were carried out on the data produced in this study. In addition, the use of
multiple signatures, testing on multiple datasets and the utilisation of different array platforms
served to reinforce the validity of the conclusions drawn.
4.2.7 Multi-Signature Comparisons
This study is the first attempt to compare and validate multiple proliferative and stromal gene
signatures in the neoadjuvant setting. A previous study compared the prognostic power of
multiple prognostic models, including gene expression signatures and somewhat surprisingly
demonstrated that the expression of a single proliferation gene AURKA, performed as well as
multi-gene signatures [568!. The authors suggested that one reason for this might be the 'over-
fitting' of data mining methods, which can occur when training and validation datasets
overlap. To avoid over-fitting in this study we first validated the Edinburgh signature on a
completely new series of patients and secondly, measured gene expressions using an
alternative microarray platform.
4. Discussion - PART 2
The Clinical Utility of the Molecular Subtypes and Multi-Gene Signatures
4.3 The Shortcomings of Current Classifications
Historically, breast cancers with similar histopathological characteristics were noted to behave
similarly leading to the notion that these classification systems were adequate. The true
heterogeneity of the disease however was underestimated and it soon became clear that
invasive ductal carcinomas showed highly variable outcomes and response to treatment
despite being classified together into relatively few histopathological groups [569!. However, the
practical means to sub-classify breast cancers did not exist until the advent of advanced
molecular biological techniques. Since then, new subtypes of breast cancer have been
identified that show distinct and more consistent behavioural characteristics despite often
having identical histopathological features 1446 447 4491. Nevertheless, there is still some
controversy regarding the exact number and definition of these subtypes.
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Histopathological assessments are also subject to potential technical errors leading to
misclassification. It has been shown for example, that up to 20% of ER, PR and HER2
quantifications in the clinical setting may be inaccurate with implications for therapeutic
strategy in those patients 1570 5711. Similarly, there is a lack of absolute concordance between
clinically validated histopathological and microarray classification in some cases, for example
in tumour HER2 status i444 572-575l 3uch discrepancies can also result in misclassifications or
the misinterpretation of published research datasets. Although yet to be proven, it would
seem likely that genetic classification systems would be more rigorous, reliable and
reproducible, whilst promising more accurate prognostication and individualised treatment.
There are however several confounders of this assumption, which are discussed below.
4.4 The Potential and Limitations of Molecular Subtyping
The advent of gene expression profiling, which promised to revolutionise breast cancer
diagnosis and treatment, was met with an initial wave of enthusiasm. As with many new
technologies however, the difficulties and limitations have gradually become more apparent
[576, 577]
The initial approach for the identification of the molecular subtypes was based upon
hierarchical clustering analysis, which is somewhat subjective and cannot be prospectively
employed for the classification of individual tumour samples [454, 578"5801. Single sample
predictors (SSP) were therefore developed which compare the expression profile of a given
tumour sample with the average expression profile of each molecular subtype 1449'457,573]. In
the last decade, three such SSPs have been published [449, 45A 573!. One of these uses
quantitative PCR to classify samples into molecular subtypes whilst the others employ gene
expression profiling techniques. 15731
Subtle variations in defining the average gene expression profile of each molecular subtype
can however change the classification of samples when using SSPs '453,581'5821. For example,
in a cohort of 295 breast cancers that were classified into molecular subtypes using different
SSPs, a concordance of only 64% was obtained. Furthermore, the classification of tumours
into the two subtypes of ER positive breast cancer, luminal A (good prognosis) or B (poor
prognosis), appears to be strongly dependent on the SSP used 14531 and on the expression of
proliferation genes within the sample 1449 457 463, 474 569 573]. In any case, the level of
proliferation gene expression most likely forms a continuum making such a binary division
somewhat arbitrary, akin to the histological division into low, intermediate and high-grade
tumours'444 473478!
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Haibe-Kains et al. have attempted to address some of the potential limitations of SSPs with
their Subtype Classification Models (SCM). The latter are based upon sets of genes whose
expressions is correlated with ER, HER 2 and Aurora Kinase A, a proliferation module chosen
to discriminate between high and low proliferation tumours [473 4771. The same group however
recently demonstrated that quantitative assessment of these three genes alone is sufficient
for the classification of the clinically relevant breast cancer subtypes and that the addition of
more genes to a classification model may be of little value whilst impeding clinical utility '583'.
The intrinsic subtype classification first proposed by Perou 1446 4471 is now considered to be an
evolving classification [584) and important discrepancies still exist with respect to the number
[450-452] ^1:],-,^^ [445,453.454.585] gncJ tf,e prognostic and predictive value of each subtype. The
useful information they provide beyond that of ER, PR, HER2 and proliferation has yet to be
established [455, 5851 and standardisation of the definitions and methods for molecular
classification has yet to be produced and validated [442 444 453 455'. The evolution of intrinsic
classification is evident with the recent addition of three further subtypes of ER negative
cancers: Interferon rich [454' 45?1; Molecular apocrine I451- 452 5861 and Claudin low [45° 587'.
Although some of the intrinsic subtypes suggest a cell of origin (e.g. luminal or basal), this
concept is likely to be erroneous [447 449- 588"592) Additionally, it has been suggested that
'Normal breast-like' cancers may simply represent an artefact of frozen tissue procurement,
rather than a distinct molecular subtype 1444450,453,457,573,5931.
PAM50 is the most recent intrinsic subtyping assay and has potential for clinical application
[573,574] u comprjses a sef 0f 50 genes identified from a total of nearly two thousand intrinsic
genes associated in proliferation, ER regulation, HER2, basal and myoepithelial
characteristics. PAM50 assays are reported in terms of a risk of relapse score (ROR), which
applies to node negative patients who are not receiving adjuvant systemic therapy [5731. It has
been argued however, that despite their potential [574], PAM50 and other "intrinsic subtype"
based genetic classifications are not yet suitable replacements for the traditional grade,
hormone receptor, Ki67 and HER2 based prognostic models [442-444'453'455].
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4.5 The Promise of Gene Signatures in Prognostication and Prediction
Molecular subtyping promises to refine the currently used clinico-pathological classification
systems, but the promise of individualised treatment planning and prognosis depends upon
the development of predictive and prognostic genetic signatures. Since the description of the
first molecular subtyping model, numerous signatures, which aim to identify key gene
expression patterns associated with prognosis or prediction of response to a variety of
systemic treatments, have been published i442"444! |n drawing from studies of gene expression
signatures, it is necessary to consider the finding that prognostic signatures can be readily
generated from random gene sets and that these may perform as well as published gene
expression signatures [594l Whilst this indicates that vast numbers of genes are associated
with proliferation and therefore correlated with cancer prognosis, the important point is that
the genes within any particular signature cannot be taken to be directly involved in the
mechanism of that cancer.
4.5.1 Prognostic Signatures
The first generation prognostic signatures contain surprisingly few genes in common, perhaps
reflecting the vast numbers of genes that are involved in the regulation of cellular proliferation
and their downstream pathways [595, 596]. Despite this, meta-analyses confirm good
concordance in their ability to classify patients into groups sharing a similar prognosis. The
signatures also confirm that ER positive and ER negative breast cancers are indeed
governed by distinct biological processes [476,477' and that the latter are associated with a poor
prognosis in the majority of cases I157459'597! Changes in the expression of proliferation genes
also distinguish between good and poor prognosis subtypes (473, 474, 598], with higher
expression being naturally associated with poorer prognosis l446 447'449 5"l it jS not surprising
therefore that these signatures can also be predictive of response to chemotherapeutic
agents, which target proliferation [442_445'476]. Nevertheless, whilst these signatures provide
relevant information for prognostication, they are yet to be incorporated into routine clinical
practice and none are supported by level I evidence for their prognostic power [442 444 455'.
Two trials addressing this issue (MINDACT and TAILORx) are ongoing.
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The fully accrued TAILORx trial (Trial Assigning Individualised Options for Treatment) is
evaluating Oncofype DX® in ER positive, HER2 negative, node negative disease to
determine the need for chemotherapy in addition to endocrine therapy I482'. Oncofype DX® is
a commercially available qPCR based analysis of 21 genes (16 cancer related and 5
reference) designed for application in ER positive, node negative breast cancers receiving
adjuvant Tamoxifen, which was shown to outperform clinico-pathological factors for predicting
10-year distant recurrence I485]. Based on the expression of genes associated with
proliferation, ER and HER2 signalling, and invasion, the test result is presented as a
continuous recurrence score RS ranging form 0-100 and equating to the risk of 10 year
disease recurrence !48Sl. The continuously variable range of ER positivity may be better
reflected in the Oncofype DX® assay. In the trial, patients with an RS score below 10 were
given hormone therapy alone; those with RS 11-25 were randomly assigned to receive
hormone therapy with or without chemotherapy and those with an RS over 25 received
standard hormonal and chemotherapy. When completed, this study should determine which
patients in the intermediate risk group have sufficiently low risk of recurrence to avoid the
need for chemotherapy [482].
Just as proliferation gene expression signatures are important in ER positive disease, it
appears that stromal and immune response gene signatures may have more relevance in ER
negative disease. Recently, second generation signatures specific for each cancer subtype
have been reported in studies of the tumour microenvironment and host immune response
[442 494 497 498] have been shown to be potential prognosticators in ER negative and
triple negative breast cancers (494 600 6011 Wang and colleagues identified a 76-gene 'activated
fibroblast' signature that predicted poorer prognosis in terms of distant metastases free
survival, which was independent of age, tumour size, grade and ER status. The authors
proposed that this signature could be used to predict patients who are unlikely to benefit from
adjuvant chemotherapy !458]. Similarly, Finak identified a 26-gene stromal prognostic signature
that was independent of tumour ER or HER2 status [4971. Whilst these results are promising
more research and evidence is required in support of their observations.
There are a variety of reasons why the first generation signatures have not become clinically
useful tools. Firstly, as we have seen, the ability to determine prognosis corresponds to the
level of expression of oestrogen dependant, proliferation and cell cycle related genes I473 477!
Therefore, it may be the case that the signatures simply represent a sophisticated
proliferation assay akin to more standardised histological grading systems and thus have little
more to add [6021. Furthermore, proliferation appears to be prognostic in ER positive but not
ER negative disease and so the signatures cannot be applied to the latter[458 459 477 597'.
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Secondly, the classification and treatment of breast cancers at either end of the spectrum of
prognosis are more easily determined than that of intermediate grade tumours. The latter not
only display intermediate phenotype and survival but are also subject to the greatest degree
of intra and inter-observer variation during classification, making prognostication and
treatment decisions extremely difficult [6031. Generally, the first generation signatures cannot
adequately subdivide intermediate tumours into subgroups that can direct treatment planning.
The application of Oncofype DX® does 'push' some intermediate grade tumours into a low
risk group that do not require chemotherapy and others into a high-risk group that do.
In one study, treatment recommendations based on standard pathological grading were
changed for 31% of patients after considering their Oncofype DX® scores and in 22.5% of
cases chemotherapy was omitted altogether 16041. However 40-60% of patients who are
classified as intermediate (Grade II) using standard histopathological means are still allocated
into the intermediate group based on their Oncofype DX® RS scores. Clinical decision¬
making is therefore not made much easier in the very group for whom prognostication and
management are already difficultl605'. In order to improve clinically useful sub-classification of
this group of tumours, better-defined predictors and prognostic markers are required. To this
end, Haibe-Kains ef at. developed a 97-gene 'GGI' score with the purpose of sub-classifying
ER positive, intermediate grade II tumours into groups with distinct clinical outcomes that are
closely related to those of high or low grade tumours 1467 4731. As with other prognostic
signatures, GGI also has predictive capabilities with GGI grade III deriving more benefit from
chemotherapy than grade I[4701.
Comparison of the GGI to other 70-gene and 76-gene prognostic signatures for their ability to
predict distant metastasis-free survival in primary, untreated node negative breast cancer
demonstrated concordance of 68-88% between signatures - the 70-gene and GGI signatures
had the highest concordance. Thus, despite limited overlap of their genes, these signatures
have similar prognostic performance [603].
A third reason for the lack of clinical utility of first generation signatures is the fact that many
of them were developed to predict short term disease recurrence (<5 years) and have shown
reduced prognostic significance after 5-10 years of follow-up, indicating that they may only be
useful in predicting early but not late disease recurrence [459 478]. Patients requiring extended
therapy due to a high risk of late disease relapse may therefore be inappropriately reassured
and have beneficial treatment discontinued.
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Fourthly, as with histopathological markers, technical artefact can diminish the accuracy and
therefore the efficacy of the first generation signatures. For example, the allocation of patients
into prognostic subgroups may be dependant upon the percentage of neoplastic versus non
neoplastic (normal breast, stromal and inflammatory) cells in a given tissue sample. The first
generation signatures were themselves derived from tissues of varying neoplastic content.
Indeed, evidence suggests that the percentage of neoplastic cells in a sample does have a
substantial impact on the final gene expression profile and on the ability to derive biologically
meaningful data [6061. On the other hand, the high levels of standardisation of some gene
expression assays such as Oncotype DX® and MammaPrint® are perhaps more reproducible
than the current assays for ER, PR and HER2 [481, 607, 608i. The vast majority of gene
expression based assays are however, not sufficiently standardised to achieve high-level
concordance between laboratories.
Finally, most of the signatures developed thus far, have been subjected to very limited
independent validation. A variety of different microarray platforms and statistical tools have
been used to analyse the data and there is little overlap between the genes of each signature.
All of these factors make comparison between studies and validation of individual studies
extremely difficult[6031.
4.5.2 The Transition from Prognostic to Predictive Signatures
Although many prognostic markers have been shown to have predictive value, efforts are
underway to find biomarkers capable of specifically predicting a patient's response or
resistance to a particular treatment so that individual they can be managed accordingly. In
fact, there is currently a strategic shift away from prescribing chemotherapy on the basis of
prognosis to doing so on the basis of prediction of response. As a mark of this transition, a
number of attempts have been made to identify predictive components within the previously
published prognostic signatures.
Flowever, one of the difficulties inherent in studies of adjuvant treatments is the need to
monitor survival endpoints that require prolonged follow-up and large patient numbers to
achieve significance.
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The clinico-pathological Pre-operative Endocrine Prognostic Index (PEPI) score combines
tumour size, nodal status, ER and Ki67 indices to give a total relapse score I155 315' This can
be used to distinguish between patients with low risk of relapse who can be treated with
endocrine therapy alone from high-risk patients who will require additional chemotherapy.
Specifically, patients with pathological stage 0 or I and a PEPI score of 0 at the time of
surgery had a sufficiently low rate of relapse to suggest that further adjuvant therapy was not
required. In contrast, patients with high pathological stage and a PEPI score of 3, required
additional adjuvant treatment. Whilst PEPI is not a genetic predictive marker, patients with
luminal-A tumours identified by PAM50 are associated with better prognosis PEPI scores
than those with luminal B tumours and a better outcome when treated with endocrine therapy
alone 13011
Over the last decade, many groups have defined multiple gene prognostic signatures with the
aim of identifying patients with a good enough prognosis to allow them to forego
chemotherapy l158 458 467 485'486'609-611l l443.444l The first of these was the 70-gene signature,
which could be applied to patients who had not received systemic therapy, in order to identify
those who were unlikely to develop distant disease within 5 years I158]. This was shown to be
an independent and better predictor of outcome and response to adjuvant chemotherapy than
standard clinico-pathological variables I157'158' 458'467.485,486,609-6n]^ |eacjjng to the development
of the commercially available version of the 70-gene signature - MammaPrint®. Other
examples include the 76-gene signature i458<6121 and the Genomic Grade Index I442-444.467 470
613-616] yytijigt Oncofype DX® RS has been shown to be predictive of benefit from the addition
of chemotherapy to Tamoxifen [501'617]i the predictive power of MammaPrint® 1615 616' and GGI
14701 have however only been tested in retrospective datasets in patients receiving multi-drug
chemotherapy.
In an exploratory study evaluating 323 different gene signatures in 550 node negative
patients who did not receive adjuvant systemic therapy, it was suggested that prognostic
predictions can be made in ER positive but not ER negative or HER2 positive disease [5981.
However other studies have identified immune regulated signatures that might predict survival
within HER2 or triple negative tumours, although within these, the good prognosis group still
demonstrated a high incidence of relapse [618, 619]. With respect to ER negative breast
cancers, a retrospective microarray analysis has identified an increased stromal meta-gene
expression that predicted resistance to FEC chemotherapy and therefore treatment failure
[496]
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In ER positive node positive disease the low risk groups as predicted by MammaPrint®,
Oncofype DX® and PAM50 have relatively high recurrence rates nonetheless (over 10% at 8-
10 years) making denial of adjuvant chemotherapy inappropriate I'57 488 489 574 62°1 However,
in a subset of patients with 1-3 positive nodes the Oncotype DX® and MammaPrint® low risk
groups have a relapse rate similar to that of node negative disease when treated with
hormone therapy alone (<10% at 5-10 years) I488-489 621!
The ongoing prospective phase III multi-centre randomised MINDACT trial (Microarray In
Node Negative and 1-3 positive lymph-node Disease may Avoid Chemotherapy) currently
aims to test whether patients with a high risk of recurrent disease according to clinico-
pathological features (Adjuvant! Online) can be spared chemotherapy if their MammaPrint®
result indicates relatively low risk 1487 622]. This is again indicative of the trend of using a
predictive utility as a prognostic test.
4.5.3 Predictive Signatures in the Adjuvant Endocrine Therapy Setting
Only a few gene expression signatures have been designed specifically to predict endocrine
response in ER positive tumours and none have yet been shown to confer benefit if
implemented in the clinical management of breast cancer patients. ER status is of course, the
main indicator for the institution of endocrine therapy. Whilst ER negative tumours almost
never respond, ER positive tumours respond in 50-70% of cases [623]. The fact that the
remaining 30-50% of ER positive tumours do not respond presents an urgent incentive to find
a means of early categorisation of these tumours based upon their likely treatment response.
Whilst PR and HER2 status provide some additional predictive information, they are not
sufficiently reliable indicators of endocrine response.
A number of endocrine predictive signatures have therefore been developed. For example,
Jansen et al. identified and validated a 44-gene signature that was predictive of response to
adjuvant Tamoxifen in advanced ER positive disease. The signature included oestrogen
regulated genes, apoptosis, ECM formation and immune response genes [5061. Furthermore,
their signature performed significantly better than traditional predictive factors although the
authors acknowledged that further research was required to validate the use of this or similar
signatures in directing the need to institute alternative adjuvant therapy in non-responders
[5061. Similarly, PAM50 has been validated in an independent cohort of ER positive patients
treated with adjuvant Tamoxifen and again outperformed standard clinico-pathological
variables including Ki67, PR and histological grade [574]. The ubiquitous Oncofype DX® is also
independently predictive in postmenopausal ER positive patients treated with Anastrozole
[488]
177
The Sensitivity to Endocrine Therapy (SET) index is based on 165 genes that are co-
expressed with the ER gene. The test categorises ER positive tumours into groups that
predict low, intermediate or high response to any endocrine therapy [479'. Effectively, this
signature aims to reflect the activity of oestrogen signalling pathways in ER +ve tumours,
therefore highlighting those where the receptor is functional. Unlike other multi-gene
signatures that essentially evaluate proliferation in ER positive tumours, the SET index
appears to be predictive of response to endocrine therapy independently of the inherent
prognosis of the tumour. SET also identifies a subgroup of tumours with excellent prognosis
in a Tamoxifen treatment group (node negative and high SET index) and in a chemo-
endocrine treatment group (high and intermediate SET index)I479!.
The Breast Cancer Index (BCI) assesses the likelihood of distant recurrence in ER positive,
node negative patients. In validation studies, the BCI stratified nearly half of such patients
treated with Tamoxifen into a low risk group for disease recurrence t611624' The BCI also
reflects the promising strategy of combining mutually complementary signatures. Unlike the
other commercialised tests, BCI has been developed from the combination of two indices: a
HOXB13: IL17BR (H-l) gene ratio, which predicts metastases in ER positive, Tamoxifen
treated patients [486! and a five proliferation gene index (MGI) which discriminates grade I from
grade III disease in a similar way to GGI |611'. Two distinct approaches to combining the HI
ratio and MGI have been investigated recently in ER positive, node negative patients and
were more or less equivalent in their stratification of the 10-year risk of breast cancer related
death [625].
A comparison of BCI, Oncofype DX® and the immunohistochemical prognostic test ICH4 for
their ability to predict long term risk of recurrence in ER positive patients found that only the
BCI accurately identified patients at risk beyond 5 years of treatment with either Anastrozole
or Tamoxifen, whilst all three could predict earlier risk. Beyond 5 years, BCI was clearly able
to distinguish those 40% of patients with a significant risk of recurrence. This of course offers
the prospect of targeting prolonged therapy to those most likely to benefit[626)
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4.5.4 Predictive Signatures in the Neoadjuvant Chemotherapy Setting
In the neoadjuvant chemotherapy setting, the elimination of detectable disease at the primary
tumour site (pathological complete response, pCR) is often used as a surrogate for systemic
response to chemotherapy agents, although it is only achieved in 20-30% of patients [627].
Pathological complete response rates to Anthracycline and Taxane based chemotherapy are
around 7% for luminal A, 17% for luminal B, 36% for HER2 and 43% for basal-like subtypes
I628]. Overall, the majority of responders are non-luminal A tumours, which helps to explain
why gene expression signatures that discriminate luminal A from other intrinsic subtypes can
also predict pcr'470'501 616'.
Straver et at. assessed the predictive value of MammaPrint® in the neoadjuvant
chemotherapy setting on 167 patients using pCR as a measure of chemosensitivity. All
patients had invasive breast cancer greater than 3cm in diameter. None of the good
MammaPrint® prognosis group achieved pCR, whereas 20% of the poor prognosis group,
which included all triple negative cancers, did. Amongst the non triple-negative group, the
response was significantly associated with the MammaPrint® classification [6161. These
findings are in keeping with the expectation that the good prognosis groups detected by
MammaPrint have lower proliferation rates and are therefore less sensitive to chemotherapy.
They nonetheless indicate the potential for MammaPrint® to be used as a predictive marker
of response to neoadjuvant chemotherapy.
Similarly, Oncofype DX® has also been correlated with pCR in patients receiving neoadjuvant
chemotherapy and was found to have predictive value for benefit from chemotherapy in
patients with ER positive, lymph node negative disease I501]. GGI has also been shown to be
a predictor of chemotherapy response in the neoadjuvant setting in both ER negative and
positive patients [470].
Several groups have attempted to identify chemotherapy response signatures by comparing
gene expression profiles in high and low responsive tumours [499 502 5041 The majority of these
studies were done using biopsies taken before neoadjuvant chemotherapy was initiated. In
this way, MD Anderson developed a 30-gene signature (DLDA-30), subsequently validated,
that predicts response to T-FAC chemotherapy better than a combination of age, grade and
ER status (sensitivity 92% versus 61%) However this finding has since been disputed in
a further independent study 16291
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4.5.5 Predictive Signatures in the Neoadjuvant Endocrine Therapy Setting
To date, the only endocrine neoadjuvant predictive signature that has been independently
validated is the Edinburgh 205-gene signature used in the present study.
Concurrently with the publications from the Edinburgh group described above, Mackay et al.
measured the molecular response before and after two weeks of treatment with either
Letrozole or Anastrozole and identified 421 genes including the classic oestrogen-response
genes, whose expression was affected by the treatment. Proliferation genes were down-
regulated and ECM associated genes up-regulated [5071. in this study, the changes in gene
expression profiles were not correlated to response to the aromatase inhibitors, but instead
related to changes in Ki-67, which could be considered as a response surrogate.
Mello-Grand et al. identified a 54-gene signature from a small group (13 matched samples) of
ER positive patients treated with Anastrozole for three months, which was predictive of
sensitivity to neoadjuvant Anastrozole in all of the patients. They also observed that
Anastrozole treatment was associated with a decreased expression of cellular proliferation
genes and an increased expression of inflammatory genes. In addition, enrichment of cell
cycle inhibition and induction of immune response genes occurred in responders I521l No
independent validation of this signature has yet been made.
More recently, the genomic grade index (GGI) has been shown to be a useful predictor of
response to neoadjuvant Letrozole in post-menopausal ER positive breast cancer patients.
Women with low GGI were shown to be more likely to respond to three months of treatment
than those with high GGI. Importantly, low proliferation following two weeks of Letrozole
therapy, as measured by GGI and Ki67, was associated with tumour response in GGI high-
grade but not GGI low-grade tumours, suggesting that the early assessment of proliferation
may be useful in predicting response, particularly in high-grade ER positive breast cancer'539].
To date, there appear to be no studies focused upon stromal gene expression changes as
predictive markers of response to endocrine treatment in either the adjuvant or neoadjuvant
settings. However, the local inflammatory component reported by Mello-Grand et al. may
potentially be associated with some aspects of the stromal microenvironment, as discussed
earlier. Of note, both Mackay's'507' and Miller's'5081 groups reported changes in extracellular
matrix gene expression during neoadjuvant endocrine treatment and Farmer's group reported
the predictive capacity of a stromal signature with respect to neoadjuvant cytotoxic
chemotherapy.
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4.5.6 Combining Markers to Improve Power
Whilst clinico-pathological variables have been shown to add prognostic information
independent of that offered by the first generation signatures l442"444)j when these variables are
standardised for histoloQical Qrade, protein receptor status and Ki67 little additional
information seems to be provided by the signatures l455 630!. Nevertheless, Oncotype DX® has
been promoted as an adjunct to clinico-pathological classification in evaluating the prognosis
of ER positive, node negative patients and in predicting their response to chemotherapy [631,
632l It has also been shown to be independently prognostic of 10-year distant recurrence in
ER positive, postmenopausal women receiving Anastrozole [488].
Just as the combination of standard clinico-pathological and genetic markers of prediction
and prognosis have, in some cases, been shown to improve their prognostic or predictive
power, it is possible that combinations of multi-gene signatures may be similarly useful,
particularly when they are associated with different cellular pathways [3391. Mefford et at. have
recently discussed the potential advantages of combining proliferation and stromal based
signatures with clinico-pathological measures to add prognostic information in breast cancer
patients [633!. They demonstrated that the incorporation of stromal cell signatures significantly
improves the performance of proliferation based first generation signatures in the adjuvant
setting.
Another example of the successful implementation of this strategy was the Breast Cancer
Index (BCI) described earlier.
Generally however, it remains to be seen whether combinations of gene signatures with or
without standard histopathological markers can significantly improve prognostication and
prediction. For the time being, it has been suggested that signatures should currently be used
only as ancillary tools rather than as a substitute for clinico-pathological staging I442"444!
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5. Future Studies
5.1 Pertaining to the Present Study
There are several avenues for further investigation that could be applied to the data collected
for the current study. These include:
(i) Analysis of the microarray data obtained from the final, three-month samples to
determine if the changes evident after two weeks of Letrozole treatment are
maintained or modified by further treatment.
(ii) Identifying the most significantly changed genes between responders and non-
responders from each of the chosen signatures and then attempting to construct a
novel, refined signature from these that has improved predictive power.
(iii) Following on from this, it would be interesting to look at the possibility of combing the
most informative genes from the proliferation and stromal signatures to determine
whether such a combination is a better predictor of response to Al therapy than either
alone.
(iv) Investigating the ontology of these most significantly changed genes to see whether
this can cast light on the mechanisms underlying resistance to aromatase inhibitors
or identify new targets for breast cancer treatment. Such an investigation must
consider the comments of Venet et al. discussed above I594].
(v) Verifying or refuting the stromal signature result observed in this study using other
published stromal signatures. It may also be worthwhile correlating the stromal gene
expression of the samples to their stromal content at baseline to ensure that stromal
signatures are not simply reflective of relatively high stromal content.
(vi) Similarly, attempting to correlate the present results with the measurement of the
ratio of tumour epithelium and stroma for each sample at baseline.
(vii) Expanding the response groups by taking account of long-term follow-up data, to
determine whether some members of the intermediate response group can be
redefined as responders or non-responders and then to determine if this could have
been predicted at two weeks using the gene signatures under investigation.
(viii) Assessing the efficacy of the predictive signatures with respect to pathological
tumour response (e.g. central scar formation, mitoses) at three months and not just
tumour size on USS.
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(ix) Comparing the predictive power of the chosen signatures with that of standard
baseline clinico-pathological markers for correlation and to determine if additional
power is obtained by combining the two.
(x) Correlating response prediction based on the chosen signatures with long-term
patient outcome data.
5.2 General Considerations for Future Studies
The present study highlights some of the difficulties experienced when trying to compare data
derived from different studies, carried out on different populations defined by different
standards and under different conditions. No two studies are quite alike, with each research
group attempting to carve out their own niche of expertise. Nevertheless, reliable and
comparable results will only come from large, well-designed studies with a high degree of
standardisation in the definitions and methods used. Ideally, standardisation should include:
i) Study inclusion and exclusion criteria
ii) Sampling time-points and technique.
iii) Classification of the ratio of tumour to stroma ratio in biopsy samples to allow better
comparison between published results and to help distinguish the relative roles of
these components.
iv) Tighter definitions of endpoints such as pCR and reduction in tumour volume.
v) Better definition of response cut-off points.
vi) Microarray inter-platform translation methods
vii) Microarray data processing
viii) Statistical analysis and reporting
With this in mind, there are a number of questions that need to be answered by future
studies. One of the most pressing is how best to accurately and reliably re-define
intermediate grade tumours, as defined by a variety of classification systems, into responders
or non-responders to a given treatment. This is the most difficult group of patients on whom to
plan treatment and determine prognosis and is consequently the most likely to be treated
ineffectively, subjecting them to unnecessary physical side effects and wasting valuable
resources. Furthermore the sensitivity and specificity of genetic signatures are not perfect.
Even with the most promising predictive signatures, including those used in this study, there
are individual cases with poor predictive scores who are nonetheless clearly responding to
treatment.
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It seems likely that the next generation of prognostic and predictive multi-gene signatures will
only be applicable to specific drugs and subtypes of breast cancers since the nature of these
subtypes and their mechanisms of resistance to different drugs appear to be fundamentally
different. Several groups are already investigating prognostic and predictive signatures for
each subgroup independently. However, most available studies are carried out on broader
groups of breast cancer patients for whom the use of such pooled data will have a tendency
to discriminate between the subtypes but have less power to predict response within a
subtype. Thus the predictive value of a potential biomarker for a single subtype would be
diluted by the presence of other subtypes in such studies.
A further target for future studies is to improve prognostication and prediction for ER negative
disease. Many cell cycle and proliferative genes are predictive of outcome for ER positive
disease but relatively few genes predict outcome of ER negative cancers. Recent studies
have indicated that ER negative disease expresses immune response genes that provide
prognostic information but further research is certainly needed because the 5 year relapse
rate, even in patients given a good prognosis, is approximately 20%, too high to justify
withholding adjuvant chemotherapy [445 475'477 494]
The current range of available treatment options is of course limited and there may seem to
be little point in being able to sub-classify breast cancers to a greater degree than the number
of treatment options available. For example, if aromatase inhibitors are the only treatment
option for two putative subtypes of breast cancer, what is the purpose of being able to
distinguish between these two groups? The answer is two-fold. Firstly, clinicians would be
able to better inform the patients of their chances of response and secondly, attempting to do
so will help to identify groups for whom the currently available treatments are inadequate. The
genetic profiles of these groups of patients could then be investigated further with the aim of
identifying novel targets and strategies for treatments or means of circumventing their
mechanisms of drug resistance.
Finally, an intelligent combination of transcriptional signatures such as those studied in this
project, with data on DNA and protein levels will help to provide biologically driven integrative
approaches for future tumour classifications and response prediction.
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6. Conclusions
Breast cancer is a predominant cause of cancer deaths worldwide and especially in the West.
The management of breast cancer is undertaken with a combination of surgery, and systemic
therapies. Choosing the most appropriate therapy for an individual patient and providing them
with a prognosis, is currently an imprecise science based upon the clinico-pathological
features of their cancer. Many patients do not respond to treatment as anticipated and many
others are given unnecessary treatments from which they will derive no benefit. In either
scenario, the personal wellbeing of the patient and the financial wellbeing of healthcare
systems are put under considerable strain.
The work presented in this thesis, is an attempt to assess and validate the efficacy of five
multi-gene signatures for their ability to predict response to neoadjuvant endocrine therapy
treatment in ER positive breast cancer patients. By observing changes in gene expression at
an early stage of treatment, it is hoped that patients who are predicted to respond, will
continue their treatment assured in the knowledge that it is likely to be effective. The
remainder can be converted to alternative, more effective treatments at the earliest
opportunity. The aims and objectives of this project have been fully achieved.
Patients treated with neo-adjuvant Letrozole have been continuously enrolled into the study to
generate a new dataset with which to evaluate the capacity for response prediction using
various transcriptional signatures.
Amongst these was the previously published 205-gene Edinburgh neo-adjuvant endocrine
response predictive signature. For the first time, this signature was tested against an
independent dataset and was confirmed to be significantly associated with response.
Moreover, this validation was performed in a platform-independent manner.
Subsequently, the performance of the Edinburgh signature was compared to that of four other
recently published signatures: two associated with proliferation (Nagalla 2013, Dai 2005) and
two signatures associated with stromal rearrangement (Farmer 2009, Beck 2008).
Furthermore, the proliferation and stromal signatures were compared to each other.
In order to diversify the comparison populations, the analysis was expanded to include a
previously published dataset, thereby providing results for both datasets as well as a
combined dataset.
Of those studied, only the Nagalla 2013 proliferation signature demonstrated performance
similar to that of the Edinburgh neoadjuvant signature.
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Both proliferation signatures demonstrated consistent, statistically significant association with
neo-adjuvant response in all datasets after 2 weeks of treatment but not at pre-treatment
baseline. The change in proliferation gene expression between these two time-points was
associated with response for only one signature (Nagalla 2013) and then in only one of the
studied datasets.
The stromal signatures were not associated with neo-adjuvant response to Letrozole either
before or at two weeks of treatment. However, changes in gene expressions in both stromal
signatures showed association with response in the newly collected dataset only and not in
the previously published dataset.
In light of the strong performance of proliferation signatures, we conducted two extended sub-
analyses, focused on selected proliferation genes and markers and using alternative
laboratory methods: qPCR and IHC.
Quantitative PCR was used to measure the expression of genes associated with different
phases of the cell cycle. The G2-M-phase transcriptional changes (NUSAP1 and Cyclin B1)
were significantly correlated with clinical response, which was not the case for genes involved
in the G0-G1 transition (Cyclins D1, CDK 4). This sub-analysis highlighted the potential utility
of NUSAP1 and Cyclin B1 as anti-proliferative response markers during neo-adjuvant
treatment with Letrozole.
Ki67 IHC staining was related to long-term outcome and was found to be significantly
predictive both in respect to the absolute expression levels at baseline and three months and
with respect to the change in these levels during treatment.
Taken together our results confirm the utility of transcriptional markers for predicting response
to neo-adjuvant endocrine treatment and provide a new dataset to compare alternative
signatures and markers.
Nevertheless, the currently available multi-gene signatures and molecular markers are not
sufficiently reliable to justify withholding therapy in the clinical environment. Therefore it
seems likely that traditional histopathological classification systems, combined with clinical
staging will remain the mainstay of prognostication and prediction for a while longer. Further
characterisation of the genes whose expression is altered during treatment and the molecular
pathways they contribute to, should lead towards a better understanding of the disease and
new opportunities for intervention.
However, considerable challenges lie ahead.
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Appendix I: The American Joint Committee on Cancer (AJCC) and the
International Union against Cancer UICC Staging Systems.
STAGE T N M COMMENTS
Stage 0 Tis NO MO
In situ cancer - confined to the ducts, lobules or nipple. No spread to nearby tissue.
No spread to lymph nodes.
No spread to distant sites.
Stage 1 T1 NO MO
The tumour is 2 cm or less in diameter.
No spread to lymph nodes.
No spread to distant sites.
TO
N1
No tumour is found in the breast.
Tumour is found in 1-3 axillary lymph nodes.
No spread to distant sites.
Stage IIA T1 MO
The tumour is 2 cm or less in diameter.
Tumour is found in 1-3 axillary and/or internal mammary lymph nodes.
No spread to distant sites.
T2 NO
The tumour is larger than 2 cm, but less than 5 cm in diameter.
No spread to lymph nodes.




The tumour is larger than 2 cm, but less than 5 cm in diameter.
Tumour is found in 1-3 axillary and/or internal mammary lymph nodes
No spread to distant sites.
T3 NO
The tumour is larger than 5 cm in diameter.
No spread to lymph nodes
No spread to distant sites.
TO
No tumour is found in the breast
Tumour is found in 4-9 axillary lymph nodes or in internal mammary lymph nodes.




The tumour is 2 cm or less in diameter.
Tumour is found in 4-9 axillary lymph nodes or in internal mammary lymph nodes.
No spread to distant sites.
T2
The tumour is larger than 2 cm, but not more than 5 cm in diameter.
Tumour is found in 4-9 axillary lymph nodes or in internal mammary lymph nodes.




The tumour is more than 5 cm in diameter.
Tumour is found in 1-9 axillary nodes or in internal mammary lymph nodes.






The tumour has spread to the chest wall or skin.
One of the following applies:
Tumour has not spread to any lymph nodes.
Tumour has spread to 1-9 axillary lymph nodes.
Tumour may or may not have spread to internal mammary lymph nodes.





The tumour is any size.
One of the following applies:
Tumour has spread to 10 or more axillary lymph nodes.
Tumour has spread to 1 or more infraclavicular or supraclavicular lymph nodes.
Tumour has spread to more than 3 axillary lymph nodes and to internal mammary
lymph nodes.
No spread to distant sites.
T4d Inflammatory breast cancer is classified as stage III (IIIB or IIIC), unless it has spread





The tumour is any size.
Any degree of lymph node involvement.
Tumour has spread to distant sites, such as the bone, liver, lung, brain or lymph
nodes far from the breast.
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Appendix II: Patient Consent Forms.
Patient Consent Form
Studies on Breast Disease
Please Initial Boxes
1. I have read and understood the attached information sheet.
2. I agree to undergo the procedure of core biopsy.
3. I understand that the purpose of the core biopsy is to determine the cause of my
breast lump.
4. I agree to allow extra samples of my breast lump to be taken.
5. I understand how the sample will be collected and that giving this sample is voluntary
and that I am free to withdraw my approval for use of the sample at any time without
giving a reason and without my medical treatment or legal rights being affected.
6. I understand that the research performed on the extra sample may include research
to improve our understanding of how drugs influence breast disease. I understand
that if these extra samples are used for research, ethical approval will be obtained for
the research project and that I will be asked to sign a separate consent form, giving
permission so these extra samples can be used.
7. I agree to my General Practitioner being informed of my participation in this study.
Name of Patient Date Signature
Name of Person Taking Consent Date




Letrozole Audit Consent Form




1. I confirm that I have read and understood the information sheet.
2. I understand that my participation is voluntary.
3. I agree that the tissue samples obtained during the time I am taking an aromatase
inhibitor and at the time of my operation can be analysed to investigate the effects of
the drugs.
4. I agree that the tissue samples can be stored for use in future studies.
5. I agree to my General Practitioner being informed of my participation in this study.
Name of Patient Date Signature
Name of Patient Date Signature
(To reaffirm on day of sample)
Name of Person Taking Consent Date Signature
(If different from researcher)
Researcher Date Signature
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Gene Expression in Aromatase Inhibitor Treated Breast Cancer
(Prospective Study)




1. I confirm that I have read and understand the information sheet for the above study.
2. I understand that my participation is voluntary.
3. I agree that extra tissue samples and blood samples as detailed in the patient
information leaflet can be taken and stored for future analysis.
4. I understand that the analyses of the tissue and blood taken will involve using new
techniques for examining the genes in the cancer.
5. I agree to my General Practitioner being informed of my participation in this study.
Name of Patient Date Signature
Name of Person Taking Consent Date Signature
(if different from researcher)
Researcher Date Signature
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Gene Expression in Aromatase Inhibitor Treated Breast Cancer
(Retrospective Study)




1. I confirm that I have read and understood the information sheet for the above study.
2. I understand that my participation is voluntary.
3. I agree that the tissue samples obtained during the time I was taking an aromatase
inhibitor and at the time of my operation can be analysed to investigate the effects of
the drugs.
4. I agree to have one further blood sample taken and understand the purpose of this
test as explained in the patient information sheet.
5. I agree that the blood sample can be stored for use in future studies.
6. I agree to my General Practitioner being informed of my participation in this study.
Name of Patient Date Signature
Name of Patient Date Signature
(To reaffirm on day of sample)
Name of Person Taking Consent Date Signature
(If different from researcher)
Researcher Date Signature
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Appendix III: Patient Information Sheets
Edinburgh Breast Unit





Tel: 0131 537 1611
Patient Information
Studies on Breast Disease
You are about to have a core biopsy performed to determine the cause of your breast lump.
Following injection of local anaesthetic, thin slivers of tissue obtained by a biopsy needle will
be taken and sent to the pathology department to diagnose the cause of your breast lump.
The Edinburgh Breast Unit is involved in a number of research projects looking at the effect of
drugs on breast lumps. We write to invite you to allow us to take extra slivers of tissue from
your lump which might be used in future research studies should you receive any drug
treatment.
If a definite diagnosis is not obtained from the specimens we send to the pathology
department, then the stored samples will be made available to the pathology department to





We would like to invite you to take part in a medical audit looking at the drug Letrozole. The
audit will be conducted here at the Edinburgh Breast Unit, by the surgeons and medical
oncologists and has been approved by a research ethics committee. Before you decide
whether you wish to take part it is important for you to understand why the audit is being done
and what it will involve. Please take time to read the following information carefully and
discuss it with others if you wish. Ask us if there is anything that is not clear or if you would
like more information. Take time to decide whether or not you wish to take part.
Background
Approximately two thirds of all breast cancers in women whose periods have stopped need
the female hormone oestrogen to grow. Therefore one way of treating breast cancer is to use
drugs that will deprive the cancer of oestrogen. Letrozole works by stopping the body from
producing oestrogen and deprives the breast cancer of the oestrogen it requires to grow.
What are the Options for Your Treatment?
Your doctor has told you that you have breast cancer and that there are different treatments
available. He/she has decided however that the best treatment for you would be hormonal
therapy (Letrozole) in the first instance. This will mean that you take drugs either before you
have breast surgery or it may be that you continue to take hormonal drugs without having an
operation to your breast. The majority of women who have hormone sensitive tumours over
2cm in size can be made smaller using this therapy so if you do need an operation, then the
amount of surgery which will follow the treatment is likely to be less extensive than would
have been required without this treatment.
What is the Purpose of this Audit?
Although the majority of tumours can be made smaller using hormone therapy, we do not yet
have a test which will allow us to tell within a few weeks of starting treatment whether it will be
effective. At the present time therefore, we give all patients three months of treatment and
during this time we carefully measure the size of the tumour monthly using clinical
measurements and ultrasound.
During this study we would like to take a sample of your breast cancer 14 days after you start
Letrozole treatment. Only a very small amount of tissue is needed and this can be removed
with a special automatic biopsy needle. The needle test is performed after the breast skin is
numbed by injecting local anaesthetic.
It is then hoped that you will continue taking hormonal treatment for 3 months. At the end of 3
months you will either have another core biopsy or have an operation.
By comparing the changes in the biopsy 10-14 days after treatment and after 3 months of
treatment with the initial sample obtained at diagnosis, it should be possible for us to look at
changes in your tumour over the whole of the 3-month treatment course.
Description of the Drug Treatment
If you agree to take part in this audit, you will be given Letrozole 2.5mgs to take once a day
for 3 months in the first instance.
Participation in this Audit
Participation is entirely voluntary and you are free to withdraw at any time should you wish to
do so. If you refuse participation or withdraw from the audit, your medical care will not be
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affected in any way. Your doctor may discontinue your participation in the audit if he/she
judges it to be in your best interest. Your doctor will inform you of any significant new findings
related to Letrozole, which may relate to your participation in this audit. When you consent
your GP will be told that you are taking part in this audit.
You should not have any additional costs as a result of taking part in this audit because all the
extra tests will be performed during standard hospital visits.
Procedures During the Three Months of Treatment
Diagnostic Core Biopsy
(Positive for Oestrogen Receptors)
I

























This treatment should reduce the size of your tumour, which if you do have an operation
should allow you to have less extensive surgery. If you do not proceed to surgery then the
tablets will keep your breast cancer under control. This audit will allow us to determine
whether your tumour does respond to Letrozole and will help your doctor treat your cancer
more effectively.
Potential Side Effects of Letrozole
In trials in which patients were treated with Letrozole for breast cancer, side effects were
generally mild to moderate and rarely ever enough to require stopping treatment.
The more common side effects that have been seen in patients treated with Letrozole 2.5mg
daily are: Tiredness, hot flushes or increased sweating, changes in weight, dizziness, itching
and skin rash, headache, changes in appetite, water retention, nausea and sickness,
constipation or diarrhoea, stomach upset or pain.
Less common side effects are: Chest pain, viral infections, pain in the muscles, bones and
joints, shortness of breath and coughing.
Do not be alarmed by this list of side effects. You may not have any of them.
You should report any discomfort or problem that you are concerned about to your
doctor immediately.
What now?
If you wish to participate in this audit then please read and sign the consent form. Do not sign
the form until you are sure you are happy to take part. Please note that you have the right to
withdraw from this study at any time without prejudice to your legal rights or healthcare
treatment.
Thank you for considering this audit. If you do have any queries, then please do not











Dept. of Clinical Oncology
Western General Hospital
Edinburgh
Tel: 0131 537 2213
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Gene Expression in Breast Cancer Treated by Aromatase Inhibitors
(Prospective Study)
Patient Information Sheet
We would like to invite you to take part in a research study during your treatment with
Letrozole or Anastrozole. This study will involve you giving us permission to take biopsies
and blood samples for research purposes. Before you decide whether you wish to take part it
is important for you to understand why the research is being done and what it will involve.
Please take time to read the following information carefully and discuss it with others if you
wish. Ask us if there is anything that is not clear or if you would like more information. Take
time to decide whether or not you wish to take part.
What is the purpose of the study?
In some patients with breast cancer the cancer is too large or unsuitable for operation or there
are medical reasons why an operation may not be the best first option of treatment. In these
situations, it is useful to try to shrink down the cancer using drugs that block the hormone
oestrogen being produced. From our studies it is clear that most people respond well to these
drugs; others respond for a time and then the drug stops working. In a few people the drug is
not so effective at shrinking the cancer. What we don't understand is why most people benefit
but a few do not.
In this study we plan to look both at a sample of cancer, that will be taken from your cancer
while you receive hormone blocking drugs and blood samples. The samples will be tested to
see whether the changes that occur as a result of taking these drugs relate to how much the
cancer shrinks. This will allow us to see if there is any way of predicting who will respond to
these drugs, and importantly, tell us who might not respond.
These samples will be analysed using new techniques for examining the genes in the cancer
and also the proteins the cancer produces. The human body contains thousands of genes
and different proteins inside the cells and when a person develops a disease, there are
changes in the genes and the proteins in the part that is diseased. Changes in genes and
proteins also occur after treatment, and may allow us to tell whether or not a specific drug is
having a beneficial effect.
Although this process involves analysis of genes, this is not the same as genetic testing for
looking at the risk of breast cancer to the rest of your family. Instead, it is to look only at your
cancer and the samples we already have stored. All of these samples are coded before we
analyse them so you won't receive an individual result from these tests.
What is involved for me if I choose to take part?
You will be invited to have extra biopsies and blood tests taken and stored for research
purposes. This is likely to involve one or two extra visits to hospital, at two weeks following
commencement of your treatment and then again at three months. We would also make
some measurement of your tumour at these visits by ultrasound. Other than this all that is
required is that you read and discuss this information sheet with your friends or relatives and
then make a decision on whether you are happy to give the extra samples for storage and
further analysis.
Will my taking part in this study be kept confidential?
Yes. All the samples will be coded, and cannot be traced back to you except by Mr Dixon's
research team in the Edinburgh Breast Unit.
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What now?
If you wish to allow us to use your samples then please read and sign the consent form. Do
not sign the form until you are sure you are happy to take part in the study. Please note that
you have the right to withdraw from this study at any time without prejudice to your legal rights
or healthcare treatment.
Thank you for considering this study. If you do have any queries then please do not
hesitate to contact us.
If you wish to obtain independent advice on this study, you can contact Dr Ian Kunkler on
0131 537 2213.
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Gene Expression in Aromatase Inhibitor Treated Breast Cancer
(Retrospective Study)
Patient Information Sheet
You will recall during your treatment with Letrozole or Anastrozole for your breast cancer you
gave us permission to take biopsies for research purposes. We would now like to ask you to
take part in a research study using those biopsy samples and invite you to have one further
blood test. Before you decide whether you wish to take part it is important for you to
understand why the research is being done and what it will involve. Please take time to read
the following information carefully and discuss it with others if you wish. Ask us if there is
anything that is not clear or if you would like more information. Take time to decide whether
or not you wish to take part.
What is the purpose of the study?
In some patients with breast cancer, the cancer is too large or unsuitable for operation or
there are medical reasons why an operation may not be the best first option of treatment. In
these situations, it is useful to try to shrink down the cancer using drugs that block the
hormone oestrogen being produced. From our studies it is clear that most people respond
well to these drugs. Others respond for a time and then the drug stops working. In a few
people the drug is not so effective at shrinking the cancer. What we don't understand is why
most people benefit but a few do not.
In this study we plan to look at the samples of cancer that have been taken from your cancer
while you were taking these hormone-blocking drugs and some cells from a recent blood test.
These samples will be tested to see whether the changes that occur as a result of taking
these drugs relate to how much the cancer shrinks. This will allow us to see if there is any
way of predicting who will respond to these drugs, and importantly, tell us who might not
respond.
These samples will be analysed using new techniques for examining the genes in the cancer
and blood cells. The human body contains thousands of genes and different proteins inside
the cells and when a person develops a disease, there are changes in the genes and the
proteins in the part that is diseased. Changes in genes and proteins also occur after
treatment, and may allow us to tell whether or not a specific drug is having a beneficial effect.
Although this process involves analysis of genes, this is not the same as genetic testing for
looking at the risk of breast cancer to the rest of your family. Instead, it is to look only at
changes related to your cancer in the samples we already have stored and in the further
blood test. All of these samples are coded before we analyse them so you won't receive an
individual result from these tests.
What is involved for me if I choose to take part?
You have already had the biopsies taken and these have been stored but have not yet been
tested. You are simply required to have one further blood test. This involves taking 2
teaspoons (10mls) of blood during one extra visit to hospital. All that is required from you is
to read this consent form, discuss it with your friends or relatives and make a decision on
whether you are happy for us to use the samples we already have stored and to have the
extra blood test. It you are happy, then sign the attached consent form and return it to us in
the envelope provided.
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Will my taking part in this study be kept confidential?
Yes. All the samples are already coded, and cannot be traced back to you except by Mr
Dixon's research team in the Edinburgh Breast Unit. It is possible that during the course of
the study we will share information with other research teams across the world. Please be
reassured that none of the information supplied to these teams will be traceable back to you,
except by Mr Dixon's research team.
What now?
If you wish to allow us to use your samples then please read and sign the consent form. Do
not sign the form until you are sure you are happy to take part in the study.
Please note that if you should decide to participate in this study we will be informing your GP
as a matter of courtesy, unless you express a wish otherwise.
Travel Expenses
Any travel expenses incurred during the course of your participation in this study will be
honoured in full.
Thank you for considering this study. If you do have any queries, then please do not
hesitate to contact us.
If you wish to obtain independent advice on this study, you can contact Professor Ian Kunkler
on 0131 537 2213.
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Appendix IV: Signature Gene Lists
BECK
WISP1PDGFRL CDH11 C0L3A1 DKK3 SPARC EDNRA C0L6A1 C0L1A2
C0L5A1 C0L11A1 CSPG2 FBN1 ADAM12 ADAMTS2AEBP1 ANGPTL2 COL5A2 FN1
LOX MMP11 PLAU THBS2 WNT2 COL8A1 MAFB THY1 RAB31 LUM SPON1
ITGB5 CTSK LOXL1RARRES2DPYSL3 NBL1 FBLN2BGN COL1A1 CTGF ID3INHBA
MFAP2 ROR2 SDC1 SERPINH1 COL12A1 C7orf10 GREM1 OLFML2B POSTN
SRPX2 SULF1TWIST1 GJA1 ECM2 MN1 COL6A2 MYL9 D2S448 FHOD3
KIAA1295 LOC83468 LRRC15 ODZ4 RNF144
FARMER
DCN CSPG2 CDH11 COL3A1 FAP SERPINF1 FBN1 PDGFRL CTSK PRSS11
ASPN SPARC COL5A2 LOXL1MMP2 SPON1 SFRP4 ITGBL1 CALD1 COPZ2
MFAP2 ANGPTL2 PLAU COL1A2 LRRC17 C1QTNF3 SNAI2 PCOLCE POSTN ECM2
FBLN1ADAM12 MMP11 AEBP1 PDGFRB GAS1 COL6A3 RARRES2COL6A1 C1R
NDN TGFB3 LRP1 COL10A1 DPYSL3 OLFML2B MMP14 DACT1 MGC3047THBS2
NAGALLA
TOP2A BIRC5 KIAA0101 FOXM1 TYMS CCNB2 CDC20 UBE2C MAD2L1 PTTG1
BUB1B DLGAP5 ZWINT TRIP13 AURKA NDC80 CKS2 KIF11 NEK2 TTK
MELK CENPA CCNE2 CENPE GINS1 KIF14 CENPF KIF2C BUB1 CDKN3 RRM2
TPX2 CDK1 MKI67 NCAPH CCNA2 CCNB1 PRC1 NUSAP1 KIF4A CEP55 DTL
NCAPG HJURP KIF20A MLF1IP PBK KIF15 ASPM MCM10 CDCA3 CDCA8
KIF18B RACGAP1
DAI
STK15STK6 UBCH1D ID-GAP BUB1 PTTG2 FLJ11252 CCNB2 KNSL6
DFKZp762E1 PRC1 CENPA CDC45L STK12MAD2L1 ORC6L KIAAD165PKMYT1
E2F1 KPNA2 E2-EPF BIRC5TK1 CDC6 DJ742C19.2 CCNE2 LOC512D3 KNSL5
BLM BMD39 H2AFZ LOC51659 SNRPA1 PSMD7 YWHAZ NTN4 FST BTD
MILLER
ADSL ITM2B C3orf63 TERF1 GGH MLF1IP PPM1A SSFA2 STK19RPS10
ARPP-19 FAM128A TLE1 PIGA ARGLU1 GRB10 MOCOS RPS9 GORASP2 RPL24
RFC3 KIAA0101 BNIP1 HIVEP2 RBL2 COQ10B MAPRE2 FAM60A RPL12EIF4B TNIP1
RPL13A NDEL1 ILVBL LOC730052 III RNPEP III TMEM189 III TMEM189-UBE2V1 III
UBE2V1 DAZAP2 FLJ22222 RPS20 CHRDL1 ZNF223 BAZ2B SLC9A6 CLCC1
PER2 PAQR3 MOBKL3 MY05A GIT1 UCRC FAM120A CDC2 TNFRSF10B DDX10
RPS29 IMPDH2 ATP5I III MFSD7 WDR45 ZNF434 MMD INSIG1 PEX16PTGS1
ITSN2 SOS2 hCG_16001 III hCG_2001000 III RPL23A KIAA0265 MCM9 DLEU2 HDAC3
ARMC8 MTF2 RPL27RPS21 TMEM97 DHFR RPL37KLHL2NUSAP1 RPS13 SMAD2
ARL17P1 DIP2C ATP6V1D ABCA1 HERC1 SETD2 RPS17 MLX DTNA EIF5B
FAM32A SSBP3 CCDC93 CMAH BLVRA SNRPF DMXL1 RPLPO RAB33B
RUFY1 SC02 RPS12 NBL1 FHL2 DDX28 HOXC6 RPS2 SULT1A3 III SULT1A4
DEDD KIAA0226 LOC729362 III RPL36A FDPS PLSCR3 STX16MAD2L1 PLSCR1 WDR1
EXPH5 ARFGAP1RNF6 ATF4 MAGED2 KIAA0564 FMR1 SAP18SIRT1 ACSL3 RPS4X
RRM2 MAGED1 SPAG7 AMPD3 GNPTAB DRD2 LOC402057///RPS17 JUND PARP2
LOC646912 USP22 TMEM80 PSMD14 KIF5B TK2 NCK1 CRTAP ATP5I DI02
TNFSF10 SEC31A LIMA1 CBX1 ATP8A1 RPLPO///RPLPO-like RPLP1 GNA11
ANKHD1 CTBS PRPF4B CASP8 CDKN2AIP RPS6 C22orf28 LAMP2 C2orf33
CD81 FAM13A1 R3HCC1 PCGF3
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